UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL

INSTITUTO DE CIÊNCIAS BÁSICAS DA SAÚDE

PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS: BIOQUÍMICA

ENVOLVIMENTO DO ESTRESSE OXIDATIVO E HIPERCOLESTEROLEMIA NA ATEROSCLEROSE E AVALIAÇÃO DO EFEITO PROTETOR DO CAROTENÓIDE ASTAXANTINA

Tese de doutorado

PAULA ROSSINI AUGUSTI

Porto Alegre, RS

2010

PAULA ROSSINI AUGUSTI

ENVOLVIMENTO DO ESTRESSE OXIDATIVO E HIPERCOLESTEROLEMIA NA ATEROSCLEROSE E AVALIAÇÃO DO EFEITO PROTETOR DO CAROTENÓIDE ASTAXANTINA

Tese apresentada ao Programa de Pós-Graduação em Ciências Biológicas: Bioquímica do Instituto de Ciências Básicas da Saúde da Universidade Federal do Rio Grande do Sul como requisito parcial para obtenção do título de Doutor em Ciências Biológicas-Bioquímica.

Orientadora:

Profa. Dra. Tatiana Emanuelli

Porto Alegre, RS

2010

UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL
INSTITUTO DE CIÊNCIAS BÁSICAS DA SAÚDE
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS: BIOQUÍMICA

A Comissão Examinadora, abaixo assinada, aprova a Tese de Doutorado

ENVOLVIMENTO DO ESTRESSE OXIDATIVO E HIPERCOLESTEROLEMIA NA ATEROSCLEROSE E AVALIAÇÃO DO EFEITO PROTETOR DO CAROTENÓIDE ASTAXANTINA

elaborada por

Paula Rossini Augusti

como requisito parcial para a obtenção do título de

Doutor em Ciências Biológicas-Bioquímica

Comissão examinadora:

Profª. Dra. Tatiana Emanuelli

(Presidente/Orientador)

Prof. Dr. José Cláudio Fonseca Moreira (UFRGS)

Profª. Dra. Andreza Fabro de Bem (UFSC)

Profa. Dra. Cristina Wayne Nogueira (UFSM)

Dedico esse trabalho a minha orientadora Tatiana Emanuelli, por me acompanhar nessa jornada de quase 10 anos e me ajudar a ser uma profissional e uma pessoa melhor...

AGRADECIMENTOS

ÍNDICE

Manuscrito submetido à publicação ao periodico *British Journal of Nutrition* em   27/06/2010.

       Termo de consentimento livre e esclarecido assinado pelos participantes do estudo envolvendo seres humanos.

       Normas para preparação de manuscritos para submissão ao periódico Clinical Biochemistry

       Comprovante de submissão do manuscrito "Astaxanthin improves paraoxonase activity and oxidative status in hypercholesterolemic rabbits: a lipid-lowering independent effect" ao periodico *British Journal of Nutrition.*

APRESENTAÇÃO

A presente Tese de Doutorado encontra-se organizada em três partes principais:

A **Parte I** representa a **Introdução**, a qual contém o referencial teórico utilizado para a construção das hipóteses investigadas nesta Tese. Em seguida, os **Objetivos** (Geral e Específicos) trazem o principal questionamento do trabalho realizado e as questões de pesquisa específicas que nortearam a realização desta Tese.

A **Parte II** está subdividida em três **Capítulos**. O **Capítulo I** traz um manuscrito em preparação para submissão à publicação; o **Capítulo II** contém um artigo já publicado; o **Capítulo III** contém um artigo submetido à publicação; As seções Materiais e Métodos, Resultados, Discussão e Referências Bibliográficas encontram-se nos próprios manuscritos e artigo e representam na íntegra este estudo.

A **Parte III** abrange **Discussão, Conclusões, Perspectivas e Referências Bibliográficas.** A **Discussão** representa uma interpretação geral dos dados obtidos em todos os trabalhos. As **Conclusões** contêm um resumo dos principais resultados da tese. Em seguida, está apresentada a seção **Perspectivas**, a qual sugere possíveis estudos futuros a partir dos resultados obtidos nesta ivestigação. A seção **Referências Bibliográficas** apresenta a bibliografia citada nas seções Introdução e Discussão desta Tese.

PARTE I

RESUMO

A aterosclerose consiste na formação de placas que reduzem o diâmetro dos vasos sanguíneos e é a principal causa das doenças cardiovasculares. O estresse oxidativo tem sido apontado como um importante mecanismo no processo de aterogênese induzido pela hipercolesterolemia. A astaxantina (ASX) é um carotenóide presente em algas e frutos-do-mar, amplamente estudado por suas propriedades antioxidantes. No presente trabalho, avaliou-se a ocorrência de estresse oxidativo em diferentes estágios de hipercolesterolemia em humanos e a relação entre o estresse oxidativo e o processo inflamatório nesses indivíduos. Adicionalmente, o potencial antiaterogênico da ASX foi avaliado em coelhos hipercolesterolêmicos. No primeiro capítulo demonstramos que a peroxidação lipídica e oxidação de proteínas aumentou em indivíduos com níveis de LDL considerados de alto risco para doenças cardiovasculares (>160mg/dL), enquanto os níveis de LDLox, LDLoxAB, do marcador de processo inflamatório hs-CRP e a atividade das enzimas TrxR-1 e SOD aumentaram em indivíduos com níveis de colesterol considerados altos, mas clinicamente aceitáveis (130-160mg/dL), persistindo este aumento nos sujeitos com LDL > 160mg/dL. A enzima PON1 não teve sua atividade modificada em nenhum dos estágios de hipercolesterolemia estudados. Os resultados apresentados no capítulo I permitem concluir que o estresse oxidativo ocorre concomitantemente ao processo inflamatório durante a hipercolesterolemia. Além disso, a utilização da atividade da enzima PON1 sérica como fator de risco independente para doenças cardiovasculares necessita maiores esclarecimentos. No segundo e terceiro capítulos, observamos que a adição de colesterol (1%) na dieta de coelhos (60 dias) induziu hiperlipidemia sérica, estresse oxidativo no soro e tecido aórtico e formação de ateroma no tecido aórtico. A suplementação de ASX (50-100mg%) concomitante com o colesterol atenuou o estresse oxidativo de maneira mais acentuada no tecido aórtico do que no soro, mas não preveniu o aumento dos lipídios séricos nem a formação de ateroma nos coelhos. Estes resultados indicam que apesar da ausência de efeito hipolipidêmico e antiaterogênico da ASX, esse carotenóide exerce efeitos antioxidantes no soro e tecido aórtico de coelhos hipercolesterolêmicos. Em conjunto, os dados desta Tese indicam a ocorrência de estresse oxidativo durante a hipercolesterolemia em humanos e a ocorrência de aterosclerose e estresse oxidativo em coelhos hipercolesterolêmicos. Apesar da ASX não ter apresentado efeito antiaterogênico neste trabalho, mais estudos são necessários antes de uma conclusão definitiva sobre o potencial deste carotenóide como adjunto na prevenção e tratamento de doenças cardiovasculares.

ABSTRACT

Atherosclerosis consists in the formation of plaques that reduces blood vassels diameter and it is the major cause of cardiovascular diseases. Oxidative stress has been pointed as an important mechanism in atherogenesis process induced by hypercholesterolemia. Astaxanthin (ASX) is a carotenoid present in algaes and seafoods, widely studied by its antioxidant properties. In the present study it was evaluated the ocurrence of oxidative stress at different stages of hypercholesterolemia in humans and the relathionship between oxidative stress and inflamatary process in these subjects. Additionally, the antiatherogenic potential of ASX was evaluated in hypercholesterolemic rabbits. In the first chapter, we demonstrated that lipid peroxidation and protein oxidation increased in subjects with LDL levels considered of high risk for cardiovascular diseases (>160mg/dL), while the levels of LDLox, LDLoxAB, the marker of inflamatory process hs-CRP and the activity of the enzymes TrxR-1 and SOD increased in subjects with LDL levels considered high, but clinically acceptable (130-160mg/dL), persisting this increase in subjects with LDL > 160mg/dL. The enzyme PON1 did not have its activity modified in none of the studied stages of hypercholesterolemia. The results presented in chapter I allow to conclude that oxidative stress ocurrs concomitantly to the inflamatory process during hipercholesterolemy. Besides, the use of enzyme PON1 activity in serum as an independent risk factor for cardiovascular diseases needs more clarification. In the second and third chapters, we observed that the addition of cholesterol (1%) in the diet of rabbits (60 days) induced serum hyperlipidemia, oxidative stress in serum and aortic tissue and atheroma formation in aortic tissue. ASX supplementation (50-100mg%) concomitant with cholesterol atenuated oxidative stress in a more pronounced way in aortic tissue than in serum, but did not prevent the increase in serum lipids nor atheroma formation in rabbits. These results indicate that despite the absence of hypolipidemic and antiatherogenic effect of ASX, this carotenoid exerts antioxidant effects in serum and aortic tissue of hypercholesterolemic rabbits. Taken together, the data of this thesis indicate the ocurrence of oxidative stress during hypercholesterolemia in humans and the ocurrence of atherosclerosis and oxidative stress in hypercholesterolemic rabbits. Despite ASX not having presented antiatherogenic effect in this work, more studies are necessary before a final conclusion about the potential of this carotenoid as an adjunct in prevention and therapy of cardiovascular diseases.

LISTA DE ABREVIATURAS

AG – Ácidos graxos

ANOVA – Análise de variância

ASX – Astaxantina

CAT – Catalase

CT – Colesterol total

DHA – Ácido docosahexaenóico

DTNB – Ácido 5,5'-ditio*bis*-2-nitrobenzóico

EPA – Ácido eicosapentaenóico

EROs – Espécies reativas de oxigênio

GSH – Glutationa

GR – Glutationa Redutase

GSH-Px – Glutationa peroxidase

HDL – Lipoproteína de alta densidade

Hs-CRP – Proteína C reativa

LDL– Lipoproteína de baixa densidade

LDLox – LDL oxidada

LDLoxAB – Anticorpos contra LDL oxidada

MCP-1 – proteína quimiotáxica para monócitos

M-CSF – fator estimulador das colônias de monócitos

MDA - Malondialdeído

MUFA – Ácidos graxos monoinsaturados

NADPH – Nicotinamida adenina dinucleotídeo

NPSH – Grupos tiólicos não-protéicos

PON1 – Paraoxonase 1

PUFA – Ácidos graxos poliinsaturados

SEM – Erro padrão da média

SH – Grupo sulfidrila

SOD – Superóxido dismutase

TBARS – Substâncias reativas ao ácido tiobarbitúrico

TG - Triglicerídeos

TrxR-1 – Tioredoxina redutase 1

Trx-1 – Tioredoxina 1

SFA – Ácidos graxos saturados

USFA- Ácidos graxos insaturados

LISTA DE FIGURAS

INTRODUÇÃO

1. Doenças cardiovasculares e aterosclerose

De acordo com dados da Organização Mundial da Saúde (WHO), as doenças cardiovasculares, tais como doença arterial coronariana, acidente vascular cerebral, doença arterial periférica, doença arterial congênita e falência cardíaca são a principal causa de morte ao redor do mundo, sendo responsáveis por 17,1 milhões de mortes no ano de 2004, ou seja, 29% do número de mortes mundial (WHO, 2009). Nessa estimativa, 7,2 milhões de mortes estão associadas a ataques cardíacos e 5,7 milhões de mortes estão associadas a acidente vascular cerebral. Em 2002 o Brasil apareceu em 9º lugar na lista dos países com maior número de mortes (números absolutos) por doenças cardíacas (139.601mortes) e em 6º em mortes por acidente vascular cerebral (129.172 mortes) (WHO, 2004). Nesse contexto, estima-se que em 2030 23,6 milhões de pessoas morram de doenças cardiovasculares (WHO, 2009).

A aterosclerose é definida como uma doença inflamatória crônica caracterizada pela formação de placas de constituição fibrosa e lipídica (ateromas) que diminuem progressivamente o diâmetro de vasos sanguíneos, podendo resultar na obstrução dos mesmos (Berliner et al., 1995). Essa patologia, induzida ou influenciada por acúmulo de lipídios, é a principal causa de infarto agudo do miocárdio, acidente vascular cerebral e demais doenças vasculares (Glass e Witztum, 2001) e sua prevenção passa pela identificação e controle do conjunto dos fatores de risco (Sociedade Brasileira de Cardiologia, 2001). Os fatores clássicos no desenvolvimento da arterosclerose são tabagismo, hipertensão arterial sistêmica, diabetes melito, idade, histórico familiar (Sociedade Brasileira de Cardiologia, 2001), níveis elevados de colesterol total (CT), lipoproteína de baixa densidade (LDL) e triglicerídeos (TG), níveis baixos de lipoproteína de alta densidade (HDL) (Brewer, 2004) e aumento dos níveis dos marcadores inflamatórios (Libby, 2002) e agregação plaquetária (Furman et al., 1998).

2. Hipercolesterolemia

A hipercolesterolemia, particularmente altos níveis de LDL, é um fator de risco independente para o desenvolvimento da aterosclerose, podendo acelerar o desenvolvimento e progressão da aterogênese (McKenney, 2001). Enquanto a HDL é constituída por 52% de proteínas e 48% de lipídios (Forti e Diament, 2006), a LDL é composta por 78% de lipídios (sendo 45% de colesterol livre ou esterificado) e 22% de proteínas (Figura 1) e constitui a principal forma de transporte de colesterol na circulação (Farmer e Gotto, 2002). Assim, um aumento na ingestão de colesterol na dieta implica diretamente em aumento pronunciado nos níveis de LDL.

Figura 1: Ilustração da estrutura da LDL, onde observamos a fração protéica (apo-B, rosa), fosfolipídios (verde) e colesterol livre (amarelo). Extraído de Steinberg (2002).

3. Ácidos graxos

A quantificação de ácidos graxos (AG) circulantes no plasma seja na forma livre ou esterificada (TG, fosfolipídios e ésteres de colesterol) tem sido empregada como instrumento

na avaliação objetiva do tipo de gordura consumida por humanos (Andersen et al., 1999). Além do consumo via dieta, onde são transportados pelas lipoproteínas, os AG podem ser sintetizados endogenamente por processos de elongação e dessaturação, gerando AG monoinsaturados (MUFA) e AG poliinsaturados (PUFA) (Vaz et al., 2006). AG essenciais, como o ácido linolênico (18:3 n-3) e ácido linoléico (18:2n-6), não são sintetizados endogenamente nos seres humanos e em alguns animais, devido à carência de enzimas dessaturases e hidrogenases específicas. Esses AG são sintetizados, exclusivamente, pelo reino vegetal e obtidos através da dieta (Schaefer, 2002), podendo sofrer modificações no organismo humano. Portanto, os PUFAs ácido eicosapentaenóico (EPA, 20:5 n-3) e docosahexaenóico (DHA, 22:6 n-3), são produtos do metabolismo do ácido α-linolênico, assim como o PUFA araquidônico (20:4 n-6) é o produto do metabolismo do ácido linoléico (Schaefer, 2002). Após os processos de absorção, transporte intracelular e plasmático e síntese, os AG serão utilizados como fonte de energia, na estrutura de membranas e, no caso dos AG essenciais, como precursores de eicosanóides. Os AG também serão importantes em uma série de sistemas fisiológicos, e como mediadores das respostas imune e inflamatória (Vaz et al., 2006). Um exemplo disso é a relação positiva entre níveis circulantes adequados de PUFA, especialmente os da série n-3, e a função cardiovascular (Harris e Isley, 2001). Uma partícula de LDL típica contém 2700 moléculas de AG incorporadas nas várias classes de lipídios, sendo que 50% desses AG são PUFA (Keaney e Frei, 1994). Uma vez que os PUFAs são suscetíveis à processos de oxidação (Keaney e Frei, 1994), o comprometimento desses AG pode ter conseqüências significativas para a função do sistema cardiovascular.

4. Modificação oxidativa da LDL

As lipoproteínas atravessam as células endoteliais intactas por transporte vesicular (transcitose), o qual não requer receptores. A magnitude desse transporte é concentração-dependente; níveis elevados de LDL resultam em aumento da quantidade do composto que atinge a íntima, através de endotélio intacto (Schenke e Carew, 1989a; Schenke e Carew, 1989b). Níveis elevados de colesterol induzem um aumento na síntese de prostaglandinas pela via das ciclooxigenases, fazendo com que as células endoteliais e celulas musculares lisas liberem ânion superóxido durante o processo (Lee e Prasad, 2003).

Durante a síntese de prostaglandinas pela via enzimática, as ciclooxigenases incorporam oxigênio molecular aos ácidos graxos poliinasturados (PUFAs), presentes em grandes quantidades na LDL, gerando hidroperóxidos lipídicos. Os PUFAs com elétrons desemparelhados seguem a rota oxidativa em sucessivas reações em cadeia, desencadeando o processo de peroxidação lipídica (Steinbrecher et al., 1990). Dessa maneira, por ação do ânion superóxido e das ciclooxigenases, ocorre há a formação de LDL minimamente oxidada (LDL mmox), caracterizada pela oxidação dos componentes lipídicos da LDL, com poucas alterações na fração protéica (Berliner et al., 1995). A LDL mmox induz a produção, pelas células endoteliais, de potentes ativadores dos monócitos, como a proteína quimiotáxica para monócitos (MPC-1) e o fator estimulador das colônias de monócitos (M-CSF), resultando na ativação de monócitos circulantes que migram para o espaço subendotelial e são diferenciados até macrófagos. Os macrófagos secretam espécies reativas de oxigênio (EROs), causando a oxidação da fração protéica da LDL, originando a LDL altamente oxidada (LDLox) (Berliner et al., 1995). A LDLox deixa de ser reconhecida pelos receptores normais dos macrófagos, responsáveis pelo efluxo de colesterol e passa a ser reconhecidas por receptores específicos nos macrófagos, denominados receptores "scavenger" (Sparrow et al., 1989). Tais receptores não sofrem regulação e acumulam LDLox ilimitadamente em seu interior, originando as células espumosas. Essas células são características das estrias gordurosas presentes nas

lesões ateroscleróticas, que podem progredir até a ruptura, precipitando eventos clínicos como ataque cardíaco e derrames (Stocker e Keaney, 2004). A representação do processo de oxidação da LDL até a formação das estrias gordurosas pode ser visualizada na figura 2.

Figura 2: Ilustração do processo de oxidação da LDL e formação das células espumosas. Adaptado de Steinberg et al. (1989). LDLox = LDL oxidada; M-CSF = fator estimulador das colônias de monócitos; MCP-1 = proteína quimiotáxica para monócitos.

5. EROs, estresse oxidativo e aterosclerose

O estresse oxidativo pode ser definido como uma condição resultante do desequilíbrio entre a produção de espécies oxidantes (como as EROs) e os sistemas de remoção das espécies oxidantes, denominados sistemas antioxidantes (Sies, 2000). A produção de radicais livres e o estresse oxidativo têm sido apontados como causa do desenvolvimento da aterosclerose durante a hipercolesterolemia (Prasad e Kalra, 1993), uma vez que a modificação biológica mais relevante da partícula de LDL é causada por reações de oxidação (Morel et al., 1984). Tais reações são associadas a EROs como o ânion radical superóxido

[˙O$_2^-$], radical hidroxil [˙OH] e peróxido de hidrogênio [H$_2$O$_2$] (figura 3) (Morel et al., 1984). O radical superóxido é gerado em todas as células aeróbias a partir da redução parcial do oxigênio molecular por um elétron na cadeia de transporte de elétrons, particularmente entre os complexos I e III (Carreras, 2004). Adicionalmente, vários sistemas enzimáticos podem levar a geração de radical superóxido, participando assim de eventos oxidativos relevantes ao processo aterogênico. Um desses sistemas é o sistema NADPH oxidase, que quando ativado em células fagocíticas (como os macrófagos) origina o ânion superóxido, que será utilizado na formação de ácido hipocloroso, espécie reativa tóxica para microrganismos (Sies, 1985). O radical superóxido pode ser gerado também durante a síntese de prostaglandinas no retículo endoplasmático liso das células. Nesse processo de conversão do ácido araquidônico a prostaglandinas ocorre adição de oxigênio molecular em algumas etapas de reação, o que pode levar a geração de ânion superóxido se sua redução for incompleta (Nelson e Cox, 2000). Ambos os sistemas enzimáticos estão intimamente relacionados com o estresse oxidativo durante a aterosclerose (Madamanchi et al., 2005). Outro sistema enzimático importante na geração de ânion superóxido é o sistema da xantina oxidase, envolvido no catabolismo de purinas e formação de ácido úrico. Durante as reações desse sistema, há geração de radical superóxido (Murray et al., 1996). Tem sido descrita a ativação do sistema xantina oxidase em pacientes com doença arterial coronariana (Spiekermann et al., 2003). Independentemente do sistema gerador, a formação do radical superóxido parece ser um evento importante durante a aterosclerose induzida por hipercolesterolemia (Ohara et al., 1993).

A eliminação do radical superóxido pode ser feita pela enzima superóxido dismutase (SOD), resultando na formação de peróxido de hidrogênio (figura 3) (Halliwell e Gutteridge, 1990). De acordo com Stralin et al. (1995), a SOD na sua isoforma extracelular (ECSOD) é a isoforma majoritária na parede arterial, participando de forma ativa na remoção do ânion

superóxido gerado em eventos pré-ateroscleróticos. Assim, por ação da SOD, as vias geradoras de radical superóxido indiretamente contribuem para a formação de peróxido de hidrogênio. Entretanto, outros eventos como a oxidação de ácidos graxos nos peroxissomos celulares e a oxidação de flavoproteínas desidrogenases pelo oxigênio molecular também contribuem para a geração desta ERO (Nelson e Cox, 2000). Recentemente foi demonstrado que o peróxido de hidrogênio é um regulador da proliferação de células vasculares em humanos durante eventos ateroscleróticos (Panchenko et al., 2009).

O peróxido de hidrogênio pode ser removido pela enzima catalase (CAT), que atua na remoção do peróxido de hidrogênio gerando oxigênio e água (figura 3) (Hunt et al., 1998). Outro sistema removedor de peróxido de hidrogênio é composto pelo tripeptídeo glutationa (GSH) em conjunto com duas enzimas, a glutationa peroxidase (GSH-Px) e a glutationa redutase (GR). Esse sistema opera em ciclos, uma vez que a GSH reduz o H_2O_2 a H_2O em reação catalisada pela GSH-Px. Nesse processo a GSH é oxidada e, em um segundo momento, é regenerada pela GR utilizando equivalentes redutores da nicotinamida adenina dinucleotídeo (NADPH) (figura 3) (Flohé e Brand, 1969). Apesar de compartilhar o mesmo substrato (H_2O_2), ambos os sistemas enzimáticos funcionam de forma diferenciada. Enquanto a GSH-Px remove pequenas quantidades de H_2O_2 (Km da enzima é de 1 μM) (Flohé e Brand, 1969), a CAT age de forma mais significativa contra níveis elevados de H_2O_2 (Km da enzima é de 25 mM) (Aebi, 1984). Recentemente, a atividade reduzida da GSH-Px foi apontada como um fator de risco independente para eventos cardiovasculares em pacientes com doença arterial coronariana (Blankenberg et al., 2003).

O radical hidroxil [HO$^-$] é a ERO mais deletéria ao organismo, pois devido a sua meia-vida muito curta dificilmente pode ser seqüestrado *in vivo*. Adicionalmente, mamíferos não possuem sistemas de detoxificação enzimáticos desse radical (Sies, 1985). Assim, antioxidantes não enzimáticos como a GSH, as vitaminas C e E, bem como flavonóides e

carotenóides têm sido apontados como os principais agentes removedores do radical hidroxil (Sies, 1993). Além disso, extratos de plantas contendo substâncias antioxidantes têm mostrado potencial na remoção desse radical (Gao et al., 1999; Silva et al., 2007). O principal efeito deletério do radical hidroxil reside na sua ação sobre lipídios de membrana, processo denominado peroxidação lipídica. O radical hidroxil ataca a cadeia lipídica em sítios susceptíveis como o grupo metilênico alílico, convertendo-o em novo centro de radical livre, desencadeando reações em cadeia que culminam com a formação de produtos de oxidação biologicamente ativos, como o malondialdeído (MDA) e o 4-hidroxinonenal (Barreiros e David, 2006).

6. Tioredoxina redutase

Em conjunto com as enzimas removedoras de H_2O_2 clássicas (CAT e GSH-Px), a enzima tioredoxina redutase (TrxR) também participa de forma ativa na remoção de H_2O_2 e outros peróxidos (figura 3). A TrxR é uma selenoflavoproteína que em conjunto com a proteína Trx e o NADPH forma o sistema da tioredoxina, um sistema efetivo para a redução de proteínas na forma dissulfeto (Holmgren & Björnstedt, 1995). O sistema da tioredoxina exerce diversas funções importantes em nível celular, como a regulação da apoptose e da resposta imune (Nordberg & Arnér, 2001). Adicionalmente, esse sistema atua como doador de elétrons durante a síntese de DNA (Powis & Montfort, 2001) e para a GSH-Px plasmática (Björnstedt et al., 1994) permitindo que essa enzima reduza hidroperóxidos mesmo com baixos níveis de GSH disponíveis (Wassmann et al., 2004).

Três isoformas das TrxR já foram identificadas incluindo a TrxR citosólica (TrxR-1), a mitocondrial (TrxR-2) e uma terceira isoforma isolada de mitocôndria de testículos de ratos (TrxR-3) (Nordberg & Arnér, 2001). Uma característica particular da TrxR-1 é a ampla especificidade de substratos, uma vez que a TrxR-1 é responsável pela redução não apenas da

Trx, mas também de hidroperóxidos (May et al., 2002), ácido lipóico, ubiquinona e deidroascorbato (Nordberg & Arnér, 2001). Assim, tem sido atribuído ao sistema tioredoxina uma função primordial na manutenção do estado redox da célula, podendo atuar no sistema de regulação da expressão de genes redox-sensíveis, através da ativação de fatores de transcrição (Nordberg & Arnér, 2001). Adicionalmente, sugere-se que a TrxR possa funcionar como um sensor redox celular (Sun et al., 1999).

Apesar do papel importante da enzima TrxR na defesa antioxidante e controle da da produção de EROs intracelular (Nordberg & Arnér, 2001), seu papel em eventos cardiovasculares ainda não está bem definido. A proteína Trx é muito expressada em células endoteliais e células musculares lisas de artérias normais (Okuda et al., 2001) e a expressão da enzima aumenta significativamente em placas ateroscleróticas de roedores, particularmente em células endoteliais e macrófagos (Takagi et al., 1998). Em concordância com o aumento da expressão da Trx em placas ateroscleróticas, Furman et al. (2004) demonstraram que a expressão da enzima TrxR-1 aumenta em macrófagos humanos oriundos de placas ateroscleróticas em resposta a LDLox. Adicionalmente, em um estudo de Hägg et al. (2006) a LDLox induziu um aumento na expressão da TrxR em macrófagos oriundos de ateromas humanos e em sistema *in vitro*. Em conjunto, essas evidências sugerem que Trx e TrxR cooperam mutuamente na defesa antioxidante durante o processo de aterogênese.

Apesar das evidências existentes sobre a cooperação da Trx e TrxR em nível celular, o funcionamento do sistema tioredoxina no ambiente extracelular ainda não foi totalmente elucidado. Sabe-se que os níveis de Trx aumentam no plasma em condições associadas a estresse oxidativo e inflamação, como a artrite reumatóide (Yoshida et al., 1999), infarto agudo do miocárdio (Miyamoto et al., 2003), angina (Hokamaki et al., 2005) e falência cardíaca crônica (Jekell et al., 2004). Esses relatos também sustentam a associação entre os níveis de Trx e doenças cardiovasculares. Entretanto, existem poucas evidências do

comportamento da enzima TrxR no plasma e sua relação com eventos cardiovasculares. Söderberg et al. (2000) demonstraram pela primeira vez a presença de TrxR no plasma de indivíduos saudáveis e a secreção da enzima parece ser realizada por monócitos circulantes como efeito protetor dessas células contra os radicais livres gerados durante a resposta inflamatória. Uma vez que os monócitos circulantes estão envolvidos na resposta contra a LDLox, é possível que a atividade da TrxR plasmática sofra alterações durante eventos cardiovasculares, tais como hipercolesterolemia e aterosclerose.

Figura 3: Principais EROs e reações de remoção de EROs pelas enzimas antioxidantes celulares. $O_2^{\cdot-}$ = ânion superóxido; H_2O_2 = peróxido de hidrogênio; $HO^{\cdot}$ = radical hidroxila; SOD = superóxido dismutase; CAT = catalase; GPX = glutationa peroxidase; Trx = tioredoxina; TrxR = tioredoxina redutase; NADPH = nicotinamida adenina dinucleotídeo; GSH = glutationa; GSSG = glutationa dissulfeto; GR = glutationa redutase. Inspirado em imagem do sítio na internet www2.iq.usp.br/redoxoma (acessado em 10/07/2010).

7. Ações da LDLox

A LDL-ox induz a formação de anticorpos específicos (LDLoxAB) e ambos têm sido encontrados em lesões ateroscleróticas e no sangue de pacientes hipercolesterolêmicos e portadores de doenças cardiovasculares (Palinski et al. 1990; Yla-Herttuala et al. 1994; Duarte et al., 2007; Itabe e Ueda 2007). A presença de LDLoxAB em lesões ateroscleróticas é apontada como um mecanismo preventivo, uma vez que tais anticorpos bloqueiam a captação da LDLox pelos macrófagos, prevenindo a formação das células espumosas (Shaw et al., 2001; Matssura et al., 2006).

Além da secreção de anticorpos específicos, a oxidação da LDL induz a produção de mediadores inflamatórios como a proteína C reativa (hs-CRP), um marcador de fase aguda de processos inflamatórios presente na doença arterial coronariana (Toss et al.,1997) e na hipercolesterolemia (Duarte et al., 2009). Em populações sem antecedentes cardiovasculares e de forma independente dos fatores de risco normalmente avaliados, níveis elevados de PCR são preditores de infarto do miocárdio e acidente vascular encefálico (Esporcatte et al., 2004). A presença de altas concentrações de hs-CRP inibe a síntese do óxido nítrico nas células endoteliais, facilitando a apoptose destas células e bloqueia a angiogênese (Verma et al., 2002). Seus efeitos pró-aterogênicos são evidenciados pelo estímulo à migração e proliferação das células musculares lisas, bem como a produção de espécies reativas de oxigênio (EROs) (Wang et al., 2003; Verma et al., 2004).

8. Paraoxonase

Enquanto a presença de LDL em níveis elevados no sangue é apontada como o principal fator de risco para doenças cardiovasculares, estudos epidemiológicos indicam uma relação inversa entre os níveis sanguíneos de HDL e o risco de doença aterosclerótica

(Assmann e Gotto, 2004; Asheikh et al., 2005; Linsel-Nitschke e Tall, 2005). Classicamente, esse efeito protetor está relacionado à função primordial da HDL, o transporte do colesterol dos tecidos para o fígado, que faz a conversão desse colesterol em sais biliares (Fielding e Fielding, 1995). Entretanto, um mecanismo alternativo tem sido sugerido para o papel da HDL na prevenção da aterosclerose: a capacidade dessa lipoproteína em prevenir a oxidação da LDL via mecanismos enzimáticos (Durrington e Mackness, 2001). Embora muitas enzimas associadas a HDL tenham sido relacionadas à capacidade antioxidante dessa lipoproteína, numerosas evidências sugerem que a enzima paraoxonase (PON1) é o principal componente da HDL responsável pela inibição da oxidação da LDL (Mackness et al., 1997; Aviram et al., 1999). A PON1 é uma enzima sintetizada no fígado e carreada na corrente sanguínea, mais conhecida por sua habilidade em hidrolizar metabólitos ativos de muitos inseticidas organofosforados (Costa et. al, 2005). Adicionalmente, a PON1 possui a capacidade de hidrolizar hidroperóxidos lipídicos (Mackness et al., 1991a). Essa capacidade tem sido associada à atividade de esterase, peroxidase e fosfolipase, que permite a PON1 inibir a formação de lipídios oxidados proinflamatórios ou degradá-los se houver sua formação. Assim, a PON1 modula a oxidação lipídica tanto na HDL quanto na LDL (Costa et al., 2003).

9. Carotenóides

Considerando que o estresse oxidativo está envolvido nos eventos que antecedem a patogênese da aterosclerose, manipulações na dieta com substâncias antioxidantes são descritas como alternativas de prevenção e controle da doença (Atkin et al., 2005). Os carotenóides são pigmentos naturais, sintetizados por plantas e microrganismos, conhecidos por suas propriedades antioxidantes. Devido ao fato de que a maioria dos carotenóides é transportada por lipoproteínas na corrente sanguínea, essas substâncias têm sido estudadas na

prevenção de doenças cardiovasculares (Agarwal e Rao, 2000). Osganian et al. (2003) observaram correlação inversa entre os níveis circulantes de β-caroteno e a ocorrência de doença arterial coronariana. Entretanto, tal correlação não foi observada para carotenóides como luteína, zeaxantina e β-criptoxantina. Além disso, o efeito protetor do carotenóide licopeno na prevenção de doenças cardiovasculares descrito por Fuhrman et al. (1997) ainda é controverso, uma vez que Frederiksen et al. (2007) relataram que a suplementação de coelhos hiperlipidêmicos com extrato de tomates rico em licopeno durante 24 semanas não foi capaz de reduzir a incidência da aterosclerose nesses animais. Apesar da controvérsia, já está disponível no mercado um medicamento a base de licopeno, o Ateronon[TM], indicado para prevenção e tratamento de doenças cardiovasculares. Dessa maneira, o real papel dos carotenóides nas doenças cardiovasculares ainda necessita ser elucidado.

10. Astaxantina

A astaxantina (ASX) é um pigmento pertendente a classe dos carotenóides oxigenados ou xantofilas, sintetizado principalmente por algas (*Haematococcus pluvialis*) e fungos (*Phaffia rizoma*) (Kurashige et al., 1990). A ASX é o principal pigmento em aves como o flamingo, peixes como o salmão e crustáceos como camarão e lagosta, que acumulam esse carotenóide após o consumo de algas produtoras. Por essa razão, a ASX é muito utilizada na aquicultura de salmão, camarão e lagosta a fim de conferir a coloração laranja adequada à comercialização dessas espécies (Higuera-Ciapara, 2006).

A estrututura química da ASX pode ser descrita como uma longa cadeia hidrocarbonada (40 átomos de carbono) com duplas ligações conjugadas e um anel aromático

contendo um grupo hidroxil e um grupo carbonil em cada extremidade da cadeia (Goto et al., 2001) (Figura 4).

Figura 4: Estrutura química da ASX. Extraído de Goto et al., (2001).

Embora não possua atividade pró-vitamina A, a ASX possui grande potencial antioxidante, sendo 100-500 vezes mais potente que o α-tocoferol (Naguib et al., 2000), além de combater eficientemente o radical hiroxil e o oxigênio singlete (Wu et al., 2006). Adicionalmente, a síntese de ASX em fungos é estimulada por ânion superóxido, peróxido de hidrogênio e oxigênio singlete, provavelmente como resposta de defesa contra essas EROs (Schroeder e Johnson, 1993; Schroeder e Johnson, 1995; Liu e Wu, 2006). Essa elevada atividade antioxidante é associada à estrutura química da ASX, onde os grupos hidroxil dos anéis polares removeriam radicais livres na superfície da membrana e a cadeia hidrocarbonada agiria como antioxidante no interior hidrofóbico da membrana (Goto et al., 2001).

Apesar do elevado potencial antioxidante da ASX e da participação do estresse oxidativo no início e manutenção da aterosclerose, existem poucos estudos avaliando o potencial antiaterogênico deste carotenóide. Em um estudo de Li et al. (2004), a ASX conferiu estabilidade às placas ateromatosas por diminuir a infiltração de macrófagos e a apoptose das células, enquanto Iwamoto et al. (2000) relataram a inibição da oxidação de LDL humana *in vitro* pela ASX**.** Adicionalmente, Spiller et al. (2006) demonstraram que a

suplementação de indivíduos saudáveis com 4 mg/dia de ASX durante 8 semanas causou uma redução nos níveis circulantes de hs-CRP, sugerindo que a ASX diminuiu a ocorrência do processo inflamatório nestes indivíduos. Entretanto, Jacobsson et al. (2004) observaram que a suplementação de coelhos hiperlipidêmicos com ASX durante 16 semanas não inibiu a oxidação da LDL ou a ocorrência de aterosclerose nesses animais. Adicionalmente, um estudo recente tem apontado a ASX como um novo potencial tratamento para o estresse oxidativo e inflamação em doenças cardiovasculares, particularmente na injúria causada por isquemia-reperfusão e na oclusão trombótica vascular (Paskow et al., 2008). Apesar da existência de vários estudos comprovando o potencial antioxidante da ASX, seu uso na prevenção e tratamento de doenças cardiovasculares permanece controverso, provavelmente devido às diferenças entre os estudos no que diz respeito aos modelos utilizados (*in vitro*, animais, humanos). No Brasil, a ASX é disponível para uso na aqüicultura por importação de empresas estrangeiras, o que causa um aumento nos custos de produção de pescados e frutos-do-mar. Além disso, existem poucos suplementos nutracêuticos à base deste carotenóide para consumo humano, sendo freqüentemente comercializados como uma mistura de carotenóides (Calibex, 2008). Desta maneira, a elucidação do real potencial desse carotenóide contra doenças cardiovasculares, pode estimular um aumento na produção de nutracêuticos à base de ASX e introduzir o Brasil no mercado produtor de ASX para uso na aqüicultura.

OBJETIVOS

1. Objetivo geral

Verificar a participação do estresse oxidativo e hipercolesterolemia no processo de aterogênese em animais e humanos, bem como verificar o potencial antioxidante, hipolipidêmico e antiaterogênico do carotenóide ASX.

2. Objetivos específicos

- Avaliar parâmetros de estresse oxidativo no soro de indivíduos com diferentes níveis de LDL, correlacionando com os níveis do indicador de processo inflamatório hs-CRP.

- Avaliar o comportamento da enzima TrxR-1 no soro e tecido aórtico de coelhos hipercolesterolêmicos bem como no soro de indivíduos com diferentes níveis de LDL.

- Avaliar a atividade da enzima PON1 no soro de coelhos hipercolesterolêmicos e de indivíduos com diferentes níveis de LDL.

- Avaliar o potencial hipolipidêmico, antiaterogênico e antioxidante da ASX em coelhos hipercolesterolêmicos.

.

PARTE II

CAPÍTULO I

Thioredoxin reductase and paraoxonase activities in subjects with different low density lipoprotein levels: relationship with oxidative and inflammatory processes.

Paula R. Augusti, Greicy M.M. Conterato, Juliana T. Vicentini, Sabrina Somacal, Andréia Quatrin, Amanda R. Ruviaro, Marta M.M.F. Duarte, Tatiana Emanuelli

Thioredoxin reductase and paraoxonase activities in subjects with different low density lipoprotein levels: relationship with oxidative and inflammatory processes.

Paula R. Augusti[1,2], Greicy M.M. Conterato[3], Juliana T. Vicentini[3], Sabrina Somacal[3], Andréia Quatrin[3], Amanda R. Ruviaro[3], Marta M.M.F. Duarte[4], Tatiana Emanuelli[3*].

[1] Graduate Program on Biological Sciences/Biochemistry, Department of Biochemistry, Institute of Health Basic Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil;

[2] Center for Agricultural Sciences, Foundation Federal University of Pampa, Itaqui, RS, Brazil.

[3] Integrated Center for Laboratory Analysis Development (NIDAL), Department of Food Technology and Science, Center of Rural Sciences, Federal University of Santa Maria, Santa Maria, RS, Brazil.

[4] Departament of Health Sciences, Lutheran University of Brazil, Santa Maria, RS, Brazil.

*Corresponding author: tatiemanuelli@gmail.com (Tatiana Emanuelli)
Tel.: +55 55 3220 8547; fax: +55 55 3220 8353.

Abstract

Objectives: This study aimed at assessing paraoxonase (PON1) and thioredoxin reductase (TrxR-1) activities and their relationship with lipids, oxidative stress and inflammation in subjects with different low-density lipoprotein (LDL) levels.

Design and Methods: Serum lipids, high-sensitivity C-reactive protein (hs-CRP), lipids and proteins oxidation, oxidized LDL (LDLox) and LDLox autoantibodies (LDLoxAB) levels, PON1, TrxR-1 and superoxide dismutase (SOD) activities were measured in group I (N=42, LDL levels <130 mg/dL), group II (N=34, LDL levels between 130 and 160 mg/dL) and group III (N=41, LDL levels >160 mg/dL).

Results: Lipid and protein oxidation increased in group III, while LDLox, LDLoxAB and hs-CRP levels as well as TrxR-1 and SOD activities increased equally in groups II and III. PON1 activity did not change among groups.

Conclusion: Inflammatory and oxidative events initiate when LDL levels are clinically acceptable and the meaning of TrxR-1 and PON1 behaviors in this study needs to be elucidated.

Keywords: Hypercholesterolemia; Protein carbonyl content; Thiobarbituric acid reactive substances; Oxidized low density lipoprotein.

1. Introduction

Atherosclerosis is the main underlying mechanism of leading causes of death, such as heart and brain disorders [1]. Hypercholesterolemia (HC), especially high levels of low density lipoprotein-cholesterol (LDL), seems to be an important risk factor accounting for severe atherosclerotic diseases, since LDL enters into vessels by a concentration-dependent mechanism [2]. Once into the endothelium, LDL suffers oxidative attack by reactive oxygen species (ROS) on its lipid and protein components, generating oxidized LDL (LDLox) [3]. Additionally, LDLox can initiate and enhance the inflammatory process, which plays a pivotal role in the development of atherosclerotic changes [4]. Accordingly, the levels of highly sensitive C-reactive protein (hs-CRP), an inflammation marker, are enhanced in patients with high levels of total cholesterol [5].

It has been suggested that high density lipoprotein (HDL) protects LDL particles from the oxidative process and subsequent inflammation [6]. This protective action of HDL is due to its associated enzyme paraoxonase1 (PON1) [6]. Although PON1 protects against atherosclerosis in both *in vitro* and *in vivo* models [7] and PON1 activity is inversely associated to the incidence of coronary artery disease [8], there is no data on the behavior of PON1 during different stages of HC.

Another line of defense against oxidative stress during HC set on enzymatic defenses such as superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px), which play an important role in alleviating negative effects from ROS generation. Thioredoxin reductase (TrxR-1) is a redox-active selenoprotein that efficiently regenerates oxidized thioredoxin protein (Trx-1) to its reduced form [9]. Reduced Trx-1 acts as antioxidant maintaining the reduced state of many proteins [9]. Furthermore, TrxR-1 is overexpressed and released during oxidative stress and has been recently detected in plasma [10]. Although elevated Trx-1 levels have been found during heart failure, fulminant

myocarditis and coronary vasospasm in humans [11-13], few reports are available on TrxR-1 participation during coronary events and/or in patients with major risk factors, such as HC.

Considering the growing evidences about reduced PON1 activity as a predictive factor for cardiovascular diseases in humans and the link between HC, oxidative stress and inflammation in atherogenesis, the aim of this study was to evaluate the behavior of PON1 activity at different stages in the development of HC and the association between PON1 activity, oxidative stress and inflammation markers and circulating lipids in the blood of subjects with different LDL levels. We also investigated the behavior of TrxR-1 activity at different stages of HC and its relationship with the oxidative and inflammatory processes. Results will contribute to clarify the role of PON1 and TrxR-1 in atherosclerosis.

2. Material and methods

2.1. Study population

Population studied consisted of patients from LABIMED (Santa Maria, RS, Brazil). All subjects gave written informed consent to participate in the study. The protocol was approved by the Research Ethics Committee of the Federal University of Santa Maria (Protocol number: 23081.019182/2007-10). Subjects were divided into three groups according to serum LDL levels, as follows: group I, LDL levels <130 mg/dL (3.4 mmol/L); group II, LDL levels ranging from 130 to 160 mg/dL (3.4-4.15 mmol/L); and group III, LDL levels > 160 mg/dL (4.15 mmol/L). These LDL ranges were selected to correspond approximately to the actual clinical interval criterion for cardiovascular risk factors, where LDL levels < 130mg/dL are considered safe; between 130 to 160 mg/dL are clinically acceptable, but close to the limit; and LDL levels > 160 mg/dL are considered to be well above the safe limit for risk of cardiovascular disease. Smokers, patients with blood glucose

levels >95 mg/dL and patients undergoing hypolipemic or anti-inflammatory treatment were excluded from the study.

2.2. Sample collection and analysis

Blood samples were collected after a 12-h overnight fasting by venous puncture into Vacutainers® (BD Diagnostics, Plymouth, UK) tubes with no anticoagulant. Blood samples were routinely centrifuged within 1 h of collection for 15 min at 2500 x g, and aliquots of serum samples were immediately used to assess TBARS levels and TrxR-1 activity. Then, serum samples were stored at −20°C for a maximum of 4 weeks before remaining measurements. Total cholesterol (TC) and triglyceride (TG) concentrations were measured by standard enzymatic methods using Ortho-Clinical Diagnostics® reagents on a fully automated analyzer (Vitros 950® dry chemistry system; Johnson & Johnson, Rochester, NY, USA). HDL cholesterol was measured after precipitation of apolipoprotein B-containing lipoproteins with dextran sulfate and magnesium chloride, as previously described [14]. LDL was estimated with the Friedewald equation [15]. Hs-CRP was measured by nephelometry (Dade Behring, Newark, DE, USA), while LDLox was determined by a capture ELISA according to the manufacturer instructions (Mercodia AB, Uppsala, Sweden) and as described before [16]. LDLoxAB were determined using ELISA as described by Wu and Lefvert [17]. Lipid peroxidation, measured as TBARS levels, was assessed after the addition of 7.2 mM of butylated hydroxytoluene to prevent further oxidation, reaction with thiobarbituric acid and extraction with *n*-butanol as previously described [18]. The reaction product was determined at 535 nm using a standard curve of 1,1,3,3-tetraethoxypropane. Protein oxidation was assessed as protein carbonyl content based on the reaction of the carbonyl groups with 2,4-dinitrophenylhydrazine to form 2,4-dinitrophenylhydrazone [19]. Samples were read at 370 nm and carbonyl content was calculated using the molar absorption coefficient for aliphatic

29

hydrazones (22,000 M^{-1} cm^{-1}). SOD activity was determined at 480 nm using 50 mM glycine buffer, pH 10.2, and 1 mM epinephrine at 30°C [20]. SOD activity was expressed as the amount of enzyme that inhibits the auto-oxidation of epinephrine to adrenochrome by 50%, which is equal to 1 unit. TrxR-1 activity was determined using 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) and adenine dinucleotide phosphate reduced. The method is based on the reduction of DTNB, which is indicated by an increase in absorbance at 412 nm [21]. PON1 activity was assessed by measuring the rate of paraoxon hydrolysis to yield p-nitrophenol, at 412 nm and 25°C [22]. The amount of p-nitrophenol generated was calculated using the molar extinction coefficient 17,000 M^{-1} cm^{-1} and 1 U of PON1 activity is defined as 1 nmol p-nitrophenol generated per minute [22].

2.3. Statistical analysis

Data were analyzed by one-way analysis of variance (ANOVA) followed by Duncan's test when appropriate. Data that did not exhibit a normal distribution were transformed (log or square root transformation) in order to meet ANOVA assumptions before analysis. When a variable was found not following normal distribution even after log or square root transformation, it was analyzed by the nonparametric Kruskal-Wallis ANOVA followed by the *post hoc* Dunn´s test when appropriate. The associations between variables were evaluated by Pearson's correlation for variables that had a normal distribution and by Spearman's rank order correlation for variables that did not exhibit a normal distribution. Results were considered significant when $p < 0.05$.

3. Results

Population characteristics are shown in Table 1. No significant differences were found between groups concerning age ($p > 0.05$). TC levels increased significantly along with the

increase in LDL levels among groups (p<0.05). TG levels were also higher in the high-LDL group when compared to the low-LDL group (p<0.05), but no differences were observed between the low and intermediate LDL groups. In contrast, HDL values of the low-LDL group were similar to those of the two other groups, but the intermediate-LDL group had higher HDL levels than the high-LDL group (p>0.05).

One-way ANOVA revealed that patients from high-LDL group showed significantly increased TBARS levels and protein carbonyl content when compared to the low and intermediate-LDL groups (p<0.05, table 2). The nonparametric Kruskal-Wallis test revealed that LDLox levels and the levels of the inflammatory marker hs-CRP increased in groups along with the increase in LDL levels (p<0.05, table 2), while LDLoxAB levels of patients from the intermediate and high-LDL groups were significantly higher than those from low-LDL groups (p<0.05, table 2).

SOD and TrxR-1 activity were significantly higher in patients from the intermediate and high-LDL groups compared to the low-LDL group (p<0.05), but no significant differences were found between the intermediate and high LDL groups (figures 1A e 1B). No significant differences were observed in PON1 activity among groups (p>0.05, figure 1C).

LDL levels were positively correlated to TC, TBARS levels, protein carbonyl content, LDLox, LDLoxAB and hs-CRP levels as well as SOD activity (p<0.05, table 3). In contrast, LDL levels had no significant correlation with age, HDL levels, TG levels, TrxR-1 or PON1 activities (p>0.05, table 3). TrxR-1 activity was positively correlated with SOD activity (p<0.05, figure 2A), while hs-CRP was positively correlated with LDLox as well as LDLoxAB (p<0.05, figure 2B and 2C). In addition, a positive correlation between TBARS and LDLox levels was also found (p<0.05, figure 2D).

4. Discussion

Cardiovascular diseases (CVD) are clearly the major cause of death in the Western world and there is no doubt that elevated plasma cholesterol levels play a dominant role in these diseases [23]. This can be evidenced by the occurrence of atheroma in aorta of hypercholesterolemic rabbits [24]. Thus, the control of LDL levels, which is the major cholesterol carrier in circulation, is an important step in the prevention of CVD [23]. The injury theory of atherosclerosis holds that circulating LDL accumulates at susceptible sites where they undergo modifications including oxidation of its protein and lipid components, generating LDLox [25]. LDLox, in turn, participates in the inflammatory processes, contributing to lesion progression [25]. Our results corroborate this theory, since elevated concentrations of TBARS and protein carbonyl groups, products of lipid and protein oxidation respectively, were found in patients from the high-LDL group. These results indicate that LDL levels above the safe limit induce serum lipid and protein oxidation. Accordingly, oxidation in serum lipids and proteins has been observed in hypercholesterolemic rabbits [26]. However, increased oxidation of LDL was found in the intermediate-LDL group even without lipid or protein oxidation. This can be explained because TBARS and protein carbonyl assays evaluated lipid and protein oxidation in the whole serum, not only LDL oxidation, which would render them less sensitive to oxidative changes in LDL. In addition, TBARS values mainly reflect malondialdehyde (MDA), an aldehyde derived from the oxidation of unsaturated fatty acids, providing little information about the extent of oxidation in other lipoprotein lipids, such as cholesterol [27]. Despite this, we observed a positive correlation between TBARS and LDLox, reinforcing that TBARS levels are at least partially associated to LDLox levels. Concerning the protein oxidation process, sometimes amino groups from LDL are attacked by oxidant species and proteins are converted to non-carbonyl species [28]. Thus, the protein carbonyl content assay may not reflect the whole extension of protein oxidation. Furthermore, increased LDLox levels in the

intermediate-LDL group suggest that LDL oxidation takes place even when LDL levels are considered clinically acceptable. We also observed that LDLox increased in the intermediate-LDL group accompanied by LDLoxAB elevation, probably as an attempt to prevent LDLox citotoxicity. In agreement, it has been demonstrated that LDLoxAB blocks the uptake of oxidized LDL by macrophages [29]. However, while LDLox levels increased in the high-LDL group when compared to the intermediate-LDL group, this increase was not accompanied by LDLoxAB elevation. This may indicate that the immune system plays a modifying important role in atherosclerosis under more "normal" conditions, as previously suggested [30]. Thus, in severely proatherogenic conditions, such as hypercholesterolemic situations, this role may be overshadowed by the proatherogenic lipoproteins [30]. This explanation is supported by the fact that mouse lacking both B and T cells (RAG-1 knockout) and apoE develop significantly less atherosclerosis than apoE single knockout mice when fed standard chow, but not when mice are fed a cholesterol-rich diet [31]. Although we found a positive correlation between LDL and LDLoxAB levels, we can not rule out that the immune response in the high-LDL group has been eclipsed by high LDL levels. All these data, along with the correlations between LDL levels and TBARS levels, protein carbonyl content, LDLox, LDLoxAB indicate that oxidative stress is an early event in the evolution of hyperlipidemia, as previously suggested [32].

Plasma lipoproteins are protected against oxidative modification by the antioxidant defense system of the organism, constituted by the enzymes SOD, glutathione peroxidase and catalase, as well as non-enzymatic hydrophilic antioxidants such as ascorbate, reduced glutathione and urate. All these molecules react with ROS or block free radical chain reactions [33]. The enzyme TrxR-1 along with protein Trx-1 has been recognized as an essential component for cellular redox control and antioxidant defense [34,35]. In this study, we demonstrated for the first time the behavior of serum TrxR-1 activity during different

stages of HC in humans, although an elevation in serum Trx-1 has already been described in patients with HC [36]. Additionally, results from our research group revealed an increase in serum TrxR-1 activity in hypercholesterolemic rabbits (unpublished data). We observed that TrxR-1 activity increased in the intermediate and high-LDL groups when compared to the low-LDL group. Thus, LDL levels close to limit, but still clinically acceptable may induce an increase of TrxR-1 activity, in order to prevent oxidative events. This hypothesis is corroborated by increased TrxR-1 expression in atherosclerotic plaques when compared to health tissue from the same patients [37]. The thioredoxin system (TrxR-1 and Trx-1) acts as a hydrogen peroxide (H_2O_2) scavenging system, reducing H_2O_2 to H_2O [38]. SOD activity had a behavior similar to that of TrxR-1 along the LDL-groups, which may indicate that TrxR-1 activity was increased to remove H_2O_2 produced by SOD. In fact, we found a weak, but significant correlation between TrxR-1 and SOD activities. The elevation of SOD activity in this study occurred most likely to counteract superoxide anion overproduction caused by HC [39]. Besides scavenging H_2O_2, we can speculate that TrxR-1 activity increased in the intermediate-LDL group in order to prevent protein oxidation in this group, by regenerating oxidized Trx-1 to its reduced form [9]. Thus, reduced Trx-1 can act as antioxidant maintaining the reduced state of many proteins [9]. Accordingly, we did not observe protein oxidation in the intermediate-LDL group when compared to the low-LDL group. Interestingly, SOD and TrxR-1 activities did not differ between the intermediate and high-LDL groups, which suggests that both enzymes may have an important role in early hypercholesterolemic events. Moreover, SOD and TrxR-1 activities are susceptible to oxidative stress [40, 41] and we can not rule out that the lack of changes in both enzymes in the high-LDL group when compared to the intermediate-LDL group may reflect a balance state between induction and inactivation process. Furthermore, we observed increased protein oxidation in the high-LDL group when compared to the low-LDL group, which probably is a

result from mild TrxR-1 inhibition process. Despite the interesting changes in TrxR-1 activity in this study, no correlation was observed between LDL levels and TrxR-1 activity.

Similar to TrxR-1, the behavior of PON1 activity at different stages of HC has not been demonstrated yet. PON1 is believed to be responsible for the antioxidant effects of HDL [6] and its activity is inversely associated with the progression of atherosclerosis and the incidence of coronary artery disease [42]. In agreement, previous results from our group revealed diminished serum PON1 activity along with atherosclerotic plaque in the aorta of hypercholesterolemic rabbits (unpublished data). Moreover, a large prospective study pointed low serum PON1 activity as an independent risk factor for coronary events in men at high risk of coronary heart disease [43]. However, we did not found differences in PON1 activity among the three studied groups or significant correlations between LDL levels and PON1 activity. This could be explained by an established balance between PON1 inactivation by oxidant species [43] and PON1 elevation in order to provide a protecting mechanism against oxidant species and atherosclerotic plaque progression [45]. In fact, PON has previously been shown to accumulate in the artery wall during atherosclerosis, with an increase in PON immunoreactivity with the progression of disease from fatty streaks to advanced plaques [45]. Also, these differences in PON1 activity between previous studies and ours can be due the fact that studies concerning PON1 and cardiovascular diseases usually evaluated the relationship between serum enzyme activity and plaque formation [46] or cardiovascular events such as myocardial infarction [43]. Here, we evaluated the relationship between PON1 activity and another known predicting factor for cardiovascular diseases, the LDL levels. Interestingly, despite the known inhibitory effect of LDLox on PON1 activity [47], we found no association between PON1 activity and LDLox levels. In fact, the lack of associations between LDLox and PON1 activity has already been described in conditions such as type 2 diabetes [48] and familial HC [49]. Moreover, PON1 seems not play a role in early

atherosclerosis, although it may play a role in a later stage of cardiovascular diseases [49]. Since the atheroma formation was not evaluated in this study, we can not rule out that unchanged PON1 activity and the lack of associations between PON1, LDL and LDLox levels are most likely because LDL levels evaluated in this study corresponded to early stages of atherosclerosis. Thus, the involvement of serum PON1 in subclinical vascular events, such as HC, needs further investigation before a final statement.

Oxidative stress leads to an inflammatory process as well as the inflammatory process induces continued oxidative stress [50]. Accordingly, we observed a significant correlation between LDLox and hs-CRP, a marker of inflammatory process. The level of hs-CRP in the serum of patients with different levels of TC and its relationship with LDLox has already been demonstrated [51]. Moreover, those authors found that serum hs-CRP increased only in the group with the highest levels of TC and with LDL levels similar of those of the high-LDL group of the present study. In contrast, we observed increased serum hs-CRP also in the intermediate-LDL group, which indicates that inflammation process takes place even when LDL levels are considered safe.

In conclusion, the present study demonstrated that inflammatory and oxidative events initiate even when LDL levels are clinically acceptable. Moreover, important changes in TrxR-1 activity in patients with intermediate and high-LDL levels were found in this study and need further investigations. Also, the actual role of serum PON1 as a predictor of cardiovascular events remains controversial.

References

[1] A. Tavridou, V. G. Manolopoulos, Novel molecules targeting dyslipidemia and atherosclerosis, Curr. Med. Chem. 5 (2008) 792-802.

[2] H. S. Kruth, Lipoprotein cholesterol and atherosclerosis, Cur.r Mol. Med. 1 (2000) 633-653.

[3] M. Batlouni, Hipótese oxidativa da aterosclerose, Arq. Bras. Cardiol. 68 (1997) 55-63.

[4] G. Francisco, C. Hernández, R. Simó, Serum markers of vascular inflammation in dyslipemia, Clin. Chim. Acta. 369 (2006) 1-16.

[5] R. R. S. Packard, P. Libby, Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction, Clin. Chem. 54 (2008) 24-38.

[6] M. Aviram, M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, B. N. La Du, Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase, J. Clin. Invest. 101 (1998) 1581-1590.

[7] M. I. Mackness, S. Arrol, C. Abbott, P. N. Durrington, Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase, Atherosclerosis 104 (1993) 129-135.

[8] M. Aviram, Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med. Today 5 (1999) 381-386.

[9] S. Gromer, L. Johansson, H. Bauer, L. D. Arscott, S. Rauch, D. P. Ballou, C. H. Williams, R. H. Schirmer, E. S. Arnér, Active sites of thioredoxin reductases: why selenoproteins? Proc. Natl. Acad. Sci. U S A 100 (2003) 12618-12623.

[10] A. Söderberg, B. Sahaf, A. Rosén, Thioredoxine reductase, a redoxactive selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma, Cancer Res. 60 (2000) 2281- 2289.

[11] C. Kishimoto, K. Shioji, H. Nakamura, Y. Nakayama, J. Yodoi, S. Sasayama, Serum thioredoxin (TRX) levels in patients with heart failure, Jpn. Circ. J. 65 (2001) 491 - 494.

[12] K. Shioji, Y. Matsuura, T. Iwase, S. Kitaguchi, H. Nakamura, J. Yodoi, T. Hashimoto, C. Kawai, C. Kishimoto, Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: A case report, Circ. J. 66 (2002) 977-980.

[13] K. Miwa, C. Kishimoto, H. Nakamura, T. Makita, K. Ishii, N. Okuda, A. Taniguchi, K. Shioji, J. Yodoi, S. Sasayama, Increased oxidative stress with elevated serum thioredoxin level in patients with coronary spastic angina, Clin Cardiol, 26 (2003) 177-181.

[14] P. S. Bachorik, J. J. Albers, Precipitation methods for quantification of lipoproteins, Methods Enzymol. 129 (1996) 78-100.

[15] W. T. Friedewald, R. I. Levy, D. S. Fredrickson, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge, Clin. Chem. 18 (1972) 499-502.

[16] P. Holvoet, J. M. Stassen, J. Van Cleemput, D. Collen, J. Vanhaecke, Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease, Arterioscler. Thromb. Vasc. Biol. 18 (1998) 100-107.

[17] R. Wu, A. K. Lefvert, Autoantibodies against oxidized low density lipoprotein (OxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL, Clin. Exp. Immunol. 102 (1995) 174-180.

[18] H. Ohkawa, N. Ohishi, K. Yagi, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Anal Biochem. 95 (1979) 351-358.

[19] R. L. Levine, D. Garland, C. N. Oliver, A. Amici, I. Climent, A. G. Lenz, B. W. Ahn, S. Shaltiel, E. R. Stadtman, Determination of carbonyl content in oxidatively modified proteins, Method. Enzymol. 186 (1990) 464-478.

[20] H. P. Misra, I. Fridovich, The role of superoxide anion in the auto-oxidation of epinephrine and a simple assay for superoxide-dismutase, J. Biol. Chem. 247 (1972) 3170-3175.

[21] A. Holmgren, M. Björnstedt, Thioredoxin and thioredoxin reductase, Meth. Enzymol. 252 (1995) 199-208.

[22] I. M. Bolayirli, M. Aslan, H. Balci, T. Altug, M. Hacibekiroglu, A. Seven, Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine, Life Sci. 81 (2007) 121-127.

[23] D. Steinberg, A.M. Gotto, Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside, J. Am. Med. Ass. 282 (1999) 2043-2050.

[24] P. R. Augusti, G. M. M. Conterato, S. Somacal, R. Sobieski, A. Quatrin, L. Maurer, M. P. Rocha, I. T. Denardin, T. Emanuelli. Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits, J. Cardiovasc. Pharmacol. Ther. 14 (2009) 314-322.

[25] D. Steinberg, Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin, Mol. Nutr. Food. Res. 49 (2005) 995-998.

[26] S. Aydin, H. Uzun, V. Sozer, T. Altug, Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits, Pharmacol. Res. 59 (2009) 242-247.

[27] A. E. Scoccia, M. S. Molinuevo, A. D. McCarthy, A. M. Cortizo, A simple method to assess the oxidative susceptibility of low density lipoproteins, BMC. Clinical. Pathol. 1 (2001) 1-7.

[28] L. Yan, J. K. Lodge, M. G. Traber, S. Matsugo, L. Packer, Comparison between copper-mediated and hypochlorite-mediated modifications of human low density lipoproteins evaluated by protein carbonyl formation, J Lipid Res 38 (1997) 992-1001.

[29] P. X. Shaw, S. Horkko, S. Tsimikas, M. Chang, W. Palinski, G. J. Silverman, P. P. Chen, J. L. Witztum, Human derived anti oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1333-1339.

[30] J. Hulthe, J. Wikstrand, A. Lidell, I. Wendelhag, G. K. Hansson, O. Wiklund, Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1203-1211.

[31] H. M. Dansky, S. A. Charlton, M. M. Harper, J. D, T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse, Proc. Natl. Acad. Sci. U S A 94 (1997) 4642- 4646.

[32] R. Yang, Y. Shi, G. Hao, W. Li, G. Le, Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index, J. Clin. Biochem. Nutr. 43 (2008) 154-158.

[33] B. Halhwell, J. M. C. Gutteridge, The importance of free radicals and catalytic metal ions in human diseases. Molec. Aspects Med. 8 (1985) 89- 193.

[34] J. Nordberg, E.S.J. Arner, Reactive oxygen species, antioxidants, and the mammalian thioredoxin system, Free Radic. Biol. Med. 31 (2001) 1287-1312.

[35] A. Sakurai, K. Yuasa, Y. Shoji, S. Himeno, M. Tsujimoto, M. Kunimoto, N. Imura, S. Hara, Overexpression of thioredoxin reductase I regulates NF-kappa B activation, J. Cell. Physiol. 198 (2004) 22-30.

[36] M. Kunihisa, K. Chiharu, H.Nakamura, T. Makita, K. Ishii, N. Okuda, J. Yodoi, S. Sasayama, Serum thioredoxin and α-tocopherol concentrations in patients with major risk factors, Circ. J. 69 (2005) 291-294.

[37] C. Furman, A.K. Rundlof, G. Larigauderie, M. Jaye, G. Bricca, C. Copin, A.M. Kandoussi, J.C. Fruchart, E.S.J. Arner, M. Rouis, Thioredoxin reductase 1 is upregulated in

atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins, Free Radic. Biol. Med. 37 (2004) 71-85.

[38] A. Holmgren, Antioxidant function of thioredoxin and glutaredoxin systems, Antioxid. Redox. Signal. 2 (2000) 811-820.

[39] Y. Ohara, T. E. Peterson, D. G. Harrison, Hypercholesterolemia increases endothelial superoxide anion production, J. Clin. Invest. 91 (1993) 2546-2551.

[40] D. C. Salo, R. E. Pacifini, K. J. N. Davies, Superoxide dismutase is preferentially degraded by a proteolytic system from red blood cells following oxidative modification by hydrogen peroxide, Free Radic. Biol. Med. 5 (1988) 335-339.

[41] Q. A. Sun, Y. Wu, F. Zappacosta, K. T. Jeang, B. J. Lee, D. L. Hatfield, V. N. Gladyshev, Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases, J. Biol. Chem. 274 (1999) 24522-24530.

[42] M. Aviram, Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med. Today. 5 (1999) 381-386.

[43] B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, M. Mackness, Low paraoxonase activity predicts coronary events in the Caerphilly prospective study, Circulation 107 (2003) 2775-2779.

[44] M. Aviram, Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases, Free Rad. Biol. Med. 37 (2004) 1301-1303.

[45] B. Mackness, R. Hunt, P. N. Durrington, M. I. Mackness, Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1233-1238.

[46] N. Jayakumari, G. Thejaseebai, High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease, J. Clin. Biochem. Nutr. 45 (2009) 278-284.

[47] M. Aviram, M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C. L. Bisgaier, R. S. Newton, B. La Du, Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants, Free Rad. Biol. Med. 26, (1999) 892-904.

[48] S. Kopprasch, J. Pietzsch, E. Kuhlisch, J. Graessler, Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus, J. Clin. Endocrinol.Metab. 88 (2003) 1711-1716.

[49] T.M. Van Himbergen, M. Roest, J. de Graaf, E.H. Jansen, H. Hattori, J.J. Kastelein, H.A. Voorbij, A.F. Stalenhoef, L.J. Van Tits, Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia, J. Lipid. Res. 46 (2005) 445-451.

[50] R. Mazor, R. Shurtz-Swirski, R. Farah, B. Kristal, G. Shapiro, F. Dorlechter, M. Cohen-Mazorad, E. Meilinad, S. Tamarae, S. Sela, Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients, Atherosclerosis 197 (2008) 937-943.

[51] M. M. F. Duarte, V. L. Loro, J. B. T. Rocha, D. B. R. Leal, A. F. de Bem, A. Dorneles, V. M. Morsch, M. R. C. Schetinger, Enzymes that hydrolyze adenine nucleotides of patients with hypercholesterolemia and inflammatory processes, FEBS J. 274 (2007) 2707-2714.

Table 1: Characteristics of the studied groups

	Groups (LDL-cholesterol levels)		
	I (< 130 mg/dL)	II (130-159 mg/dL)	III (> 160 mg/dL)
N	42	34	41
Age (years)	52.7±1.9 (28.0-77.0)	54.8±2.3 (29.0-87.0)	55.6±2.5 (31.0-75.0)
Sex (male/female)	23/19	17/17	16/25
TC (mg/dL)	160.4±5.6[a] (72.0-243.0)	222.0±2.7[b] (198.0-270.0)	275.3±6.3[c] (226.0-449.0)
TG (mg/dL)	115.8±11.0[a] (20.0-331.0)	138.8±16.2[ab] (46.0-430.0)	148.9±9.1[b] (67.0-300.0)
LDL (mg/dL)	91.5±3.9[a] (24.0-129.6)	145.5±1.8[b] (131.6-187.4)	203.8±6.0[c] (162.0-341.8)
HDL (mg/dL)	44.0±2.2[ab] (14.0-75.0)	48.8±2.4[a] (33.0-95.0)	41.7±2.0[b] (20.0-91.0)

Results are mean ± SEM (minimum – maximum). [a,b]Values within the same line that do not share a common superscript letter are significantly different (P<0.05). TC=total cholesterol; TG=triglycerides; LDL=low-density lipoprotein; HDL=high-density lipoprotein.

Table 2: Oxidative stress and inflammatory markers in patients with different LDL levels

	Groups (LDL-cholesterol levels)		
	I (< 130 mg/dL)	II (130-159 mg/dL)	III (> 160 mg/dL)
TBARS (nmol MDA/mL)	4.9$_\pm$0.2^a (2.4-8.5)	5.1$_\pm$0.2^a (2.8-7.0)	6.3$_\pm$0.3^b (4.0-13.3)
Protein carbonyl content (nmol/mg of protein)	1.3$_\pm$0.1^a (0.2-4.9)	1.3$_\pm$0.1^a (0.7-2.3)	1.9$_\pm$0.2^b (0.5-6.7)
LDLox (mg/L)	0.28$_\pm$0.04^a (0.0-1.1)	0.42$_\pm$0.05^b (0.06-1.7)	0.71$_\pm$0.07^c (0.03-1.9)
LDLoxAB (mg/L)	11.6$_\pm$1.7^a (0.7-36.0)	26.9$_\pm$1.1^b (16.7-46.4)	32.1$_\pm$1.4^b (9.2-54.7)
hs-CRP (mg/L)	0.4$_\pm$0.04^a (0.1-1.2)	1.05$_\pm$0.32^b (0.1-7.9)	1.5$_\pm$0.26^c (0.1-7.9)

Results are mean $\pm$ SEM (minimum – maximum). N= 34-42, as shown in Table 1. [a,b]Values within the same line that do not share a common superscript letter are significantly different (p<0.05). TBARS=thiobarbituric acid reactive substances; MDA=malondialdehyde; LDLox= oxidized LDL; LDLoxAB= LDLox autoantibodies; hs-CRP= highly sensitive C-reactive protein.

Table 3. Correlations of serum LDL with age, lipid levels, PON1 activity and oxidative stress and inflammation markers.

Parameters	LDL correlations coefficient
Age (years)	0.05
TC (mg/dL)	0.95*
HDL (mg/dL)	-0.04
TG (mg/dL)	0.18
TrxR- 1 (U/L)	0.1
Protein carbonyl (nmol/mg of protein)	0.25*
TBARS (nmol MDA/mL)	0.31*
SOD (U/L)	0.38*
PON1 (U/mL)	-0.016
LDLox (mg/L)	0.51*
LDLoxAB (mg/L)	0.64*
Hs-CRP (mg/L)	0.43*

The associations between LDL versus TC, HDL, TG, TrxR-1, carbonyl groups, TBARS and SOD were evaluated by Pearson's correlation, while the associations between LDL and PON 1, LDLox, LDLoxAB and hs-CRP were evaluated by Spearman's rank order correlation. Correlations were considered significant when $p < 0.05$. TC=total cholesterol; TG=triglycerides; TBARS=thiobarbituric acid reactive substances; MDA= malondialdehyde; SOD= superoxide dismutase; TrxR-1= thioredoxin reductase 1; PON1= Paraoxonase 1; LDLox= oxidized LDL; LDLoxAB= LDLox autoantibodies; hs-CRP= highly sensitive C-reactive protein.

Figures legends:

Figure 1. SOD (A), TrxR-1 (B) and PON1 (C) activities of patients with different LDL levels. Results are mean $\pm$ SEM (n = 34-42, as shown in Table 1). Different letters indicate a significant difference at $p < 0.05$ between groups. SOD= superoxide dismutase; TrxR-1= thioredoxin reductase 1; PON1= Paraoxonase 1.

Figure 2. Significant correlations between (A) TrxR-1 and SOD, (B) hs-CRP and LDLox, (C) hs-CRP and LDLoxAB and (D) TBARS and LDLox. TBARS= thiobarbituric acid reactive substances; MDA= malondialdehyde; SOD= superoxide dismutase; TrxR-1= thioredoxin reductase 1; LDLox= oxidized LDL; LDLoxAB= LDLox autoantibodies; hs-CRP= highly sensitive C-reactive protein.

Figure 1

Figure 2

CAPÍTULO II

Astaxanthin reduces oxidative stress, but not aortic damage in atherosclerotic rabbits

Paula R. Augusti, Greicy M.M. Conterato, Sabrina Somacal, Rocheli Sobieski, Andréia Quatrin,

Luana Maurer, Marta P. Rocha, Ione T. Denardin, Tatiana Emanuelli

Astaxanthin Reduces Oxidative Stress, but not Aortic Damage in Atherosclerotic Rabbits

Paula R. Augusti, MSc, Greicy M. M. Conterato, MSc,
Sabrina Somacal, BSc, Rocheli Sobieski, BSc, Andréia Quatrin,
Luana Maurer, Marta P. Rocha, MD,
Ione T. Denardin, MSc, and Tatiana Emanuelli, PhD

We evaluated whether carotenoid astaxanthin (ASX) could prevent oxidative and atherosclerotic damage in rabbits. Rabbits received regular chow (control) or an atherogenic diet (1% cholesterol) alone or supplemented with 50, 100, and 500 mg% ASX for 60 days (n = 5-9 per group). The atherogenic diet increased the serum cholesterol levels and the ratio of the intima/media area in the aortic arch. These changes were not prevented by ASX. Atherosclerotic rabbits showed increased aortic lipid peroxidation and nonprotein thiol group (NPSH) levels along with inhibition of glutathione peroxidase (GSH-Px). All ASX doses attenuated lipid peroxidation and the increase in NPSH but not the inhibition of GSH-Px. Aortic superoxide dismutase (SOD), catalase (CAT), and thioredoxin reductase (TrxR) activities were enhanced in atherosclerotic rabbits. Although all ASX doses prevented the increase in SOD activity, only 100 and 500 mg% ASX prevented the increase in CAT activity. Furthermore, these same doses partially prevented the increase in TrxR activity, while 50 mg% ASX completely prevented the effects of the atherogenic diet on this enzyme. However, ASX did not attenuate the hypercholesterolemia or the atherosclerotic lesions caused by the atherogenic diet at any of the doses evaluated. Our results indicate that although ASX did not prevent hypercholesterolemia or atherosclerotic lesions, it could play a beneficial role by preventing lipid peroxidation and changes in antioxidant enzyme activities.

Keywords: antioxidant enzymes; carotenoids; intima/media ratio; thiobarbituric acid reactive substances

Introduction

Atherosclerosis is an inflammatory disease of the arterial wall that remains a major cause of death and disability all over the world. High plasma levels of low-density lipoprotein (LDL) and its oxidation followed by LDL accumulation into macrophages residing in the arterial wall are a central feature in the development of atherosclerosis.[1,2] Low-density lipoprotein oxidation in vivo affects both its lipid and protein components[1] and generates biologically active oxidation products. The oxidation of lipids can be assessed by measuring thiobarbituric acid reactive substances (TBARS) that are an index of oxidative

stress. The cellular uptake of oxidized LDL leads to the generation of reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide (H_2O_2), or hydroxyl radicals, which have been implicated in the development of atherosclerosis during hypercholesterolemia.[3,4] Antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and thioredoxin reductase (TrxR) are able to protect cells against oxidative damage. In addition, nonenzymatic antioxidants such as glutathione (GSH), which is the major non protein thiol-containing compound in most tissues, may also prevent free radical-induced injury.[5] Due to the convincing evidence of the involvement of ROS in the atherogenic process, it would be worthwhile to find new antioxidant substances effective to counteract atherosclerosis.

Astaxanthin (ASX), a red carotenoid pigment without provitamin A activity, is a biological antioxidant that occurs naturally in a wide variety of living organisms such as plants, algae, and seafood.[6] Despite its antioxidant potential in lipid membranes,[7] there are few reports about the antiatherogenic potential of ASX. Astaxanthin inhibits human LDL oxidation in vitro and ex vivo[8] and stabilizes atherosclerotic plaques.[9] Moreover, ASX has been suggested as a novel potential treatment of oxidative stress and inflammation in cardiovascular disease, especially in ischemia-reperfusion injury and in vascular thrombotic occlusion.[6] However, supplementation with ASX for 24 weeks did not protect Watanabe heritable hyperlipidemic rabbits against LDL oxidation and atherosclerosis.[10]

The objective of this investigation is to clarify whether dietary supplementation with ASX attenuates oxidative damage and atherosclerosis by evaluating serum total cholesterol levels along with histopathological damage and markers of oxidative stress in the aortic tissue of atherogenic rabbits.

Methods and Materials

This study was approved by the Ethics and Animal Welfare Committee of the Federal University of Santa Maria (23081.019182/2007-10). Eight-week-old male New Zealand white rabbits were housed in individual cages, under a 12:12-hour light:dark cycle with access to 100 g chow (SUPRA, São Leopoldo, Brazil) per day and water ad libitum.

After 1 week of adaptation, the rabbits weighing 1.7 ± 0.03 kg were randomly divided into 5 experimental groups. The control group was fed a standard diet chow (SUPRA); the atherosclerotic group was fed the standard diet chow enriched with 1% cholesterol (Vetec, Brazil) to induce atherosclerotic lesions; ASX 50, ASX 100, and ASX 500 groups were fed the same cholesterol-rich diet plus 50, 100, and 500 mg of natural ASX (2% powder; Fuji Chemical Industry Co Ltd, Toyama, Japan) per 100 g chow, respectively. Cholesterol and ASX were dissolved in diethyl ether and sprayed on the standard chow to yield the cholesterol-enriched and ASX-supplemented diets. The standard chow of the control group was sprayed with diethyl ether (vehicle). The standard and supplemented chows were left to allow the ether to evaporate before storage protected from light and under refrigeration. Chows were prepared once a week. All animals received a daily portion of 100 g chow and their body weight was checked once a week.

The amount of cholesterol chosen for treating the animals was based on previous studies[11,12] and on a pilot study, which demonstrated that the dietary supplementation with 1% cholesterol for 60 days induced atherosclerotic lesions. Astaxanthin concentrations in the diets were chosen based on previous studies[9,10] and on the doses considered safe for humans.[13]

After 60 days of dietary treatment, the rabbits were food-deprived for 1 night and were killed with an intravenous overdose of thiopental. Blood samples were collected into tubes without additives and centrifuged at 3000g for 10 minutes. Serum was immediately removed and stored at $-20°C$ until analysis of cholesterol levels. Aortas (between the origin and the bifurcation of iliac arteries) were immediately excised and cleaned of gross adventitial tissue. Approximately 2 cm of the aortic arch was removed for histopathological examinations, and the remaining tissue was homogenized in 10 volumes of 150 mmol/L NaCl. One part of the homogenate was used to assess the levels of nonprotein thiol groups (NPSH) and TBARS. Another part of the homogenate was centrifuged at 3000g at 4°C for 10 minutes to yield a low-speed supernatant that was used to determine antioxidant enzyme activities.

Serum Cholesterol Analyses

Serum total cholesterol was determined using commercial kit reagents (Doles, Goiania-GO, Brazil).

The assay consisted of an enzymatic method that uses cholesterol esterase, cholesterol oxidase, and peroxidase in the presence of 4-aminoantipyrine/phenol to form a quinoneimine that is measured at 510 nm.

Histopathological Analyses of Aortic Atherosclerotic Lesions

For histopathological analysis, a 10% formalin-fixed aortic segment was embedded in paraffin. Sections of 5 μm were obtained with a standard microtome and were stained with hematoxylin and eosin. The sections were examined by a pathologist without the knowledge of the experimental groups who measured the intima layer/media layer ratio. This ratio was used as an index of atherosclerosis as described before.[14] Because the lesions were not uniform, the results of each sample were expressed as the mean of 5 different measurements along the aortic section.

Lipid Peroxidation

After the addition of 7.2 mmol/L butylated hydroxytoluene to prevent further oxidation, the homogenate was used for the determination of TBARS.[15] Samples were extracted with *n*-butanol, and the reaction product was determined at 535 nm using a standard curve of 1,1,3,3-tetraethoxypropane.

Nonprotein Thiol Groups

The homogenate fraction was mixed with 10% trichloroacetic acid (1:1 v/v), followed by centrifugation. Nonprotein thiol groups were immediately determined as described by Ellman[16] using a standard curve of cysteine.

Antioxidant Enzymes

Superoxide dismutase activity was determined based on its ability to inhibit the autoxidation of adrenaline to adrenochrome at an alkaline pH.[17]

Catalase activity was determined using H_2O_2 as the substrate.[18] The pseudo-first order reaction constant (k) of the decrease in H_2O_2 absorption at 25°C was determined, and specific activity was expressed as k/g protein.

Glutathione peroxidase activity was determined using GSH reductase and nicotinamide adenine dinucleotide phosphate reduced (NADPH). The method is based on the oxidation of NADPH, which is indicated by a decrease in absorbance at 340 nm.[19]

Thioredoxin reductase-1 (TrxR-1) activity was determined using 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and NADPH.[20] The method is based on the reduction of DTNB, which is indicated by an increase in absorbance at 412 nm.

Glutathione S-transferase (GST) activity was determined by measuring the increase in absorbance at 340 nm using 1-chloro-2,4-dinitrobenzene as the substrate.[21]

Glutathione reductase (GR) activity was determined using oxidized GSH and NADPH.[22] The method is based on the oxidation of NADPH, which is indicated by a decrease in absorbance at 340 nm.

Protein Quantification

Protein was measured using bovine serum albumin as standard.[23]

Statistical Analysis

Data were analyzed using 1-way analysis of variance (ANOVA) followed by post hoc analyses with Duncan multiple range test when necessary. All variables were checked for normality. When a variable was found that did not follow normal distribution, it was logarithmically transformed before analysis. Data on GST activity and histopathological data on the intima layer/media layer ratio did not follow normal distribution even after log transformation and therefore were analyzed by the nonparametric Kruskal-Wallis test followed by the post hoc Nemenyi test. Results were expressed as the mean ± standard error (SEM), and differences were considered statistically significant when $P < .05$.

Results

No differences were found among the experimental groups with respect to the weight gain during the experimental period (data not shown). At the beginning of the experiment, the average body weight of the animals was 1.7 ± 0.03 kg and the animals grew to a final body weight of 2.7 ± 0.03 kg.

Analysis of variance revealed a significant increase in the serum total cholesterol levels of all cholesterol-fed groups when compared to the control group ($P < .05$), but no difference was found among the cholesterol groups fed with different levels of ASX (0-500 mg%; Figure 1A). The nonparametric Kruskal-Wallis test revealed an increase in the ratio

Figure 1. Serum cholesterol levels (A), intima layer/media layer ratio (B, magnification of ×40) and representative histology (C-E, magnification of ×100) of aortic arch of rabbits fed with cholesterol and/or astaxanthin (ASX)-enriched diet. Tissues were fixed in 10% formalin, embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin. C, control group. D, ASX 0 group. E, ASX 500 group. Data are means ± SEM. In (A), n = 9 for control and ASX 0 groups, n = 8 for ASX 100 and 500 groups, and n = 7 for ASX 50 group. In (B), n = 5 for all groups. *Different from control group ($P < .05$). Observe the preserved architecture of the intima layer with regular endothelial cells and the absence of foam cells in the control group (C). In the ASX 0 group (D), there is loss of endothelial architecture with high subintimal deposits of foam cells (FC) and inflammatory cells (IC) showing the extension and thickening of the aortic arch. In ASX 500 group (E), there are features identical to those observed in D, indicating the lack of effect of ASX. ASX 0, cholesterol-enriched diet; ASX 50, cholesterol-enriched diet plus 50 mg% ASX; ASX 100, cholesterol-enriched diet plus 100 mg% ASX; ASX 500, cholesterol-enriched diet plus 500 mg% ASX.

of the intima layer/media layer area in the aorta of all cholesterol-fed groups when compared to the control group ($P < .05$; Figure 1B-1E). These results confirm that the cholesterol-enriched diet induced hypercholesterolemia and caused atherosclerotic lesions. Dietary supplementation with ASX did not prevent these effects at any of the doses evaluated.

The intake of an atherogenic diet for 60 days significantly increased TBARS and NPSH content in the aortic tissue ($P < .05$; Figure 2), and ASX did prevent these effects at the doses evaluated.

Analysis of variance revealed a significant effect of the atherogenic diet on the activity of all antioxidant enzymes evaluated (Figure 3). Post hoc comparisons demonstrated that SOD, CAT, and TrxR-1 activities were increased in the aortic tissue of atherosclerotic rabbits when compared to the control group ($P < .05$; Figure 3A, 3B, and 3D). The increase in SOD activity was prevented by all ASX doses,

while only 100 and 500 mg% ASX prevented the increase in CAT activity. Only 50 mg% ASX was able to completely prevent the increase in TrxR-1 activity caused by the atherogenic diet, while 100 and 500 mg% ASX partially prevented this effect. Post hoc comparisons also demonstrated that GSH-Px activity decreased in the aortic tissue of animals that received a cholesterol-enriched diet when compared to the control group ($P < .05$; Figure 3C), and no dose of ASX prevented GSH-Px inhibition. Neither the atherogenic diet nor the ASX-supplemented diet changed the GR or GST activities in the aortic tissue (data not shown).

Discussion

Male New Zealand white rabbits fed with a high cholesterol diet were used in the current study because

Figure 2. TBARS (A) and NPSH levels (B) of aorta from rabbits fed a cholesterol and/or astaxanthin (ASX)-enriched diet. Data are means ± SEM. In (A), n = 7 for control and ASX 0 groups, n = 6 for ASX 100 group, and n = 5 for ASX 50 and 500 groups. In (B), n = 7 for ASX 50 group, n = 5 for control, ASX 0, and ASX 100 groups, and n = 6 for ASX 500 group. *Different from control group (P < .05). #Different from ASX 0 group (P < .05). ASX 0 indicates cholesterol-enriched diet; ASX 50, cholesterol-enriched diet plus 50 mg% ASX; ASX 100, cholesterol-enriched diet plus 100 mg% ASX; ASX 500, cholesterol-enriched diet plus 500 mg% ASX. MDA, malondialdehyde; NPSH, nonprotein thiol groups; TBARS, thiobarbituric acid reactive substances.

this species is well known for their tendency to develop severe hypercholesterolemia when the dietary cholesterol level is increased.[24] In addition, there is a strong relationship between the levels of plasma cholesterol and the degree of aortic lesions in this species,[24] and the distribution of atherosclerotic lesions in the rabbit model resembles atherosclerosis in humans to a certain degree.[25] Accordingly, we observed severe atherosclerotic damage along with hypercholesterolemia in animals receiving a cholesterol-enriched diet for 60 days.

In our study, the intake of the atherogenic diet significantly increased the NPSH content in the aortic tissue. This increase has been reported before[26] and seems to be related to the increased expression of GR, which was previously reported in human macrophages exposed to oxidized LDL in vitro.[27] Although GR activity was unchanged in atherosclerotic rabbits in our study, we observed decreased GSH-Px activity, which could also explain the increased NPSH levels. This enzyme uses GSH (GSH, the major NPSH) as substrate and its inhibition would result in higher GSH levels. The inhibition of this enzyme is in agreement with data from human atherosclerotic plaques, indicating the susceptibility of GSH-Px to oxidant species.[28] In fact, the deficient GSH-Px activity of the atherosclerotic tissue may significantly weaken its antioxidant potential favoring oxidative stress and atherogenic processes, even in the presence of an apparently adequate amount of low-molecular-weight scavenging

antioxidants.[29] Additionally, the lack of GSH-Px activity in atherosclerotic lesions seems to be associated with a more severe expression of atherosclerosis in humans.[28] Interestingly, atherosclerotic rabbits presented increased SOD, CAT, and TrxR-1 activities despite GSH-Px inhibition. This increase is in agreement with the increased expression of SOD, CAT, and TrxR in macrophages responding to oxidized LDL in vitro and in human atherosclerotic plaques.[27] Additionally, an increase in SOD and CAT activities in the aortic tissue of atherosclerotic rabbits has been described before.[30] The increase of antioxidant enzymes activities, as well as the rise in NPSH levels probably occurred as a defense response against free radicals. In fact, hypercholesterolemia increases superoxide anion production in the aortic tissue,[31] and SOD is one of the primary enzymes involved in arterial wall protection.[27] It is able to remove the superoxide anion by converting it to H_2O_2. The latter can be additionally removed by CAT, GSH-Px, or TrxR.

The enhanced activity of TrxR-1 may indicate that this enzyme plays a role in the decomposition of H_2O_2 generated by SOD. Thioredoxin reductase is the only class of enzymes known to reduce oxidized thioredoxin, which is involved in scavenging oxidant species such as H_2O_2 and alkyl peroxides.[32] In fact, the upregulation of TrxR in human macrophages has been described as a cellular defense against oxidized LDL and possibly modulates the development of atherosclerosis.[27] In addition, this is the first study

Figure 3. Superoxide dismutase (A), CAT (B), GSH-Px (C), and TrxR-1 (D) activities from aorta of rabbits fed cholesterol- and/or astaxanthin (ASX)-enriched diet. Data are expressed as means $\pm$ S.E.M. In (A), n = 8 for control group, n = 7 for ASX 0 group, n = 6 for ASX 50 group, and n = 5 for ASX 100 and 500 groups. In (B), n = 6 for control, ASX 0 and ASX 500 groups, and n = 5 for ASX 50 and 100 groups. In (C), n = 7 for ASX 0 and 50 groups, n = 6 for control group and n = 5 for ASX 100 and 500 groups. In (D), n = 8 for control group, n = 7 for ASX 0 group, n = 6 for ASX 50 group, and n = 5 for ASX 100 and 500 groups. *Different from control group ($P < .05$). #Different from ASX 0 group ($P < .05$). ASX 0 indicates cholesterol-enriched diet; ASX 50, cholesterol-enriched diet plus 50 mg% ASX; ASX 100, cholesterol-enriched diet plus 100 mg% ASX; ASX 500, cholesterol-enriched diet plus 500 mg% ASX; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); CAT, catalase; GSH-Px, glutathione peroxidase; SOD, superoxide dismutase; TrxR-1, thioredoxin reductase.

evaluating TrxR-1 activity in atherosclerotic rabbits. Because this is a key enzyme in redox regulation, it may play an important protective role against oxidative stress in atherosclerosis.

Despite the rise in NPSH content and antioxidant enzyme activities, we observed the occurrence of lipid peroxidation in atherosclerotic rabbits. This indicates that the free radicals generated by hypercholesterolemia exceeded the endogenous antioxidant activity and induced tissue damage. In fact, lipid peroxidation is a fundamental event in hypercholesterolemic atherosclerosis. Lipoproteins are modified by free radical-mediated reactions, leading to alterations that are a

starting point for the first events in the outcome and development of the atherogenic process.[33]

Astaxanthin, a reddish-colored carotenoid, is a powerful antioxidant that acts as a chain-breaking scavenger of free radicals.[6] A water-dispersible ASX derivative was approved as an animal food additive in 1987, and natural microalgae or shrimp shell extracts containing esterified ASX have been approved by the Food and Drug Administration (FDA) as nutraceuticals.[6] Furthermore, the derivatives of ASX are being developed for pharmaceutical applications in human disorders where oxidative stress-mediated damage may be important, including

cardiovascular diseases.[6] A human trial is currently under development to investigate whether the antioxidant and anti-inflammatory potential of ASX could be helpful in renal transplant patients, because cardiovascular disease is the major cause of morbidity in these patients.[34]

Some recent reports have described the protective effect of ASX against oxidative stress by maintaining mitochondria in the reduced state and protecting its functional integrity against oxidative stress in vitro.[35] Protection of mitochondrial function and antioxidation properties are also associated with the neuroprotective potential of ASX in vitro.[36,37] In addition, ASX attenuated oxidative stress and DNA damage caused by the anticancer drug cyclophosphamide in mouse liver.[38] In the current study, we found that all ASX doses prevented lipid peroxidation and the increase in NPSH in atherosclerotic rabbits. Lipid peroxidation proceeds as a chain reaction into the arterial wall. This reaction may be interrupted only by suitable antioxidants within LDLs themselves.[39] In fact, ASX has been demonstrated to protect against lipid oxidation at the surface and inside the phospholipid membrane in vitro by scavenging lipid radicals and destroying peroxides.[40] This effectiveness can be explained by the location of ASX inside membranes, where the polar ring of ASX most likely scavenges ROS near the membrane surface, while the polyene chain inhibits the radical chain reaction into the membrane.[40] Although all doses of ASX prevented the increase in SOD activity, only 100 and 500 mg% ASX prevented the increase in CAT activity. Furthermore, these same doses partially prevented the increase in TrxR-1 activity, while 50 mg% ASX completely prevented the effects of an atherogenic diet on this enzyme. This effect could be attributed to the high scavenging potential of ASX, protecting aortic tissue against free radicals generated by hypercholesterolemia and sparing antioxidant defenses. This protective effect of ASX against changes in antioxidant enzymes is in agreement with previous reports, which demonstrated that ASX prevented changes in the activities of SOD, GSH-Px, and CAT in animal models of gastric ulcer.[41,42] Moreover, ASX attenuated changes in antioxidant enzyme activities induced by inorganic mercury in kidneys.[43] To the best of our knowledge, this is the first report about the protective effect of ASX against changes in antioxidant enzymes in an atherosclerotic model.

However, no ASX dose prevented the impairment in GSH-Px activity.

The different effects of the varied doses of ASX on the antioxidant enzymes could be due to the distinct role of these enzymes in oxidative processes.[44] In fact, SOD catalyzes the conversion of the superoxide anion to H_2O_2, and this can be removed by CAT, GSH-Px, and TrxR-1. However, H_2O_2 can also be generated by the prostaglandin pathway, which is enhanced by the presence of high cholesterol levels.[45] Additionally, GSH-Px seems to be more sensitive to inhibition by oxidant species than other enzymes.[28] Thus, we can speculate that the inability of ASX to protect against GSH-Px inhibition is either due to a higher production of H_2O_2 associated to enzyme sensitivity and/or due to a limited capacity of ASX to prevent such production. In addition, it is possible that the location of antioxidant enzymes in the cells may influence the modulatory effect of ASX.[44] Thus, the location of CAT in peroxisomes could hamper the access of low doses of ASX. This is in agreement with β-carotene modulation of the increase of SOD induced by a high fat diet, along with the absence of effect on CAT activity.[46]

Despite its protection against oxidative damage, ASX did not prevent the increase in serum cholesterol levels nor did it protect against atherosclerotic lesions in this study. These results are in agreement with a previous study, which revealed a lack of hypocholesterolemic and antiatherogenic effects of ASX in Watanabe heritable hyperlipidemic rabbits.[10] This finding suggests that mechanisms other than oxidative damage may also contribute to the artery injury induced by hypercholesterolemia, and that these mechanisms could not be completely controlled by ASX. Alternatively, some protective effect of ASX against aortic damage may have been undetected in the current study. In fact, previous studies in Watanabe heritable hyperlipidemic rabbits revealed that ASX decreased macrophage infiltration, apoptosis, and atheroma vulnerability without an improvement in LDL oxidizability or in the macroscopic lesion size.[9,10] These findings were interpreted as a beneficial stabilizing effect of ASX on the atherosclerotic plaques that would possibly contribute to reduce the risk of rupture and thrombus formation.[9] Because plaque composition and stability were not evaluated in the current study, we cannot rule out the possibility that ASX could have had such an effect in our experimental model.

Concerning the antioxidative effects of ASX in atherosclerotic models, there are conflicting data showing the lack of ASX protection against LDL oxidation in Watanabe heritable hyperlipidemic rabbits[10] along with protection against human LDL oxidation in vitro and ex vivo.[8] These controversies could be explained by differences among studies in relation to animal species and experimental periods. Hence, there are still many controversies regarding ASX potential as an antiatherogenic agent.

In conclusion, we demonstrated that, although ASX did not prevent the increase of serum cholesterol levels or the aortic damage induced by a hypercholesterolemic diet, protection against lipid peroxidation and changes in antioxidant defenses may be achieved through the use of ASX. However, there is a need for further studies before a conclusive statement may be made on the potential usefulness of ASX as a therapeutic agent in cardiovascular diseases.

Acknowledgments

References

1. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. *J Biol Chem.* 1997;272(34):20963-20966.

2. Homa Y. Predictors of atherosclerosis. *J Atheroscler Thromb.* 2004;11(5):265-270.

3. Salvayre R, Auge N, Benoist H, Negre-Salvayre A. Oxidized low-density lipoprotein-induced apoptosis. *Biochim Biophys Acta.* 2002;1585(2-3):213-221.

4. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. *Am Heart J.* 1993;125(4):958-973.

5. Nordberg J, Arnér ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. *Free Radic Biol Med.* 2001;31(11):1287-1312.

6. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. *Am J Cardiol.* 2008;101(10A):58D-68D.

7. Kurashige M, Okimasu E, Inoue M, Utsumi K. Inhibition of oxidative injury of biological membranes by astaxanthin. *Physiol Chem Phys Med.* 1990;22(1):27-38.

8. Iwamoto T, Hosoda K, Hirano R, et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. *J Atheroscler Thromb.* 2000;7(4):216-222.

9. Li W, Hellsten A, Jacobsson LS, Blomqvist HM, Olsson AG, Yuan XM. Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits. *J Mol Cell Cardiol.* 2004;37(5):969-978.

10. Jacobsson LS, Yuan XM, Zieden B, Olsson AG. Effects of α-tocopherol and astaxanthin on LDL oxidation and atherosclerosis in WHHL rabbits. *Atherosclerosis.* 2004;173(2):231-237.

11. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. *Circulation.* 1999;99(10):1355-1362.

12. Jenner A, Ren M, Rajendran R, et al. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. *Free Radic Biol Med.* 2007;42(4):559-566.

13. Technical Report: *Haematococcus pluvialis* and astaxanthin safety for human consumption. *Mera Pharmaceuticals;* 2003. http://www.astafactor.com/techreports/tr3005-001.htm. Accessed on July 10, 2009.

14. Mortensen A, Breinholt V, Dalsgaard T, et al. 17beta-Estradiol but not the phytoestrogen naringenin attenuates aortic cholesterol accumulation in WHHL rabbits. *J Lipid Res.* 2001;42(5):834-843.

15. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem.* 1979;95(2):351-358.

16. Ellman GL. Tissue sulfhydryl groups. *Arch Biochem Biophys.* 1959;82(1):70-77.

17. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. *J Biol Chem.* 1972;247(10):3170-3175.

18. Aebi H. Catalase in vitro. *Methods Enzymol.* 1984;105:121-126.

19. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med.* 1967;70(1):158-169.

20. Holmgren A, Björnstedt M. Thioredoxin and thioredoxin reductase. *Methods Enzymol.* 1995;252:199-208.

21. Habig W, Jakoby WB. Assays for differentiation of glutathione S-transferases. *Methods Enzymol.* 1981;77:398-405.

22. Carllberg I, Mannervick B. Inhibition of glutathione reductase by interaction of 2,4,6-trinitrobenzenesulfonate with active-site dithiol. *FEBS Lett.* 1979;98(2):263-266.

23. Lowry DH, Rosebrough NJ, Farr AL, Randall RF. Protein measurement with the folin-phenol reagent. *J Biol Chem.* 1951;193(1):265-275.

24. Bocan TM, Muller SB, Mazur MJ, Uhlendorf PD, Brown EQ, Keift KA. The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. *Atherosclerosis.* 1993;102(1):9-22.

25. Wissler RW. Theories and new horizons in the pathogenesis of atherosclerosis and the mechanism of clinical effects. *Arch Pathol Lab Med.* 1992;116(12):1281-1291.

26. Deepa PR, Varalakshmi P. Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats. *Clin Chim Acta.* 2005; 355(1-2):119-130.

27. Hägg D, Englund MCO, Jerna M, et al. Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. *Atherosclerosis.* 2006;185(2):282-289.

28. Lapenna D, Gioia S, Ciofani G, et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. *Circulation.* 1998;97(19):1930-1934.

29. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaques contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. *Arterioscler Thromb Vasc Biol.* 1995;15(10):1616-1624.

30. Mantha SV, Kalra J, Prasad K. Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. *Life Sci.* 1996;58(6):503-509.

31. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest.* 1993;91(6):2546-2551.

32. Park YS, Fujiwara N, Koh YH, et al. Induction of thioredoxin reductase gene expression by peroxynitrite in human umbilical vein endothelial cells. *J Biol Chem.* 2002;383(3-4):683-691.

33. Lusis AJ. Atherosclerosis. *Nature.* 2000;407(6801): 233-241.

34. Fassett RG, Healy H, Driver R, et al. Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. *BMC Nephrol.* 2008;9:17.

35. Wolf AM, Asoh S, Hiranuma H, et al. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. *J Nutr Biochem.* 2009. [Epub ahead of print].

36. Liu X, Shibata T, Hisaka S, Osawa T. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. *Brain Res.* 2009; 1254:18-27.

37. Liu X, Osawa T. Astaxanthin protects neuronal cells against oxidative damage and is a potent candidate for brain food. *Forum Nutr.* 2009;61:129-135.

38. Tripathi DN, Jena GB. Intervention of astaxanthin against cyclophosphamide-induced oxidative stress and DNA damage: a study in mice. *Chem Biol Interact.* 2009;180(3):398-406.

39. Prasad K. Regression of hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. *Atherosclerosis.* 2008;197(1):34-42.

40. Goto S, Kogure K, Abe K, et al. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. *Biochim Biophys Acta.* 2001; 1512(2):251-258.

41. Kim JH, Choi SK, Choi SY, Kim HK, Chang HI. Suppressive effect of astaxanthin isolated from the *Xanthophillomyces dendrorhous* mutant on ethanol-induced gastric mucosal injury in rats. *Biosci Biotechnol Biochem.* 2005;69(7):1300-1305.

42. Kim JH, Kim YS, Song GG, Park JJ, Chang HI. Protective effect of astaxanthin on naproxen-induced gastric antral ulcerations in rats. *Eur J Pharmacol.* 2005; 514(1):53-59.

43. Augusti PR, Conterato GM, Somacal S, et al. Effect of astaxanthin on kidney function impairment and oxidative stress induced by mercuric chloride in rats. *Food Chem Toxicol.* 2008;46(1):212-219.

44. Palozza P, Calviello G, De Leo ME, Serini S, Bartoli GM. Canthaxanthin supplementation alters antioxidant enzymes and iron concentration in liver of Balb/c mice. *J Nutr.* 2000;130(5):1303-1308.

45. Cohen LA, Thompsond DO, Choi K, Karmalri RA, Rose DP. Dietary fat and mammary cancer. II. Modulation of serum and tumor lipid composition and tumor prostaglandins by different dietary fats: association with tumor incidence patterns. *J Natl Cancer Inst.* 1986; 77(1):43-51.

46. Blakely SR, Slaughter L, Adkins J, Knight AV. Effects of β-carotene and retinyl palmitate on corn oil-induced superoxide dismutase and catalase in rats. *J Nutr.* 1988;118(2):152-158.

CAPÍTULO III

Dietary astaxanthin improves paraoxonase activity and oxidative status in

hypercholesterolemic rabbits: a lipid-lowering independent effect

Paula R. Augusti, Greicy M.M. Conterato, Sabrina Somacal, Rocheli Sobieski, Andréia Quatrin,

Amanda R. Ruviaro, Luana H. Maurer, Marta F. F. Duarte, Tatiana Emanuelli

1   Dietary astaxanthin improves paraoxonase activity and oxidative status in hypercholesterolemic
2   rabbits: a lipid-lowering independent effect
3
4   Paula R. Augusti[1,2], Greicy M.M. Conterato[3], Sabrina Somacal[3], Rocheli Sobieski[3], Andréia
5   Quatrin[3], Amanda R. Ruviaro[3], Luana H. Maurer[3], Marta F. F. Duarte[4], Tatiana Emanuelli[3*]
6
7   [1] Graduate Program in Biological Sciences/Biochemistry, Department of Biochemistry, Institute of
8   Health Basic Sciences, Federal University of Rio Grande do Sul, 90035-003, Porto Alegre, RS,
9   Brazil;
10
11   [2]Center for Agricultural Sciences, Foundation Federal University of Pampa, 97650-000, Itaqui, RS,
12   Brazil.
13
14   [3]Integrated Center for Laboratory Analysis Development (NIDAL), Department of Food
15   Technology and Science, Center of Rural Sciences, Federal University of Santa Maria, 97105-900,
16   Santa Maria, RS, Brazil.
17
18   [4]Departament of Health Sciences, Lutheran University of Brazil, 97020-001, Santa Maria, RS,
19   Brazil.
20
21   Running title: Astaxanthin in hypercholesterolemia
22
23   *Corresponding author: T. Emanuelli, Tel.: +55 55 3220 8547; fax: +55 55 3220 8353, e-mail
24   tatiemanuelli@gmail.com.
25
26
27   *Keywords:* Thioredoxin reductase; Fatty acids; oxidised LDL; Thiobarbituric acid reactive
28   substances
29
30
31
32

Abstract

Oxidative stress plays an important role in hypercholesterolemia and atherosclerosis. This study explored the effects of the antioxidant astaxanthin on the lipid profile, oxidative stress and paraoxonase activity in hypercholesterolemic rabbits. Male New Zealand white rabbits were fed a standard or a hypercholesterolemic diet (1 % cholesterol) alone or supplemented with 50, 100 or 500 mg % of astaxanthin for 60 days. Serum levels of total cholesterol, triglycerides, oxidised LDL and oxidised LDL antibodies were measured. Thiobarbituric acid reactive substances levels and carbonyl content in proteins were also measured as lipid and protein oxidation indicators. Paraoxonase and antioxidant enzymes activities as well as fatty acids composition were evaluated in serum. The hypercholesterolemic diet increased serum total cholesterol and triglycerides levels. This increase in serum lipids was accompanied by elevated oxidised LDL and oxidised LDL antibodies, as well as lipid and protein oxidation. In addition, hypercholesterolemia decreased SFA and increased unsaturated fatty acids levels in the serum. Astaxanthin (100 and 500 mg %) attenuated protein oxidation in hypercholesterolemic rabbits, whereas 500 mg % of astaxanthin reduced protein oxidation *per se*. In addition, the activities of antioxidant enzymes superoxide dismutase and thioredoxin reductase were enhanced, while paraoxonase activity was inhibited in hypercholesterolemic rabbits. Although all astaxanthin doses prevented changes in thioredoxin reductase and paraoxonase activities, the change in superoxide dismutase activity was not improved by astaxanthin. Our study suggests that astaxanthin could play a beneficial role in hypercholesterolemia by preventing protein oxidation as well as changes in thioredoxin reductase and paraoxonase activities.

Introduction

Hypercholesterolemia is widely accepted as one of the major risk factors for the development of atherosclerosis[1]. LDL, which is the major carrier of cholesterol in the circulation, can undergo oxidative modification by endothelial cells, vascular smooth muscle or macrophages within the arterial wall. The cellular uptake of oxidised LDL (LDLox) also leads to the generation of reactive oxygen species (ROS)[2]. Accordingly, increased levels of LDLox and oxidised LDL antibodies (LDLoxAB) have been found in the serum of hypercholesterolemic (HC) subjects[3].

The imbalance between ROS production and antioxidant mechanisms in the arterial wall and circulating cells leads to oxidative stress, which appears to play an important role in hypercholesterolemia and atherosclerosis[4]. LDL oxidation in vivo affects both its lipid and protein components and can be assessed by measuring thiobarbituric acid reactive substances (TBARS) and protein carbonyl contents[5]. In addition, LDL size and oxidisability seem to be related to its fatty acid composition[6]. However, the relationships between LDL oxidisability, fatty acid composition and oxidant/antioxidant status in hypercholesterolemia are still not clear.

As LDL oxidation can initiate atherogenesis, antioxidant status should have a major impact not only on the rate of LDL oxidation but also on the development of atherosclerosis[4]. Thus, the administration of antioxidant substances could make LDL less sensitive to oxidation. Another line of defence against oxidative stress might be the hydrolysis of specific oxidative products by hydrolases such as paraoxonase (PON1). PON 1 is a circulating enzyme that is attached to HDL. It protects plasma lipoproteins (including LDL) from oxidative modification by hydrolysing bioactive lipid hydroperoxides and reducing peroxides to their respective hydroxides[7]. In humans, low PON1 activity is an independent predictor of acute coronary events[8].

Supplementation with antioxidant-containing foodstuffs such as polyphenol-[9,10] and carotenoid-rich[11-12] fruits showed a beneficial effect against cardiovascular diseases. Astaxanthin (ASX) is a naturally occurring carotenoid with no pro-vitamin A activity and strong antioxidant properties. This red pigment is synthesised by plants and algae and is distributed mainly in marine seafood[13]. Although ASX has been suggested as a novel potential treatment for oxidative stress and inflammation in cardiovascular disease[14], there are still many controversies about the protective potential of ASX in cardiovascular events. ASX had no protective effect against LDL oxidation and atherosclerotic lesion formation in Watanabe heritable hyperlipidemic (WHHL) rabbits[15] or against aortic damage in atherosclerotic New Zealand rabbits[16]. Moreover, no studies have examined the role of ASX in PON1 activity during experimental hypercholesterolemia.

100   The objective of the present investigation is to determine the effects of ASX on

101   hypercholesterolemia by evaluating lipid levels, PON1 activity, oxidative status and fatty acid

102   composition in the serum of HC rabbits.

103   **Experimental methods**

104   *Animals and diets*

105   This study was approved by the Ethics and Animal Welfare Committee of the Federal University of

106   Santa Maria (23081.019182/2007-10) and experimental procedures followed the Institutional and

107   National guidelines for the care and use of animals. Eight-week-old male New Zealand white

108   rabbits were housed in individual cages, under a 12:12 hour light:dark cycle with access to 100 g of

109   chow per day and water ad libitum.

110   After 1 week of adaptation, the rabbits weighing 1.83 ± 0.33 kg were randomly divided into

111   eight experimental groups, each one with six animals. The control group was fed a standard diet

112   chow (SUPRA, São Leopoldo, Brazil); the HC group was fed a diet enriched with 1 % cholesterol

113   (Vetec, Brazil); and the supplemented groups were fed natural ASX (2% powder, Fuji Chemical

114   Industry Co. Ltd., Toyama, Japan) at 50, 100 and 500 mg % in standard or HC diets. The standard

115   diet chow had (g/kg) 120 moisture, 170 crude protein, 20 ether extract, 140 ash, 130 crude fibre, 12

116   phosphorus, and 6 calcium. Cholesterol and ASX were dissolved in diethyl ether and sprayed on the

117   standard chow to yield the cholesterol-enriched and ASX-supplemented diets. The standard chow of

118   the control group was sprayed with diethyl ether (vehicle). The standard and supplemented chows

119   were left to allow the ether to evaporate before storage, protected from light and under refrigeration.

120   Chows were prepared once a week. All animals received a daily portion of 100 g chow, and their

121   body weight was checked once a week.

122   The cholesterol dose was chosen based on a previous study, where dietary supplementation

123   with 1 % of cholesterol for 60 days increased serum total cholesterol (TC), LDL and triglycerides

124   (TG) levels[17]. Furthermore, we conducted a pilot experiment in order to corroborate this

125   experimental model. ASX concentrations in diets were based on a previous study[15] and on doses

126   considered safe for humans[18]. Blood samples were collected from rabbits fasted for twelve hours

127   by cardiac puncture before (baseline) and after 60 days of treatment. At the end of the experimental

128   period, animals were sacrificed with an intravenous overdose of thiopental. Blood samples were

129   collected into tubes without additives and centrifuged at 3,000 *g* for 10 min. Serum was removed

130   immediately and stored at -20°C until biochemical analyses.

131

132   *Serum lipids*

Total cholesterol (TC) and triglycerides (TG) levels were determined by enzymatic methods, using commercial kit reagents (Doles, Goiania-GO, Brazil).

Lipid peroxidation (LPO)

After the addition of 7.2 mM butylated hydroxytoluene to prevent further oxidation, LPO was estimated by the measurement of TBARS in serum samples as previously described[19]. Samples were extracted with *n*-butanol and the reaction product was determined at 535 nm using a standard curve of 1,1,3,3-tetraethoxypropane.

Protein oxidation

Protein oxidation was determined based on the reaction of the carbonyl groups with 2,4-dinitrophenylhydrazine (DNPH) to form 2,4-dinitrophenylhydrazone[20]. Samples were read at 370 nm and carbonyl content was calculated using the molar absorption coefficient for aliphatic hydrazones ($22,000 \ M^{-1} \ cm^{-1}$).

LDLox and LDLoxAB

LDLox was determined by a capture ELISA according to the manufacturer's instructions (Mercodia AB, Uppsala, Sweden)[21]. LDLoxAB were determined using ELISA as previously described[22].

PON1 activity

PON1 activity was assessed by measuring the rate of paraoxon hydrolysis to yield p-nitrophenol, at 412 nm and 25°C. The amount of p-nitrophenol generated was calculated using the molar extinction coefficient $17,000 \ M^{-1} \ cm^{-1}$ and 1 U of PON1 activity was defined as 1 nmol p-nitrophenol generated per min[23].

Antioxidant enzymes

Superoxide dismutase (SOD) activity was determined based on its ability to inhibit the autoxidation of epinephrine to adrenochrome at an alkaline pH[24]. SOD activity was expressed as the amount of enzyme that inhibits the oxidation of epinephrine by 50 %, which is equal to 1 unit.

Thioredoxin reductase-1 (TrxR-1) activity was determined using 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) and adenine dinucleotide phosphate reduced (NADPH). This method is based on the reduction of DTNB, which is indicated by an increase in absorbance at 412 nm[25].

Fatty acid composition

167 Fatty acids in serum were determined by a one-step reaction[26] with some modification. Serum (50

168 µl) was mixed with 1 ml methanol/isooctane (4:1, v/v) and 100 µl acetyl chloride and was

169 incubated at 100°C for 60 min; then 60 g/l aqueous potassium carbonate containing 100 g/l sodium

170 chloride was added. The mixture was shaken for 10 min at room temperature and centrifuged at

171 1,800 g for 5 min. The isooctane phase, containing the fatty acid methyl esters, was subjected

172 directly to GLC using an Agilent Technologies gas chromatograph (HP 6890) fitted with a capillary

173 column DB-23 (50 % cyanopropyl-methylpolysiloxane, 60 m × 0.25 mm × 0.25 μm) and flame

174 ionisation detection. The temperature of the injector port and the detector was set at 250°C, and the

175 carrier gas was nitrogen (0.6 ml/min). After injection (1 μl, split ratio 50:1), the oven temperature

176 was held at 120°C for 5 min, increased to 240°C at a rate of $4°C\ min^{-1}$, and held at this temperature

177 for 10 min. Standard fatty acid methyl esters (37-component FAME Mix, Sigma, Saint Louis, MO,

178 USA) were run under the same conditions and the subsequent retention times were used to identify

179 the fatty acids. Fatty acids were expressed as percentage of the total fatty acids content.

180

181 *Protein quantification*

182 Protein was measured using bovine serum albumin as the standard, as described previously[27].

183

184 *Statistical analysis*

185 Data were analysed using two-way ANOVA (2 cholesterol doses x 4 ASX doses) followed by post

186 hoc Duncan's multiple range test when necessary using the Statistica® 6.0 software system (Statsoft

187 Inc., 2001). Results were expressed as the mean and standard error of the means (SEM) and

188 differences were considered statistically significant when $p < 0.05$.

189

190 **Results**

191 No differences were found among the experimental groups with respect to weight gain during the

192 experimental period (data not shown). At the beginning of the experiment, the average body weight

193 of the animals was 1.86 ± 0.04 kg, and the animals grew to a final body weight of 2.68 ± 0.22 kg.

194 Also, no differences were found among the experimental groups with respect to all evaluated

195 parameters before the experimental period (baseline values, data not shown).

196   The profile of the major serum fatty acids in rabbits is presented in Table 1. Feeding rabbits

197 a HC diet for 60 days increased the serum concentration of oleic acid (18 : 1*n*-9) along with an

198 increase in total unsaturated fatty acids (UFA), MUFA and UFA/SFA ratio when compared to the

199 no-ASX control group (p<0.05). Also, decreased levels of palmitic acid (16 : 0), estearic acid (18 :

200 0), arachidonic acid (20 : 4*n*-6) and total SFA were found in HC rabbits when compared to the no-

201 ASX control group (p<0.05). ASX did not affect changes in fatty acid composition induced by a

202 HC diet at any of the evaluated doses (p>0.05). In addition, neither cholesterol nor ASX

203 supplementation changed the content of linoleic (18 : 2n-6) and linolenic (18 : 3n-3) acids or total

204 PUFA in serum of rabbits.

205   The cholesterol enriched diet increased TC and TG serum levels when compared to control

206 groups (Fig. 1, p<0.05), which confirms that the cholesterol-enriched diet induced hyperlipidemia.

207 Dietary supplementation with ASX did not prevent the increase in serum lipids at any of the doses

208 evaluated (Fig. 1).

209   The HC diet significantly increased TBARS content, protein carbonyl content, as well as

210 LDLox and LDLoxAB levels when compared to the control group (Fig. 2, p<0.05). Although the

211 increased levels of TBARS, LDLox and LDLoxAB were not attenuated by any dose of ASX, 100

212 and 500 mg % of ASX did prevent the increase of protein carbonyl content. In addition, 500 mg %

213 of ASX decreased protein carbonyl content *per se.*

214   The HC diet inhibited PON1 activity, but increased SOD and TrxR-1 activities when

215 compared to the control group (p<0.05; Fig. 3). Although the increase in TrxR-1 activity and PON1

216 inhibition were attenuated by all ASX doses evaluated, no ASX doses prevented the increase in

217 SOD activity.

218

219 **Discussion**

220 Cholesteryl esters are the major form of circulating cholesterol in the plasma of cholesterol-fed

221 rabbits[28] and the esterification process requires NEFA, mainly MUFA[29]. Therefore, cholesterol-

222 enriched diets induce MUFA synthesis[29]. Accordingly, we observed increased levels of serum 18 :

223 1n-9 and total MUFA after feeding rabbits with a HC diet for 60 days. Moreover, we found

224 decreased levels of 16 : 0, 18 : 0 and total SFA, along with increased levels of total UFA and

225 UFA/SFA ratio in these animals. In fact, the SFA 16 : 0 and 18 : 0 are consumed to synthesise

226 MUFA as 18 : 1n-9[29]. Thus, induction of MUFA synthesis by way of a cholesterol enriched diet

227 would increase plasma lipids and lipoproteins and may lead to cardiovascular diseases[29].

228 Accordingly, the HC diet increased levels of serum TC and TG along with changes in the fatty acid

229 profile.

230   Hypercholesterolemia increases the synthesis of prostaglandins and leukotrienes from

231 arachidonic acid and during this process ROS are produced[30]. For this reason,

232 hypercholesterolemia is particularly associated with the increased susceptibility of LDL to

233 oxidation[30]. Accordingly, in the present study we observed that hypercholesterolemia caused

234 arachidonic acid depletion accompanied by LDL oxidation. In addition, we observed increased lipid

and protein oxidation in the serum of HC rabbits. These results indicate that free radicals generated by hypercholesterolemia caused LDL oxidation, particularly in its protein and lipid components. The oxidisability of LDL is dependent on the presence of oxidisable lipids, such as PUFA[31]. However, an increase in LDLox in HC rabbits was not accompanied by PUFA elevation, which can be a result of a balance between PUFA synthesis and degradation. In fact, PUFA may be lost by oxidation in salmon and oxidative events induce a compensatory overproduction of PUFA in order to replace this loss[32].

In our study, ASX supplementation did not prevent changes in the fatty acid composition in HC rabbits. This finding was expected because xanthophylls, such as ASX, are found in chylomicrons and in the serum of humans in a non-esterified free form[33]. Consequently, this carotenoid does not require fatty acids for its transport and does not interfere in fatty acid metabolism. In accordance with the lack of protective effect of ASX against changes in fatty acid composition, this carotenoid was also not able to reduce the increased lipid levels in the serum of HC rabbits. Although these results are in agreement with a previous study that revealed a lack of hypolipidemic effect of ASX in Watanabe heritable hyperlipidemic rabbits[15], this study is the first to evaluate the effects of ASX on serum fatty acid composition during experimental hypercholesterolemia.

LDL oxidation in vivo affects its lipid and protein components at different stages[5]. In the first stage, lipids are oxidised with minor protein oxidation. In the second stage, both lipids and proteins are attacked by free radicals[5]. Moreover, oxidative modifications in these molecules by free radical-mediated reactions are involved in the molecular mechanisms leading to endothelial dysfunction during atherosclerosis induced by hypercholesterolemia[34]. In agreement, HC rabbits showed increased serum lipid and protein oxidation along with high levels of LDLox. LDLox may damage membrane proteins and phospholipids, which can impair the endothelial function[35]. Oxidative modification of LDL induces the formation of immunogenic epitopes in the LDL molecule, leading to the formation of LDLoxAB, which can be detected in serum[35]. Moreover, LDLoxAB in atherosclerotic lesions have been shown to block the uptake of LDLox by macrophages, suggesting a possible role in preventing the formation of foam cells[36]. Accordingly, we observed increased LDLoxAB levels in serum of HC rabbits, which supports the idea that antibodies were secreted in order to combat LDLox toxicity.

ASX did not prevent LPO at any of the doses evaluated in the present study, however, protein oxidation was attenuated by 100 and 500 mg % of dietary ASX. Moreover, 500 mg % of ASX alone decreased protein oxidation, even in the absence of cholesterol in the diet. In fact, ASX is a potent scavenger of oxygen radicals and inhibits the oxidation of proteins[13, 37] alone as well as

269   in the presence of prooxidant treatment[37]. Due to its polarity, ASX is assumed to be attached to the

270   surface of the chylomicrons and lipoproteins as well as in association with serum albumin[38]. Thus,

271   we cannot rule out the thought that ASX would be in a favourable location to prevent protein

272   oxidation rather than lipid oxidation. In fact, LPO proceeds as a chain reaction, which may be

273   terminated only by suitable antioxidants within LDLs themselves[39]. Because ASX seems to be

274   located in the lipoprotein surface rather than in the lipid core, this could hamper its protective

275   ability against LPO. In addition, the lack of protection of ASX against LPO could be responsible for

276   its inability to restore LDLox and LDLoxAB levels. This study is the first to evaluate ASX

277   behaviour against LDLox and LDLoxAB levels.

278   Despite protection against protein oxidation, no ASX doses prevented the increase in SOD

279   activity induced by hypercholesterolemia. In our study, we measured SOD activity in serum, which

280   represents extracellular SOD. This SOD isoenzyme is found in the extracellular matrix of tissues

281   and in extracellular fluids, which allows superoxide anion removal in this specific location[40]. In

282   addition, extracellular SOD is mainly synthesised and secreted from vascular smooth muscle cells

283   and macrophages, playing a central role in cardiovascular antioxidant mechanisms[41]. Accordingly,

284   increased SOD activity in serum is in agreement with the increase in the activity of this enzyme in

285   aortic tissue[42]. SOD activity increased in HC rabbits most likely to remove superoxide anion

286   generated during hypercholesterolemia[42] and superoxide production seems to have exceeded the

287   antioxidant capacity of ASX. SOD catalyses the conversion of the superoxide anion to H_2O_2 and

288   this can be removed by other antioxidant enzymes, such as TrxR-1.

289   TrxR-1 is a redox-active selenoprotein that efficiently regenerates oxidised thioredoxin.

290   Reduced thioredoxin is responsible for maintaining proteins, such as peroxiredoxins, in their

291   reduced state in order to remove H_2O_2 and alkyl peroxides[43]. The increased TrxR-1 activity in HC

292   rabbits may indicate that TrxR-1 plays a protective role in protein oxidation induced by

293   hypercholesterolemia. These facts are supported by the overexpression and release of TrxR-1 in

294   oxidative stress events[44]. Moreover, it suggests a role of TrxR-1 in the decomposition of H_2O_2

295   generated by SOD because TrxR-1 has peroxidase activity, directly reducing H_2O_2[45]. Thus, ASX

296   protection against protein oxidation could explain why it also protected against the increase of

297   TrxR-1 activity because ASX spares this antioxidant enzyme. This protective effect of ASX against

298   changes in TrxR-1 activity has previously been reported in the aortic tissue from atherosclerotic

299   rabbits[16], but this is the first report on serum TrxR-1 activity.

300   PON1 is an enzyme almost exclusively located on serum HDL that is mainly responsible

301   for the breakdown of lipid peroxides before they can accumulate in LDL[7]. PON1 can also inhibit

302   cholesterol biosynthesis in arterial cells and it can stimulate HDL-mediated cholesterol efflux from

68

303 macrophages[46]. Despite the important effects of PON1, its enzymatic activity is sensitive to

304 oxidative stress and is readily inactivated by oxidants[47]. Accordingly, PON1 activity was inhibited

305 along with increased LDLox in serum of HC rabbits in the present study. All ASX doses prevented

306 PON1 inhibition in our study. This protective effect could be explained by the absorption,

307 metabolism and transport of xanthophylls, such as ASX, in the blood stream of Atlantic salmon[48]

308 because these processes in salmon are similar to mammalian systems[48]. ASX is transferred to HDL

309 from VLDL and LDL during the transport of these lipoproteins through the blood in salmon[38].

310 Thus, we suggest that ASX could be next to the attachment site of PON1 in HDL and exerting its

311 antioxidant effects. Although PON1 activity was restored by ASX, this carotenoid did not prevent

312 LDL oxidation in rabbits fed a cholesterol-enriched diet. These findings suggest that factors other

313 than PON1 may influence LDL oxidation and that these factors could not be completely controlled

314 by ASX. In fact, HDL-associated enzymes other than PON1, such as lecithin/cholesterol

315 acyltransferase (LCAT) and platelet-activating factor acyl hydrolase (PAF-AH) were also

316 implicated in the antioxidative properties of HDL[46]. Although the protective effect of ASX on

317 PON1 has been described here for the first time, the effects of ASX on LCAT and PAF-AH still

318 remain unknown.

319   All protective effects of ASX in the present study could be attributed to the high scavenger

320 potential of ASX, which protects against free radicals generated by hypercholesterolemia, sparing

321 antioxidant defences. ASX stabilises free radicals by adding them to its long double-bond chain

322 rather than donating an atom or electron to the radical[13]. Consequently, it can resist chain reactions

323 that occur when a fatty acid is oxidised, thus allowing it to scavenge or quench longer than

324 antioxidants that cannot stop this chain reaction[13]. For these reasons, natural microalga or shrimp

325 shell extracts containing ASX have been approved by the Food and Drug Administration (FDA) as

326 nutraceuticals[14]. Furthermore, derivatives of ASX are being developed for pharmaceutical

327 applications in human health where oxidative stress-mediated damage may be important, including

328 cardiovascular diseases[14].

329   In recent years, a number of studies on ASX have demonstrated its antioxidant effects, such

330 as against hepatocellular injury following ischemia/reperfusion[49] and oxidative stress,

331 inflammation and apoptosis induced by high-glucose in kidney cells[50]. In addition,

332 neuromodulatory effects of ASX have been described *in vitro*[51,52] and *in vivo*[53] as well as

333 protective action against oxidative damage in diabetic rats[54] and UVA-induced oxidative

334 damage[55]. Concerning cardiovascular diseases, ASX has been suggested as a potential treatment

335 for oxidative stress and inflammation[14]. Although some reports have shown that ASX does not

336 protect against LDL oxidation[15] and aortic damage in rabbits[15,16], ASX prevented the oxidation of

337 human LDL *in vitro*[56] and stabilised atherosclerotic plaques in rabbits[57].

338   In the present study, we demonstrated that ASX improves PON1 activity and oxidative

339 status in HC rabbits but has no lipid-lowering effect. Thus, we propose that protection against

340 protein oxidation and changes in PON1 and TrxR-1 activities are the likely mechanisms underlying

341 the beneficial role of ASX in HC rabbits. Moreover, the absence of ASX effects on fatty acids could

342 underlie the lack of lipid-lowering effect of this carotenoid.

343

359

360 **References**

361

362 1.   Kruth HS (2003) Lipoprotein cholesterol and atherosclerosis. *Curr Mol Med* **1**, 633-653.

363 2.   Prasad K & Kalra J (1993) Oxygen free radicals and hypercholesterolemic atherosclerosis:

364   effect of vitamin E. *Am Heart J* **125**, 958-973.

365 3.   Duarte MMF, Rocha JBT, Moresco RN *et al*. (2009) Association between ischemia-modified

366   albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. *Clin

367   Biochem* **42**, 666-671.

368 **4.**   Catapano AL, Maggi FM & Tragni E (2000) Low density lipoprotein oxidation, antioxidants,

369   and atherosclerosis. *Curr Opin Cardiol* **5**, 355-363.

370 5. Berliner JA, Navab M, Fogelman AM *et al.* (1995) Atherosclerosis: Basic Mechanisms.
371   Oxidation, inflammation, and genetics. *Circulation* **91**, 2488-2496.

372 6. Kondo A, Murunaka Y, Ohta I *et al.* (2001) Relationships between TG concentrations and LDL
373   size evaluated by malonadehyde-modified LDL. *Clin Chem* **47**, 893-900.

374 7. Mackness MI, Mackness B & Durrington PN (2002) Paraoxonase and coronary heart disease.
375   *Atheroscler Suppl* **3**, 49-55.

376 8. Mackness B, Durrington P, McElduff P *et al*. (2003) Low paraoxonase activity predicts
377   coronary events in the caerphilly prospective study. *Circulation* **107**, 2775-2779.

378 9. Kurowska EM, Spence JD, Jordan J *et al.* (2000) HDL cholesterol-raising effect of orange juice
379   in subject with hypercholesterolemia. *Am J Clin Nutr* **72**, 1095-1100.

380 10. Albers AR, Varghese S, Vitseva O *et al.* (2004) The anti-inflammatory effects of purple grape
381   juice consumption in subjects with stable coronary artery disease. *Arterioscler Thromb Vasc*
382   *Biol* **24**, e179-e180.

383 11. Madrid AE, Vasques ZD, Levton AF *et al.* (2006) Short-term Lycopersicum esculentum
384   consumption may increase plasma high density lipoproteins and decrease oxidative stress. *Rev*
385   *Med Chil* **134**, 855-872.

386 12. Aizawa K & Inakuma T (2009) Dietary capsanthin, the main carotenoid in paprika (Capsicum
387   annuum), alters plasma high-density lipoprotein-cholesterol levels and hepatic gene expression
388   in rats. *Br J Nutr* **102**, 1760-1766.

389 13. Kurashige M, Okimasu E, Inoue M *et al.* (1990) Inhibition of oxidative injury of biological
390   membranes by astaxanthin. *Physiol Chem Phys Med* **22**, 27-38.

391 14. Pashkow FJ, Watumull DG & Campbell CL (2008) Astaxanthin: a novel potential treatment for
392   oxidative stress and inflammation in cardiovascular disease. *Am J Cardiol* **22**, 10158-10168.

393 15. Jacobsson LS, Yuan XM, Ziedén B *et al.* (2004) Effects of α-tocopherol and astaxanthin on
394   LDL oxidation and atherosclerosis in WHHL rabbits. *Atherosclerosis* **173**, 231-237.

395 16. Augusti PR, Conterato GMM, Somacal S *et al*. (2009). Astaxanthin reduces oxidative stress,
396   but not aortic damage in atherosclerotic rabbits. *J Cardiovasc Pharmacol Ther* **14**, 314-322.

397 17. Prasad K (1999) Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in
398   rabbits by secoisolariciresinol diglucoside isolated from flaxseed. *Circulation* **99**, 1355-1362.

399 18. Mera Pharmaceuticals. (2003) Technical Report. *Haematococcus pluvialis* and Astaxanthin
400   Safety for Human Consumption. http://www.astafactor.com/techreports/tr3005-001.htm
401   (accessed May 2010).

402 19. Ohkawa H, Ohishi N & Yagi K (1979) Assay for lipid peroxides in animal tissues by
403   thiobarbituric acid reaction. *Anal Biochem* **95**, 351-358.

404   20. Levine RL, Garland D, Oliver CN *et al*. (1990). Determination of carbonyl content in
405   oxidatively modified proteins. *Method Enzymol* **186**, 464-478.

406   21. Holvoet P, Stassen JM, Van Cleemput J *et al*. (1998) Oxidized low density lipoproteins in
407   patients with transplant-associated coronary artery disease. *Arterioscler Thromb Vasc Biol* **18**,
408   100-107.

409   22. Wu R & Lefvert AK (1995) Autoantibodies against oxidized low density lipoprotein (OxLDL):
410   characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of
411   oxLDL. *Clin Exp Immunol* **102**, 174-180.

412   23. Bolayirli IM, Aslan M, Balci H *et al.* (2007) Effects of atorvastatin therapy on
413   hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and
414   homocysteine. *Life Sci* **81**, 121-127.

415   24. Misra HP & Fridovich I (1972) The role of superoxide anion in the auto-oxidation of
416   epinephrine and a simple assay for superoxide-dismutase. *J Biol Chem* **247**, 3170-3175.

417   25. Holmgren A & Björnstedt M (1995) Thioredoxin and thioredoxin reductase. *Meth Enzymol*
418   **252**, 199-208.

419   **26.** Lepage G & Roy CC (1986) Direct transesterification of all classes of lipids in a one-step
420   reaction. *J Lipid Res* **27**, 114-120.

421   27. Lowry DH, Rosebrough NJ, Farr AL *et al.* (1951) Protein measurement with the folin-phenol
422   reagent. *J Biol Chem* **93**, 265-275.

423   28. Rose HG. (1972) Origin of cholesterol esters in the blood of cholesterol-fed rabbits: relative
424   contributions of serum lecithin-cholesterol acyltransferase and hepatic ester synthesis. *Biochim*
425   *Biophjs Acta* **260**, 312-326.

426   29. Ntambi JM (1999) Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and
427   cholesterol. *J Lipid Res* **40**, 1549-1558.

428   30. Lee P & Prasad K. (2003) Suppression of oxidative stress as a mechanism of reduction of
429   hypercholesterolemic atherosclerosis by cyclooxygenase inhibitors. *Int J Angiol* **12**, 13-23.

430   31. Balkan J, Kanbagli O, Mehmetcik G *et al*. (2002) Increased lipid peroxidation in serum and
431   low density lipoproteins associated with aging in humans. *Int J Vitam Nutr Res* **72**, 315-320.

432   32. Bell JG, McEvoy J, Tocher DR *et al*. (2000) Depletion of α-tocopherol and astaxanthin in
433   Atlantic Salmon (*Salmo salar*) affects autoxidative defense and fatty acid metabolism. *J Nutr*
434   **130**, 1800-1808.

435   33. Wingerath T, Stahl W & Sies H (1995) Beta-cryptoxanthin selectively increases in human
436   chylomicrons upon ingestion of tangerine concentrate rich in beta-cryptoxanthin esters. *Arch*
437   *Biochem Biophys* **324**, 385-390.

438   34. Reaven PD, Napoli C, Merat S *et al.* (2000) Lipoprotein modification and atherosclerosis in
439   aging. *Exp Gerontol* **34**, 527-537.

440   35. Tinahones FJ, Gómez-Zumaquero JM, Garrido-Sánchez L *et al.* (2005) Influence of age and
441   sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general
442   population. *J Lipid Res* **3**,452-457.

443   36. Shaw PX, Horkko S, Tsimikas S *et al.* (2001) Human derived anti oxidized LDL autoantibody
444   blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo.
445   *Arterioscler Thromb Vasc Biol* **21**, 1333-1339.

446   37. Augusti PR, Conterato GMM, Somacal S *et al.* (2008) Effect of astaxanthin on kidney function
447   impairment and oxidative stress induced by mercuric chloride in rats. *Food Chem Toxicol* **46**,
448   212-219.

449   38. Aas GH, Bjerkeng B, Storebakken T *et al. (*2000) Blood appearance, metabolic transformation
450   and plasma transport proteins of 14C-astaxanthin in Atlantic salmon *(Salmo salar* L.). *Fish*
451   *Physiol Biochem* **21**, 325-334.

452   39. Noguchi N (2002) novel insights into the molecular mechanisms of the antiatherosclerotic
453   properties of antioxidants: the alternatives to radical scavenging. *Free Rad Biol Med* 33, 1480-
454   1489.

455   40. Marklund SL (1982) Human copper-containing superoxide dismutase of high molecular
456   weight. *Proc Natl Acad Sci USA* **79**, 7634-7638.

457   41. Stralin P, Karlsson K, Johansson BO *et al.* (1995) The interstitium of the human arterial wall
458   contains very large amounts of extracellular superoxide dismutase. *Arterioscler Thromb Vasc*
459   *Biol* **15**, 2032-2036.

460   42. Ohara Y, Peterson TE & Harrison DG (1993) Hypercholesterolemia increases endothelial
461   superoxide anion production. *J Clin Invest* **91**, 2546-2551.

462   43. Arnér ESJ & Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin
463   reductase. *Eur J Biochem* **267**, 6102-6109.

464   44. Söderberg A, Sahaf B & Rosén A (2000) Thioredoxin reductase, a redoxactive selenoprotein, is
465   secreted by normal and neoplastic cells: presence in human plasma. *Cancer Res* **60**, 2281-2289.

466   45. Björnstedt M, Hamberg M, Kumar S *et al.* (1995) Human thioredoxin reductase directly
467   reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via
468   catalytically generated. *J Biol Chem* **270**, 11761-11764.

469   46. Aviram M (2004) Introduction to the serial review on paraoxonases, oxidative stress, and
470   cardiovascular diseases. *Free Rad Biol Med* **37**,1301-1303.

471   47. Mackness MI & Durrington PN (1995) HDL, its enzymes and its potential to influence lipid
472   peroxidation. *Atherosclerosis* **115**, 243-253.

473   48. Rajasingh H, Øyehaug L, Våge DI *et al.* (2006) Carotenoid dynamics in Atlantic salmon. *BMC*
474   *Biol* **4**, 10-24.

475   49. Curek GD, Cort A, Yucel G et al. (2010) Effect of astaxanthin on hepatocellular injury
476   following ischemia/reperfusion. *Toxicology* **267**, 147-153.

477   50. Kim YJ, Kim YA & Yokozawa T (2009) Protection against oxidative stress, inflammation, and
478   apoptosis of high-glucose-exposed proximal tubular epithelial cells by astaxanthin. *J Agric*
479   *Food Chem* **57**, 8793-8797.

480   51. Liu X, Shibata T, Hisaka S *et al.* (2009) Astaxanthin inhibits reactive oxygen species-mediated
481   cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective
482   mechanism. *Brain Res* **1254**, 18-27.

483   52. Ikeda Y, Tsuji S, Satoh A *et al.* (2008) Protective effects of astaxanthin on 6-
484   hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. *J Neurochem*
485   **107**, 1730-1740.

486   53. Shen H, Kuo C-C, Chou J *et al.* (2009) Astaxanthin reduces ischemic brain injury in adult rats.
487   *FASEB J* **23**, 1958-1968.

488   54. Nakano M, Onodera A, Saito E *et al.* (2008) Effect of astaxanthin in combination with α-
489   tocopherol or ascorbic acid against oxidative damage in diabetic ODS rats. *J Nutr Sci Vitaminol*
490   **54**, 329-334.

491   55. Camera E, Mastrofrancesco A, Fabbri C *et al.* (2008) Astaxanthin, canthaxanthin and βcarotene
492   differently affect UVA-induced oxidative damage and expression of oxidative stress-responsive
493   enzymes. *Exp Dermatol* **18**, 222-231.

494   56. Iwamoto T, Hosoda K, Hirano R *et al.* (2000) Inhibition of low-density lipoprotein oxidation
495   by astaxanthin. *J Atheroscler Thromb* **7**, 216-222.

496   57. Li W, Hellsten A, Jacobsson LS *et al.* (2004) Alpha-tocopherol and astaxanthin decrease
497   macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits. *J*
498   *Mol Cell Cardiol* **37**, 969-978.

499

Legends

501

502 Fig. 1. Total cholesterol (A), triglycerides (B), HDL cholesterol (C) and LDL cholesterol (D) levels

503 of rabbits fed with a cholesterol and/or ASX enriched diet. Data are expressed as means ± S.E.M (n

504 = 6). *Different from control groups (p < 0.05).

505

506 Fig. 2. TBARS levels (A), protein carbonyl content (B), LDLox (C) and LDLoxAB (D) levels of

507 rabbits fed with a cholesterol and/or ASX enriched diet. Data are expressed as means ± SEM (n =

508 6). *Different from control groups (p < 0.05). †Different from ASX 0-Chol group (p < 0.05). ‡

509 Different from ASX 0-control group (p < 0.05). MDA = malondialdehyde.

510

511 Fig. 3. PON1 (A), SOD (B) and TrxR1 (C) activities of rabbits fed with a cholesterol and/or ASX

512 enriched diet. Data are expressed as means ± S.E.M (n = 6). *Different from control groups (p <

513 0.05). † Different from ASX 0-Chol group (p < 0.05).

Table 1 Fatty acid composition (% of total fatty acids) of serum from rabbits fed with a cholesterol and/or ASX enriched diet† (Mean values and standard error of the means for 6 animals per group)

Fatty acids	Control								Cholesterol							
	ASX0		ASX50		ASX100		ASX500		ASX0		ASX50		ASX100		ASX500	
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM
16 : 0	25.0	1.0	25.9	0.4	25.3	0.7	26.8	0.3	20.9*	0.3	21.8*	0.8	22.7*	1.2	23.3*	0.5
18 : 0	13.4	0.8	14.1	0.4	14.0	0.5	13.4	0.4	7.7*	0.4	7.6*	0.7	8.0*	0.7	8.3*	0.3
18 : 1n-9	19.4	1.8	17.2	0.9	17.2	0.9	19.0	0.1	30.2*	0.9	31.3*	0.6	29.4*	1.1	29.7*	0.4
18 : 2n-6	29.2	1.9	31.1	1.0	31.8	0.8	30.1	2.7	26.4	0.9	26.7	2.2	27.5	1.1	25.5	1.7
18 : 3n-3	4.1	1.0	4.0	0.3	3.7	0.5	4.0	0.3	3.3	0.2	3.3	0.2	3.9	0.4	3.6	0.4
20 : 4n-6	2.1	0.2	2.3	0.3	2.0	0.3	1.7	0.2	1.2*	0.1	1.5*	0.5	1.2*	0.1	1.2*	0.1
Σ SFA	43.4	1.9	45.6	0.8	45.1	1.7	45.3	1.2	33.7*	1.4	33.0*	2.5	34.2*	2.4	33.7*	1.7
Σ UFA	56.5	2.5	54.3	0.5	54.8	1.7	54.6	1.2	66.2*	1.5	66.9*	2.5	65.6*	2.4	66.1*	1.7
Σ MUFA	21.4	2.0	18.1	1.0	18.5	0.8	20.2	0.5	35.1*	0.7	35.4*	0.7	32.4*	1.5	33.8*	0.9
Σ PUFA	35.1	1.6	36.7	1.8	36.2	1.4	33.3	2.2	31.3	1.0	30.6	2.5	33.3	1.2	32.4	1.8
UFA/SFA ratio	1.4	0.1	1.3	0.0	1.3	0.1	1.3	0.1	2.0*	0.1	2.1*	0.2	2.0*	0.2	2.0*	0.1

ASX, astaxanthin; Σ SFA, sum of SFA; Σ UFA, sum of unsaturated fatty acids; Σ MUFA, sum of MUFA; Σ PUFA, sum of PUFA. * Different from control+ASX0 group ($p < 0.05$). †Average content of C6 : 0, C8 : 0, C10 : 0, C12 : 0, C14 : 0, C14 : 1, C15 : 0, C15 : 1, 16 : 1, C17 : 0, C17 : 1, C18 : 3n-6, C20 : 0, C20 : 1n-9, C21 : 0 and C24 : 0, were lower than 0.5 % of total fatty acids and for this reason, are not shown in the table.

Figure 1

Figure 2

Figure 3

PARTE III

DISCUSSÃO

O envolvimento do estresse oxidativo na etiologia da aterosclerose é conhecido uma vez que a liberação do ânion superóxido pelas células vasculares, no processo de formação de endoperóxidos cíclicos e prostaglandinas, pode ser responsável pelo início de processos oxidativos em algumas condições, tais como elevados níveis de colesterol na LDL (Lee e Prasad, 2003). Adicionalmente, a participação da lipoxigenase no processo de peroxidação lipídica na parede arterial, envolvendo a geração de hidroperóxidos lipídicos intermediários, está bem estabelecida (Steinberg, 1999). Os resultados do presente trabalho corroboram a participação da oxidação da LDL no processo aterogênico, uma vez que observamos níveis séricos elevados de LDLox concomitantemente com a formação de estrias gordurosas no tecido aórtico de coelhos hipercolesterolêmicos. A oxidação da LDL parece ocorrer em etapas distintas no interior da parede arterial, iniciando nos PUFA dos fosfolipídios da superfície da LDL e, a seguir, se propagando aos lipídios do núcleo hidrofóbico da lipoproteína, resultando em modificação oxidativa tanto dos PUFA como do colesterol e fosfolipídios. Após a propagação das reações de oxidação lipídica, iniciam-se os eventos de oxidação protéica, com modificação e degradação da Apo-B da LDL. (Batlouni, 1997).

No presente estudo, houve um aumento na oxidação lipídica no soro de coelhos e pacientes hipercolesterolêmicos, bem como no tecido aórtico de coelhos ateroscleróticos. Tal resultado indica que peroxidação lipídica é um evento importante durante a aterosclerose induzida por hipercolesterolemia, o que está de acordo com um estudo de Yang et al. (2008). Estes autores descrevem uma relação direta entre o índice aterogênico ([colesterol total – HDL] / colesterol total) e os níveis de malondialdeído, principal produto da reação de peroxidação lipídica, em pacientes em diferentes estágios de hiperlipidemia. Alguns estudos têm mostrado que

LDLs com alto conteúdo de MUFA são menos suscetíveis a peroxidação lipídica do que LDLs que contêm maior conteúdo de PUFA (Bonanome et al., 1992; Hargrove et al., 2000). Entretanto, no presente estudo os coelhos hipercolesterolêmicos apresentaram um aumento da peroxidação lipídica concomitante com um aumento nos níveis séricos de MUFA. Essa discrepância pode ser devido ao fato de que a esterificação do colesterol exógeno requer um aumento na síntese de MUFA, fazendo com que este seja facilmente incorporado às lipoproteínas (Ntambi, 1999). Dessa maneira, é possível que o efeito positivo dos MUFA nas LDLs tenha sido mascarado pelo aumento na incorporação do colesterol na LDL induzido pela síntese de MUFA. Essa hipótese é sustentada pelo aumento nos níveis de TBARS no soro de coelhos hipercolesterolêmicos mesmo com elevados níveis de MUFA nesses animais quando comparado ao grupo controle. Adicionalmente, foi observado um aumento na oxidação de proteínas no soro de coelhos e pacientes hipercolesterolêmicos no presente trabalho, o que sugere que a LDL encontra-se em sua forma altamente oxidada, com seus componentes lipídicos e protéicos modificados por processos de oxidação.

Os aumentos da peroxidação lipídica e da oxidação protéica no soro de coelhos e pacientes hipercolesterolêmicos foram acompanhados por uma elevação nos níveis séricos de LDLox, a qual induz a diferenciação de monócitos em macrófagos. Os macrófagos por sua vez, reconhecem e capturam a LDLox, originando as células espumosas, características das estrias gordurosas constituintes do ateroma (Batlouni, 1997). Em concordância, a elevação nos níveis de LDLox no soro de coelhos hipercolesterolêmicos foi acompanhada pela presença de estrias gordurosas no tecido aórtico. O acúmulo de LDLox na parede dos vasos estimula o recrutamento de leucócitos e plaquetas e a produção de anticorpos pelas células B (Angelique et al., 2005; Shoenfeld et al., 2004). De maneira semelhante, uma elevação nos níveis de LDLoxAB foi observada tanto em pacientes como em coelhos hipercolesterolêmicos no presente trabalho.

Embora os LDLoxAB sejam detectáveis em indivíduos saudáveis provavelmente como parte da reserva natural de anticorpos, uma elevação nos níveis de LDLoxAB, especificamente IgM, pode contribuir para manutenção de baixos níveis de LDLox no plasma (Fukumoto et al., 2000). Adicionalmente, LDLoxAB do tipo IgM bloqueia a captação de LDLox pelos macrófagos, prevenindo o acúmulo de LDLox e a formação de células espumosas (Shaw et al., 2001). Entretanto, a formação de células espumosas e estrias gordurosas no tecido aórtico de coelhos hipercolesterolêmicos foi observada neste estudo mesmo quando os níveis de LDLoxAB estavam elevados, o que sugere que os anticorpos produzidos não foram suficientes para conter a captação da LDLox pelos macrófagos e a formação da placa aterosclerótica. Adicionalmente, estudos recentes sugerem um efeito pró-aterogênico do LDLoxAB tipo IgG, pois os complexos desse anticorpo específico com a LDLox desencadeiam respostas inflamatórias ao se ligarem em receptores dos macrófagos (Shoenfeld et al., 2004; Kiener et al., 1995). Dessa maneira, os elevados níveis de LDLoxAB observados em coelhos hipercolesterolêmicos poderiam contribuir para a formação do ateroma. No presente trabalho observou-se também um aumento nos níveis de hs-CRP com o aumento dos níveis de LDL em pacientes. Além de induzir resposta imune, a LDLox desencadeia o processo inflamatório e em humanos um aumento crônico dos níveis de hs-CRP, um marcador de fase aguda da inflamação, é um fator de risco independente para doenças cardiovasculares (Chait et al., 2005). A elevação dos níveis de hs-CRP foi encontrada tanto em pacientes com níveis de LDL acima do valor considerado seguro (>160 mg/dl), quanto no soro de pacientes com níveis de LDL considerados clinicamente aceitáveis (130-160mg/dl). Esses resultados sugerem que os níveis séricos de hs-CRP são modificados no soro de humanos mesmo quando os níveis de LDL são considerados aceitáveis e que a hs-CRP circulante poderia ser um marcador de eventos coronarianos precoces. Essa hipótese é sustentada pela redução dos níveis

de hs-CRP e melhora no quadro de pacientes com doença cardiovascular estável por estatinas, independentemente dos níveis séricos de lipídios (Nissen et al., 2005).

Embora esteja bem estabelecida a importância da modificação oxidativa da LDL no processo aterosclerótico, outros lipídios séricos são suscetíveis à oxidação, como é o caso dos lipídios presentes na HDL (Bowry et al., 1992). A modificação oxidativa da HDL pode ocasionar efeitos que contribuem para o processo de aterogênese, como a redução da capacidade dessa lipoproteína em promover o efluxo de colesterol das células (Morel, 1994). A fim de se proteger do processo oxidativo e preservar suas funções, a HDL conta com a enzima PON1 associada a sua estrutura (Aviram et al., 1998). Assim, essa enzima protege a HDL, preservando suas funções anti-aterogênicas e, conseqüentemente, protege a LDL do processo oxidativo (Aviram et al., 1998). No presente estudo nós observamos uma redução na atividade da enzima PON1 no soro de coelhos hipercolesterolêmicos o que já foi observado em estudos anteriores onde a atividade da enzima foi inibida em indivíduos portadores de condições como a doença arterial coronariana (Karakaya et al., 1999), a hipercolesterolemia (Mackness et al., 1991b) e a hiperlipidemia (Paragh et al., 1998). Dessa maneira, nós podemos sugerir que a inibição da PON1 pode ter contribuído para a formação de estrias gordurosas no tecido aórtico de coelhos hipercolesterolêmicos no presente estudo. A redução na atividade da enzima PON1 ocorreu provavelmente devido a inibição da síntese hepática da PON1 induzida pela hiperlipidemia (Mackness et al, 1999). Adicionalmente, a inativação da PON1 pode ser o resultado da interação de lipídios oxidados da LDLox com o grupo SH livre no resíduo de cisteína 284 da PON 1 (Aviram et al., 1999). Apesar da redução na atividade da PON1 em coelhos hipercolesterolêmicos, nenhuma alteração na atividade da enzima PON1 foi observada em pacientes com níveis de LDL considerados de risco para ocorrência de doenças cardiovasculares. Tendo em vista que um aumento na concentração de PON em macrófagos é induzido a fim de

impedir a formação de placa aterosclerótica na parede arterial (Mackness et al., 1997), nós podemos sugerir que a ausência de alteração na atividade sérica da PON1 em pacientes hipercolesterolêmicos pode ser devido a um equilíbrio entre um aumento da PON1 como mecanismo de defesa contra a hipercolesterolemia e sua inativação por espécies oxidantes (Aviram, 2004). Assim, embora a PON1 seja apontada como indicador do risco independente para doenças cardiovasculares (Mackness et al., 2003), geralmente a atividade da enzima é avaliada no soro concomitantemente com a progressão na formação do ateroma. No presente estudo envolvendo humanos, a formação de ateroma não foi avaliada e por isso a importância da PON1 como fator de risco para doenças cardiovasculares não pode ser minimizada. Além disso, a associação entre a PON1 e os níveis séricos de LDL e LDLox foi observada em indivíduos com doença de Crohn, hipertensão e com pré-eclampsia (Bohen et al., 2009; Konukoglu et al., 2009; Uzun et al., 2005). Assim, mais estudos são necessários a fim de elucidar a relação entre os níveis de colesterol, estresse oxidativo e PON1 durante a HC, bem como para corroborar o papel da PON1 como indicador de eventos cardiovasculares subclínicos.

A produção EROs e o estresse oxidativo têm sido associados ao processo de aterogênese durante a hipercolesterolemia (Prasad e Kalra, 1993) e as enzimas antioxidantes SOD, CAT, GSHPx e TrxR-1 posuem a capacidade de proteger as células contra o dano oxidativo (Nordberg e Arnér, 2001). Além das enzimas antioxidantes, antioxidantes não enzimáticos como a GSH, que representa o principal composto contendo grupos tiólicos não protéicos (NPSH), podem também prevenir as injúrias induzidas por EROs (Nordberg e Arnér, 2001). No presente estudo nós observamos que a hipercolesterolemia altera o estatus antioxidante no soro e no tecido aórtico de coelhos. A atividade das enzimas SOD, CAT, TrxR-1 e os níveis de NPSH aumentaram no tecido aórtico de coelhos, bem como a atividade das enzimas SOD e TrxR-1 aumentaram no soro de coelhos e pacientes hipercolesterolêmicos. Essa elevação no estatus

antioxidante ocorreu provavelmente como uma resposta de defesa contra as EROs geradas pela hipercolesterolemia. Um aumento na expressão das SOD, CAT e TrxR-1 já foi descrito em macrófagos *in vitro* e em placas ateroscleróticas de humanos (Hägg et al., 2006). Em ambos os casos, o aumento da expressão das enzimas ocorreu provavelmente como resposta de defesa contra a LDLox (Hägg et al., 2006). Entretanto, o aumento na atividade das enzimas antioxidantes e nos níveis de NPSH não foi suficiente para prevenir a oxidação da LDL e o início do processo aterogênico no presente trabalho, uma vez que observamos elevados níveis séricos de LDLox e estrias gordurosas no tecido aórtico mesmo quando o estatus antioxidante estava elevado. Isso sugere, adicionalmente, que o estresse oxidativo induzido pela hipercolesterolemia excedeu a capacidade antioxidante endógena e induziu danos ao tecido aórtico. Adicionalmente, a formação de estrias gordurosas no tecido aórtico de coelhos observada em nosso estudo pode ser resultado da redução da atividade da enzima GSH-Px nesses animais, provavelmente devido à suscetibilidade dessa enzima a inibição por espécies oxidantes em placas ateroscleróticas (Lapena et al., 1998). A reduzida atividade da GSH-Px no tecido aórtico de coelhos ateroscleróticos também explicaria a elevação nos níveis de NPSH, uma vez que a GSH-Px inibida deixa de reduzir hidroperóxidos às custas de GSH.

Embora as alterações na atividade das enzimas antioxidantes SOD, CAT e GSH-Px durante hipercolesterolemia e a aterosclerose tenham sido amplamente descritas (Mantha et al., 1996; Erdinçler et al., 1997; Manjunatha e Srinivasan, 2007), alterações na atividade da enzima TrxR-1 no tecido aórtico e soro de coelhos hipercolesterolêmicos, bem como no soro de indivíduos com diferentes níveis de LDL foram demonstradas pela primeira vez no presente trabalho. A TrxR-1 pode reduzir hidroperóxidos diretamente (May et al., 2002) ou regenerar a proteína Trx-1, que servirá como equivalente redutor em múltiplos processos oxidativos (Wassmann et al., 2004). O sistema tioredoxina também pode regenerar proteínas inativadas por

condições oxidantes (Björnstedt et al., 1994). Assim, pode-se sugerir que o aumento na atividade da TrxR-1 sérica em coelhos e indivíduos com níveis crescentes de LDL poderia ser uma tentativa de contrabalancear a oxidação protéica observada em ambos os casos. Além disso, a remoção do H_2O_2 em excesso gerado pela SOD também poderia explicar o aumento da atividade da TrxR-1 observada no presente estudo. É interessante destacar que a elevação da atividade da TrxR-1 em humanos iniciou mesmo quando os níveis de LDL eram clinicamente aceitáveis, o que indica que essa enzima poderia ser um indicador precoce de alterações cardiovasculares. Entretanto, a falta de correlação entre os níveis de LDL e a atividade da TrxR-1 apontam a necessidade de elucidação do potencial dessa enzima como marcador de eventos cardiovasculares.

A oxidação da LDL é importante e, possivelmente, obrigatória no desenvolvimento das lesões ateroscleróticas (Batlouni, 1997). Assim, espera-se que a suplementação da dieta com compostos antioxidantes aumente a resistência da LDL contra processos oxidativos, prevenindo a incidência da aterosclerose. Antioxidantes provenientes da dieta, tais como as vitaminas C e E e carotenóides como licopeno, luteína e zeaxantina têm atraído interesse devido a alta capacidade desses compostos de remover EROs (Wilcox et al., 2008). Adicionalmente, compostos de selênio como o disseleneto de difenila são capazes de reduzir a hipercolesterolemia e estresse oxidativo em coelhos hipercolesterolêmicos devido às suas propriedades antioxidantes (de Bem et al., 2009).

No presente estudo o potencial antiaterogênico do carotenóide ASX foi avaliado no soro e tecido aórtico de coelhos. Embora todas as concentrações de ASX tenham prevenido o aumento na peroxidação lipídica causado por uma dieta hipercolesterolêmica no tecido aórtico, nenhuma concentração de ASX foi eficiente em prevenir a peroxidação lipídica no soro de coelhos hipercolesterolêmicos. O efeito protetor mais pronunciado da ASX contra a lipoperoxidação no

tecido aórtico em detrimento do soro pode ser explicado pela estrutura química deste carotenóide. A ASX circulante, devido à polaridade conferida pelos grupos hidroxila ligados a cadeia poliênica, localiza-se na superfície de quilomícrons e lipoproteínas, bem como pode estar ligada a albumina sérica (Aas et al., 2000). Assim, a localização da ASX não seria favorável para remover radicais livres no interior de lipoproteínas, local onde ocorrem as reações em cadeia de oxidação de lipídios (Noguchi, 2002). Contrariamente, nas células a ASX assume uma disposição espacial de modo que a cadeia poliênica remova radicais livres no interior hidrofóbico da membrana plasmática, enquanto os anéis polares removem radicais livres na superfície hidrofílica (figura 5) (Goto et al., 2001). Assim, no tecido aórtico a ASX removeria radicais livres eficientemente tanto no interior da membrana plasmática quanto na superfície, enquanto nas lipoproteínas o efeito antioxidante deste carotenóide seria mais pronunciado na superfície.

Figura 5: Orientação transmembrana da ASX. Adaptado de Paskow et al. (2008). EROs=espécies reativas de oxigênio; ASX=astaxantina.

De maneira semelhante, a ASX foi capaz de atenuar a elevação na atividade da SOD no tecido aórtico, mas não no soro de coelhos hipercolesterolêmicos. Uma vez que a ASX está em localização mais favorável para a remoção de EROs no tecido aórtico comparado ao soro, é plausível sugerir que a remoção de radicais livres pela ASX seja mais eficiente no tecido aórtico, poupando assim as defesas antioxidantes, como a enzima SOD.

Contrariamente ao efeito protetor da ASX no tecido aórtico em detrimento ao soro de coelhos hipercolesterolêmicos, observou-se no presente estudo que a todas as concentrações avaliadas de ASX atenuaram as alterações na atividade da TrxR-1 sérica causadas pela hipercolesterolemia. Entretanto, apenas a concentração de 50 mg% atenuou totalmente o efeito da hipercolesterolemia no tecido aórtico de coelhos enquanto as concentrações de 100 e 500mg% atenuaram parcialmente tais efeitos. Esse efeito protetor mais pronunciado no soro em comparação ao tecido aórtico pode ser um resultado direto do efeito protetor da ASX contra a oxidação protéica no soro. Uma vez que a elevação na atividade da TrxR-1 no soro de coelhos hipercolesterolêmicos parece ter ocorrido como uma resposta de defesa contra a oxidação protéica (Söderberg et al., 2000), a atenuação da oxidação de proteínas no soro pela ASX resultaria em um efeito atenuante também na atividade da TrxR-1. Apesar de a oxidação protéica causada pela hipercolesterolemia no tecido aórtico não ter sido avaliada no presente trabalho, a falta de proteção da ASX contra as alterações na atividade da TrxR-1 no tecido aórtico adicionalmente sugere que a produção de EROs se sobrepôs à capacidade antioxidante da ASX. Essa hipótese é sustentada pelo fato de que o efeito protetor da ASX contra alterações na atividade da SOD e peroxidação lipídica causadas pela hipercolesterolemia no tecido aórtico não resultou em proteção contra a formação de ateroma. Assim, os radicais livres excedentes exerceram seus efeitos na atividade da TrxR-1 e induziram a formação de placa ateromatosa.

Apesar da falta de efeito hipolipidêmico e antiaterogênico da ASX neste trabalho, estudos recentes destacam o potencial protetor desse carotenóide na prevenção de desordens associadas ao estresse oxidativo. Park et al. (2010) relataram o efeito protetor da ASX contra o estresse oxidativo e inflamação em indivíduos adultos saudáveis, bem como seu papel positivo na indução de resposta imune. Adicionalmente, a ASX preveniu a morte celular de neurônios *in vitro* induzida por peptídeo β-amilóide, o que indica um possível papel na prevenção e tratamento de doenças neurodegenerativas como a doença de Alzheimer (Chang et al., 2010). Um estudo de Cort et al. (2010) revelou a capacidade da ASX em reverter danos a retina causados por aumento na pressão intraocular em ratos.

CONCLUSÕES

Os resultados obtidos na presente Tese permitem concluir que:

1. Indivíduos com níveis séricos de LDL considerados de alto risco para ocorrência de doenças cardiovasculares (> 160 mg/dl) apresentam aumento na oxidação de lipídios e proteínas no soro, alterações na atividade de enzimas antioxidantes, bem como elevados níveis de LDLox, LDLoxAB e hs-CRP quando comparado a indivíduos com níveis de LDL considerados seguros (< 130 mg/dl). Tais resultados sugerem a ocorrência de processo oxidativo e inflamatório em indivíduos hipercolesterolêmicos.

2. A atividade da enzima TrxR-1 aumentou em indivíduos com níveis séricos de LDL considerados clinicamente aceitáveis (130-160 mg/dl) bem como em indivíduos hipercolesterolêmicos sugerindo que essa enzima poderia ser utilizada como um marcador de eventos cardiovasculares precoces. Adicionalmente, uma elevação na atividade da TrxR-1 foi observada no soro de coelhos hipercolesterolêmicos e no tecido aórtico de coelhos ateroscleróticos, indicando que essa enzima pode desempenhar um papel importante na hipercolesterolemia e aterosclerose.

3. Apesar da atividade da enzima PON1 estar inibida em coelhos hipercolesterolêmicos, sua atividade não foi afetada pela hipercolesterolemia em humanos, o que indica que estudos adicionais acerca da importância dessa enzima como preditor de eventos cardiovasculares devem ser conduzidos.

4. A adição de ASX na dieta atenuou o estresse oxidativo, mas não a hiperlipidemia e aterosclerose induzidas pela adição de colesterol na dieta, o que indica que outros fatores além do estresse oxidativo estão envolvidos no processo de aterogênese e que tais fatores não podem ser controlados pela ASX.

Considerando a participação do estresse oxidativo no processo de aterogênese, pode-se concluir que o uso de marcadores de estresse oxidativo como indicadores de eventos cardiovasculares deve ser considerado em um futuro próximo. Adicionalmente, mais estudos são necessários para elucidar completamente o papel de carotenóides como a ASX na prevenção e tratamento de doenças cardiovasculares.

PERSPECTIVAS

- Avaliar o potencial antiaterogênico de outros carotenóides visando uma possível ação na prevenção e tratamento de doenças cardiovasculares.

- Avaliar o potencial anitaterogênico de extratos de frutas nativas ricos em compostos antioxidantes.

- Padronizar metodologias mais específicas para avaliação de formação de placa ateromatosa, incluindo princípios de imunohistoquímica e marcadores de estabilidade do ateroma.

- Elucidar o papel da enzima TrxR-1 bem como da proteína Trx-1 durante a hipercolesterolemia e aterosclerose *in vitro* e *in vivo*.

- Avaliar o potencial de carotenóides na modulação da atividade da enzima PON 1.

- Elucidar o potencial da proteção conferida pela ASX sobre a atividade da TrxR-1 em patologias onde ocorre envolvimento do sistema tioredoxina.

- Realizar estudos de distribuição plasmática e tecidual de carotenóides específicos, elucidando o papel dos ácidos graxos nos processos de esterificação e transporte de carotenóides.

REFERÊNCIAS BIBLIOGRÁFICAS

Aas, G.H., Bjerkeng, B., Storebakken, T., Ruyter, B. Blood appearance, metabolic transformation and plasma transport proteins of 14c-astaxanthin in Atlantic salmon *(Salmo salar* l.). Fish Physiology and Biochemistry, 21 (4): 325-334 (1999).

Aebi, H. Catalase in vitro**.** Methods in Enzymology, 105 (1): 121-126 (1984).

Agarwal, A., Rao, A.V. Tomato lycopene and its role in human health and chronic diseases. Canadian Medical Association Journal, 163 (6): 739-744 (2000).

Andersen, L.F., Solvoll L, K., Johansson, L.R., Salminen I., Aro, A., Drevon, C.A. Evaluation of a food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose tissue and serum. American Journal of Epidemiology, 150 (1), 75-87 (1999).

Angelique, C.M., Jansen, E.S., Van Alst-cohen, M.W.T., Tanck, S.C., Fontecha, M. R., Joep, J.L., Defesche, C., Kastelein, J. J. P. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 25 (7): 1475-1481 (2005).

Asheikh, A.A., Kuvin, J.T., Karas, R.H. High-density lipoprotein cholesterol in the cardiovascular equation: Does the "good" still count? Atherosclerosis, 180 (2): 217-223 (2005).

Assmann, G., Gotto, A.M. HDL-cholesterol and protective factors in atherosclerosis. Circulation, 109 (3): 8-14 (2004).

Atkin, M.A., Gasper, A., Ullegaddi R., Powers, H.J. Oxidative susceptibility of unfractionated serum or plasma: response to antioxidants *in vitro* and to antioxidant supplementation. Clinical Chemistry, 51 (11): 2138-2144 (2005).

Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C.L., Newton R. S., La Du B. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biology and Medicine, 26 (7): 892-904 (1999).

Aviram, M. Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Free Radical Biology and Medicine, 37 (9): 1301-1303 (2004).

Barreiros, A.L.B.S., David, J.M. Estresse oxidativo: relação entre geração de espécies reativas e defesa do organismo. Quimica Nova, 29 (1): 113-123 (2006).

Batlouni, M. Hipótese oxidativa da aterosclerose e emprego dos antioxidantes na doença arterial coronária. Arquivos Brasileiros de Cardiologia, 68 (1): 55-63 (1997).

Berliner, J.A., Navab, M., Fogelman, A.M., Frank J.S., Demer, L.L., Edwards P.A., Watson A.D., Lusis, A.J. Atherosclerosis: Basic Mechanisms. Oxidation, inflammation, and genetics. Circulation, 91 (9): 2488-2496 (1995).

Bjornsted, M., Xue, J., Huang, W., Akesson, B., Holmgren, A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. The Journal of Biological Chemistry, 269 (47): 29382-29384 (1994).

Blankenberg S., Rupprecht H. J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., Lackner K.J. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. The New England Journal of Medicine, 349 (17): 1605–1613 (2003).

Boehm, D., Krzystek-Korpacka, M., Neubauer, K., Matusiewicz, M., Berdowska, I., Zielinski, B., Paradowski, L., Gamian, A. Paraoxonase-1 status in Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 15 (1): 93-99 (2009).

Bonamone, A., Pagnan A., Biffanti S., Opportuno A., Sorgato, F., Dorella, M., Maiorino M., Ursini, F. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arteriosclerosis, Thrombosis and Vascular Biology, 12 (4): 529-533 (1992).

Brewer, H.B. Focus on high-density lipoproteins in reducing cardiovascular risk. American Heart Journal, 148 (1): 14-18 (2004).

CALIBEX. Astaxanthin - price finder, 2008. Disponível em:<http://www.calibex.com/astaxanthin/zzcalibex2zB1z0--search-html>. Acesso em: 28/05/2010.

Carreras, M.C., Franco, M.C., Peralta, J.G., Poderoso, J.J. Nitric oxide, complex I, and modulation of mitochondrial reactive species in biology and disease. Molecular aspects of medicine, 25 (1-2): 125-139 (2004).

Chait, A., Han, C.Y., Oram, J.F., Heinecke, J. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? Journal of Lipid Research, 46 (3): 389-403 (2005).

Chang, C.H., Chen, C.Y., Chiou, J.Y., Peng, R.Y., Peng, C.H. Astaxanthine secured apoptotic death of PC12 cells induced by beta-amyloid peptide 25-35: its molecular action targets. Journal of Medicinal Food, 13 (3): 548-556 (2010).

Cort, A., Ozturk, N., Akpinar, D., Unal, M., Yucel, G., Ciftcioglu, A., Yargicoglu, P., Aslan, M. Suppressive effect of astaxanthin on retinal injury induced by elevated intraocular pressure. Regulatory Toxicology and Pharmacology, *In Press* (2010).

Costa L.G., Cole, T.B., Jaivik, G.P., Furlong, C.E. Functional genomics of the paraoxonase (PON1) polymorphisms: effect on pesticide sensitivity, cardiovascular disease and drug metabolism. Annual Review of Medicine, 54 (1): 371-392 (2003).

Costa, L.G., Cole, T.B., Furlong, C.E. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomedica, 76 (2): 50-57 (2005).

De Bem, A.F., Portella. R. de L., Colpo, E., Duarte, M.M., Frediane, A., Taube, P.S., Nogueira, C.W., Farina, M., da Silva, E.L., Rocha, J.B.T. Diphenyl diselenide decreases serum levels of total cholesterol and tissue oxidative stress in cholesterol-fed rabbits. Basic and Clinical Pharmacology and Toxicology, 105 (1): 17-23 (2009).

Duarte, M.M.M.F., Rocha, J.B.T., Moresco, R.N., Duarte, T., Da Cruz I.B.M., Loro, V.L., Schetinger, M.R.C. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clinical Biochemistry, 42 (7-8): 666–671 (2009).

Duarte, M.M.M.F., Loro, V.L., Rocha, J.B.T., Leal, D.B.R., De Bem A.F., Dorneles, A., Morsch V.M., Schetinger M.R.C. Enzymes that hydrolyze adenine nucleotides of patients with hypercholesterolemia and inflammatory processes. FEBS Journal, 274 (11): 2707-2714 (2007).

Durrington, P.N., Mackness, B., Mackness, M.I. Paraoxonase and Atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 21 (4): 473-480 (2001).

Erdinçler, D.S., Seven, A., Inci F., Be T., Candan G. Lipid peroxidation and antioxidant status in experimental animals: effects of aging and hypercholesterolemic diet. Clinica Chimica Acta, 265 (1): 77-84 (1997).

Esporcatte, R., Albuquerque, D.C., Rocha, L.M., Rangel, F.O.D. Aterosclerose, inflamação e infecção. Revista da SOCERJ, 17(1): 19-25 (2004).

Farmer, J.A., Gotto, A.M.J. Dyslipidemia and the vulnerable plaque. Progress in Cardiovascular Diseases, 44 (6): 415-428 (2002).

Fielding, C.J., Fielding, P.E. Molecular physiology of reverse cholesterol transport. Journal of Lipid Research, 36 (2): 211-228 (1995).

Flohè, L., Brand, I.K. Kinetics of glutathione peroxidase. Biochimica et biophysica Acta, 191 (3): 541-549 (1969).

Forti, N., Diament, J. Lipoproteínas de Alta Densidade: Aspectos Metabólicos, Clínicos, Epidemiológicos e de Intervenção Terapêutica. Atualização para os Clínicos. Arquivos Brasileiros de Cardiologia, 87 (5): 672-679 (2006).

Fukumoto, M., Shoji, T., Emoto, M., Kawagishi, T., Okuno, Y., Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arteriosclerosis, Thrombosis and Vascular Biology, 20 (3): 703-707 (2000).

Frederiksen, H., Rasmussen, S. E., Schrøder, M., Bysted, A., Jakobsen, J. Frandsen, H. Ravn-Haren, G., Mortensen, A. Dietary supplementation with an extract of lycopene-rich tomatoes does not reduce atherosclerosis in Watanabe Heritable hyperlipidemic rabbits. British Journal of Nutrition, 97 (1): 6-10 (2007).

Furman, C., Rundlof, A.K., Larigauderie, G., Jaye, M., Bricca, G., Copin, C., Kandoussi, A.M., Fruchart, J.C., Arner, E.S., Rouis, M. Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins. Free Radicals Biology and Medicine, 37 (1): 71-85 (2004).

Furman, M.I., Benoit, S.E., Bernard, M.R., Valceri, C.R., Borbone, M.I., Becker, R.C., Hechtman, H.B., Michelson, A.D. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. Journal of the American College of Cardiology, 31 (2): 352-358 (1998).

Gao, Z., Huang, K., Yang, X., Xu, H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of *Scutellaria baicalensis* Georgi. Biochimica et Biophysica Acta, 1472 (3): 643-650 (1999).

Glass, C.K.; Witztum, J.L. Atherosclerosis: the road ahead. Cell, 104 (4): 503-516 (2001).

Goto, S., Kogure, K., Abe, K., Kimata, Y., Kitahama, K., Yamashita, E., Terada, H. Effiecient radical trapping at the surface and inside the phospholipid membrane is responsible for high potent antiperoxidative activity of the carotenoid astaxanthin. Biochemica et Biophysica Acta, 1512 (2): 251-258 (2001).

Hägg, D., Englund, M.C.O., Jerna, M., Schimidt C., Wiklund O., Hultén, L. M., Ohlsson, B. G., Carlssona L. M. S., Carlsson B., Syensson P. A. Oxidized LDL induces a coordinated upregulation of the glutathione and thioredoxin systems in human macrophages. Atherosclerosis, 185 (2): 282-289 (2006).

Halliwell, B., Gutteridge, J.M.C. Role of free radicals and catalytic metal ions in human disease: an overview. Methods in Enzymology, 186 (parte B): 1-85 (1990).

Hargrove, R.L., Etherton T.D., Pearson, T.A., Harrison, E.H., Kris-Etherton, P.M. Low fat and high monounsaturated fat diets decrease human low density lipoprotein oxidative susceptibility in vitro. Journal of Nutrition, 131 (6): 1758-1763 (2001).

Harris, W.S., Isley, W.L. Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids. Current Atherosclerosis Reports, 3 (2): 174-179 (2001).

Higuera-Ciapara, L., Velenzuela, F., Goycoolea, F.M. Astaxanthin: a review of its chemistry and applications. Critical Reviews in Food Science and Nutrition, 46 (2): 185-196 (2006).

Hokamaki, J., Kawano, H., Soejima, H., Miyamoto, S., Kajiwara, I., Kojima, S., Sakamoto, T., Sugiyama, S., Yoshimura, M., Nakamura, H., Yodoi, J., Ogawa, H. Plasma thioredoxin levels in patients with unstable angina. International Journal of Cardiology, 99 (2): 225-231 (2005).

Holmgren, A., Björnstedt, M. Thioredoxin and thioredoxin reductase. Methods in Enzymology, 252: 199-208 (1995).

Hunt, C., Sim, J.E., Sullivan, S.J., Featherstone, T., Golden, W., Kapp-Herr, C.V., Hock, R.A., Gomez, R.A., Parsian, A.J., Spitz, D.R. Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. Cancer Research, 58 (17): 3986-3992 (1998).

Itabe, H., Ueda, M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. Journal of Atherosclerosis and Thrombosis, 14 (1): 1-11 (2007).

Iwamoto, T., Hosoda, K., Hirano, R. Inhibition of low-density lipoprotein oxidation by astaxanthin. Journal of Atherosclerosis and Thrombosis, 7 (4): 216-222 (2000).

Jacobsson, L.S., Yuan, X.M., Ziedén, B., Olsson, A.G. Effects of α-tocopherol and astaxanthin on LDL oxidation and atherosclerosis in WHHL rabbits. Atherosclerosis, 173 (2): 231-237 (2004).

Jekell, A., Hossain, A., Alehagen, U., Dahlstrom, U., Rosen, A. Elevated circulating levels of thioredoxin and stress in chronic heart failure. European Journal of Heart Failure, 6 (7): 883-890 (2004).

Karakaya, A., Ibis, S., Kural, T., Köse, S.K., Karakaya, A.E. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chemical-Biological Interactions, 118 (3): 193-200 (1999).

Keaney, J. F., Frei, B. in: Balz. Frei (Ed.), Natural antioxidants in Human Health and Disease, Academic Press, San Diego, 1994, 303p.

Kiener, P.A., Rankin, B.M., Davis, P.M., Yocum, S.A., Warr, G.A., Grove, R.I. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arteriosclerosis, Thrombosis and Vascular Biology, 15 (7): 990-999 (1995).

Konukoglu, D., Fırtına, S., Serin, O., Cavusoglu, C. Relationship among plasma secretory phospholipase A_2, oxidized low density lipoprotein & paraoxonase activities in hypertensive subjects treated with angiotensin converting enzyme inhibitors. Indian Journal of Medical Research, 129 (4): 390-394 (2009).

Lapenna, D., Gioia, S., Ciofani, G., Mezzetti, A., Ucchino, S., Calafiore, A.M., Napolitano, A.M., Di Ilio, C., Cuccurullo, F. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation, 97 (19): 1930-1934 (1998).

Lee, P., Prasad, K. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by cyclooxygenase inhibitors. International Journal of Angiology, 12 (1): 13-23 (2003).

Li, W., Hellsten, A., Jacobsson, L.S., Blomqvist, H.M., Olsson, A.G., Yuan, X.M. Alphatocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits. Journal of Molecular and Cellular Cardiology, 37 (5): 969-978 (2004).

Libby, P. Inflamation in atherosclerosis. Nature, 420 (6917): 868-874 (2002).

Linsel-Nitschke P., Tall, A. HDL as a target treatment of atherosclerotic cardiovascular disease. Nature Reviews Drugs Discovery, 4 (3): 193-205 (2005).

Liu, W.S., Wu, J.Y. Hydrogen peroxide-induced astaxanthin biosynthesis and catalase activity in Xanthophyllomyces dendrorhous. Applied Microbial and Cell Physiology, 73 (3): 663-668 (2006).

Mackness, M.I., Arrol, S., Durrington, P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoproteins. FEBS Letters, 286 (1-2): 152-154, (1991a).

Mackness, M.I., Harty, D., Bhatnagar, D., Winocour, P.H., Arrol, S., Ashola, M., Durrington P., N., Serum paraoxonase activity in familial hypercholesterolemia and insulin dependent diabetes mellitus. Atherosclerosis, 86 (2): 193-199 (1991b).

Mackness, B., Hunt, R., Durrington, P. N., Mackness, M. I. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 17 (7): 1233-123 (1997).

Mackness, M.I., Durrington, P.N., Ayup, A., Mackness, B. Low serum paraoxonase: a risk factor for atherosclerotic disease? Current Oppinion in Lipidology, 119 (120): 389-397 (1999).

Mackness, B., Durrington, P., McElduff, P., Yarnell, J., Azam, N., Watt, M., Mackness, M. Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study. Circulation, 107 (22): 2775-2779 (2003).

Madamanchi, N.R., Vendrov, A., Runge, M.S. Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis and Vascular Biology, 25 (1): 29-38 (2005).

Mckenney, J.M. Pharmacotherapy of dyslipidemia. Cardiovascular Drugs and Therapy, 15 (5): 413-422 (2001).

Manjunatha, H., Srinivasan, K. Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in Induced hypercholesterolemic rats. Lipids, 42 (12): 1133-1142 (2007).

Mantha, S.V., Kalra, J., Prasad, K. Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. Life Science, 58 (6): 503-509 (1996).

Matssura, E., Kobayashi, K., Tabuchi, M., Lopez, L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Progress in Lipid Research, 45 (6): 466-86 (2006).

May, J.M., Morrow, J.D., Burk, R.F. Thioredoxin reductase reduces lipid hidroperoxides and spares α-tocopherol. Biochemical and Biophysical Research Communications, 292 (1): 45-49 (2002).

Miyamoto, M., Kishimoto, C., Shioji, K., Lee, J.D., Shimizu, H., Ueda, T., Yodoi, J. Cutaneous arteriolar thioredoxin expression in patients with heart failure. Circulation Journal 67 (2): 116-118 (2003).

Morel, D.M., DiCorletto, P.E., Chisholm, G.W. Endothelial and smooth muscle cells alter low-density lipoprotein in vitro by free radical oxidation. Arteriosclerosis, Thrombosis and Vascular Biology, 4 (4): 357-364 (1984).

Morel, D.W. Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochemical and Biophysical Research Communications, 200 (1): 408-416 (1994).

Murray, R.K., Granner, D.K., Mayes, P.A., Rodwell, V.W. Harper's Biochemistry; 24 ed. Stamford: Appleton & Lange, 1996, 868p.

Naguib, Y.M. Antioxidant activities of astaxanthin and related carotenoids. Journal of Agricultural and Food Chemistry, 48 (4): 1150-1154 (2000).

Nelson, D.L., Cox, M.M. Lehninger Princípios de bioquímica. 3 ed. São Paulo: Sarvier 2000. 973p.

Nissen, S.E., Tuzcu, E.M., Schoenhagen, P., Crowe, T., Sasiela, W.J., tsai, J., Orazem, J., Magorien, R.D., O'Shaughnessy, C., Ganz, P. Statin therapy, LDL cholesterol, C-reactive

protein, and coronary artery disease. The New England Journal of Medicine, 352 (1): 29-38 (2005).

Noguchi, N. Novel insights into the molecular mechanisms of the antiatherosclerotic properties of antioxidants: the alternatives to radical scavenging. Free Radical Biology and Medicine, 33 (11): 1480-1489 (2002).

Nordberg, J., Arnér, E.S.J. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biology and Medicine., 31 (11): 1287-1312 (2001).

Ntambi, J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. Jounal of Lipid Research, 40 (9): 1549-1558 (1999).

Ohara, Y., Peterson, T.E., Harrison, D.G. Hypercholesterolemia increases endothelial superoxide anion production. The Journal of Clinical Investigation, 91 (6): 2546-2551 (1993).

Okuda, M., Inoue, N., Azumi, H., Seno, T., Sumi, Y., Hirata, K., Kawashima, S., Hayashi, Y., Itoh, H., Yodoi, J., Yokoyama, M. Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology, 21 (9): 1483-1487 (2001).

Osganian, S. K., Stampfer, M. J., Rimm, E., Spiegelman, D., Manson, J. E., Willett, W. C. Dietary carotenoids and risk of coronary artery disease in women. The American Journal of Clinical Nutrition, 77(6): 1390-1399 (2003).

Palinski, W., Ylä-Herttuala, S., Rosenfeld, M.E. Butler, S.W., Socher S., A., Parthasarathy, S., Curtiss, L., K., Witztum, J., L., Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis, 10 (3): 325-335 (1990).

Panchenko, M.P., Silva, N., Stone, J.R. Upregulation of a hydrogen peroxide responsive pre-mRNA binding protein in atherosclerosis and intimal hyperplasia. Cardiovascular Pathology, 18 (3): 167-172 (2009).

Paragh, G., Seres, I., Balogh, Z., Varga, I., Karpati, I., Matyus, J., Ujhelyi, L., Kakuk, G. The serum paraoxonase activity in patients with choronic failure and hyperlipidemia. Nephron, 80 (2): 166-170 (1998).

Park, J.S., Chyun, J.H., Kim, Y.K., Line, L.L., Chew, B.P. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & Metabolism 7 (1): 18-27 (2010).

Pashkow, F.J., Watumull, D.G., Campbell, C.L. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. The American Journal of Cardiology, 101 (10A): 10158-10168 (2008).

Prasad, K., Karla, J. Oxygen free radicals and hypercholesterolemic atherosclerosis. American Heart Journal, 125 (4): 958-971 (1993).

Powis, G., Montfort, W.R. Properties and biological activities of thioredoxins. Annual Review of Biophysics and Biomolecular Structure, 19 (2): 239-248 (2005).

Schaefer, E.J. Lipoproteins, nutrition, and heart disease. American Journal of Clinical Nutrition, 75 (2): 191-212 (2002).

Schenke, D.C., Carew, T.E. Initiation of atherosclerosis lesions in cholesterol-fed rabbits, I:focal increases in arterial LDL concentrations precede development of fatty streak lesions. Arteriosclerosis, 9 (1): 908-918 (1989a).

Schenke, D.C., Carew, T.E. Initiation of atherosclerosis lesions in cholesterol-fed rabbits, II: selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis, 9 (1): 908-918 (1989b).

Schroeder, W.A., Johnson, E.A. Antioxidant role of carotenoids in *Phaffia rhodozyma*. Journal of General Microbiology, 139 (5): 907-912 (1993).

Schroeder, W.A., Johnson, E.A. Singlet oxygen and peroxyl radicals regulate carotenoid biosynthesis in *Phaffia rhodozyma*. The Jornal of Biological Chemistry, 270 (31): 18374-18379 (1995).

Shaw, P.X., Horkko, S., Tsimikas, S., Chang, M. K., Palinski, W., Silverman, G. J., Chen, P. P., Witztum, J.L. Human derived anti oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arteriosclerosis, Thrombosis and Vascular Biology, 21 (8): 1333-1339 (2001).

Shoenfeld, Y., WU, R., Dearing, L.D., Matsuura, E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation, 110 (17): 2552-2558 (2004).

Sies, H. Oxidative stress. London: Academic, 1985, 507p.

Sies, H. Strategies of antioxidant defence. Review. European Journal of Biochemistry, 215 (2): 213-219 (1993).

Sies, H. What is oxidative stress?? In: Keaney, J.F. Jr., ed. Oxidative stress and cardiovascular diseases. Boston: Kluwer Academic Publisher, 1-18 (2000).

Silva, E.G., Behr, G.A., Zanotto-Filho, A., Lorenzi, R., Pasquali, M.A., Ravazolo, L.G., Bordignon, C.L. Jr., Silva, F.A., Aboy, A.L., Bassani, V.L., Henriques, A.T., Reginatto, F.H., Dal-Pizzol, F., Moreira, J.C. Antioxidant activities and free radical scavenging potential of

Bauhinia microstachya (RADDI) MACBR. (Caesalpinaceae) extracts linked to their polyphenol content. Biological and Pharmaceutical Bulletin, 30 (8): 1488-1496 (2007).

Sociedade Brasileira de Cardiologia. Diretrizes brasileiras sobre dislipidemias e diretriz de prevenção da aterosclerose do departamento de aterosclerose da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros de Cardiologia, 77 (III):1-48 (2001).

Söderberg, A., Sahaf, B., Rosén, A. Thioredoxin reductase, a redoxactive selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Research, 60 (8): 2281-2289 (2000).

Sparrow, C.P., Parthasarathy, S., Steinberg, D. A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. Journal of Biological Chemistry, 264 (5) 2509-2604 (1989).

Spiekermann, S., Landmesser, U., Dikalov, S., Bredt, M., Gamez, G., Tatge, H., Reepschläger, N., Hornig, B., Drexler, H., Harrison, D.G. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation, 107 (10): 1383-1389 (2003).

Steinberg, D. At last, direct evidence that lipoxygenases play a role in atherogenesis. Journal of Clinical Invesigation, 103 (11): 1487-1488 (1999).

Steinberg, D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nature Medicine, 8 (11): 1211-1217 (200 2).

Steinberg, D. Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Molecular Nutrition and Food Research, 49 (11): 995-998 (2005).

Steinbrecher, U.P., Zhang, H.F., Lougheed, M. Role of oxidatively modified LDL in atherosclerosis. Free Radical Biology and Medicine, 9 (2): 155-168 (1990).

Stocker, R., Keaney, J.F. Role of oxidative modifications in atherosclerosis. Physiological Reviews. 84 (4): 1381-1478 (2004).

Stralin, P., Karlsson, K., Johansson, B.O., Marklund, S.L. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arteriosclerosis, Thrombosis and Vascular Biology, 15 (11): 2032-2036 (1995).

Sun, Q.A., Wu, Y. Zappacosta, F., Jeang, K.T., Lee, B.J., Hatfield, D.L., Gladyshev, V.N. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. Journal of Biological Chemistry, 274 (35): 24522-24530 (1999).

Takagi, Y., Gon, Y., Todaka, T., Nozaki, K., Nishiyama, A., Sono, H., Hashimoto, N., Kikuchi, H., Yodoi, J. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries. Laboratory Investigation 78 (8): 957-966 (1998).

Toss, H., Lindahl, B., Siegbahn, A. Wallentin, L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation, 96 (12): 4204-4210 (1997).

Uzun, H., Benian, A., Madazlı, R., Topçuoglu, M.A., Aydın, S., Albayrak, M. Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia. Gynecologic and Obstetric Investigation, 60 (1): 195-200 (2005).

Vaz, J.S., Deboni, F., Azevedo, M.J., Gross, J.S., Zelmanovitz, T. Ácidos graxos como marcadores biológicos da ingestão de gorduras. Revista de Nutrição, 19 (4): 489-500 (2006).

Verma, S., Szmitko, P.E., Yeh, E.T.H. C-reactive protein: structure affects function. Circulation, 109 (16): 1914 -1917 (2004).

Verma, S., Wang, C.H., Li, S.H., Dumont, A.S., Fedak, P.W., Badiwala, M.V., Dhillon, B., Weisel, R.D., Li, R.K., Mickle, D.A., Stewart, D.J. A self-fulfilling prophecy: C-reactive protein

attenuates nitric oxide production and inhibits angiogenesis. Circulation, 106 (8): 913-919 (2002).

Wang C.H., Li, S.H., Weisel, R.D., Fedak, P.W. Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation, 107 (13): 1783-1790 (2003).

Wassmann, S., Wassmann, K., Nickenig, G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension, 44 (4): 381-386, (2004).

Willcox, B.J., Curb, J.D., Rodriguez, B.L. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. American Journal of Cardiology, 101 (10): 75-86 (2008).

World Health Organization (who). Cardiovascular diseases (CVDs). Fact sheet n°317, september 2009. http://www.who.int/entity/mediacentre/factsheets/fs317/en/index.html. Acessado em 24/05/2010.

World Health Organization (WHO). Atlas of cardiovascular diseases world health organization, 2004. http://www.who.int/cardiovascular_diseases/resources/atlas. Acessado em 24/05/2010.

Wu, T., Liao, J., Hou, W., Huang, F., Maher, T.J., Hu, C. Astaxanthin protects against oxidative stress and calcium-induced porcine lens protein degradation. Journal of Agricultural and Food Chemistry, 54 (6): 2418-2423 (2006).

Yang, R., Shi, Y., Hao, G., LI, W., LE, G. Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index, Journal of Clinical and Biochemistry and Nutrition, 43 (3): 154-158 (2008).

Yla-Herttuala, S., Palinski, W., Butler, S., Picard, S., Steinberg, D., Witztum, J. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arteriosclerosis, Thrombosis and Vascular Biology, 14 (1): 32-40 (1994).

Yoshida, S., Katoh, T., Tetsuka, T., Uno, K., Matsui, N., Okamoto, T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. Journal of Immunology 163 (1): 351-358 (1999).

ANEXOS

ANEXO I

Termo de consentimento livre e esclarecido assinado pelos participantes do estudo envolvendo seres humanos

TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO

Você está sendo convidado a participar de um estudo intitulado "POTENCIAL ANTIATEROGÊNICO DE CAROTENÓIDES IN VIVO E IN VITRO", que tem como objetivo geral avaliar os indicadores de estresse oxidativo em pacientes com diferentes níveis de colesterol e sua relação com o processo inflamatório. Este projeto é importante para verificar se diferentes níveis de colesterol afetam as defesas antioxidantes do organismo.

O estudo será desenvolvido no Núcleo Integrado de Desenvolvimento em Análises Laboratoriais (NIDAL) (Departamento de Tecnologia e Ciência dos Alimentos) da Universidade Federal de Santa Maria e no laboratório de Análises Clínicas Labimed na cidade de Santa Maria. Este estudo envolverá pacientes com diferentes níveis de colesterol da cidade de Santa Maria, Rio Grande do Sul. Os pacientes serão selecionados aleatoriamente no laboratório de Análises Clínicas Labimed antes de se submeterem a coleta de amostra. Após a realização dos exames laboratoriais, as amostras serão enquadradas nos grupos estudados. Eventualmente, quando a amostra pertencer a um grupo que já esteja completo, tal amostra não será utilizada e será descartada.

Os pesquisadores responsáveis pelo estudo são a Profa. Dra. Tatiana Emanuelli e a Msc. Paula Rossini Augusti, aluna do Programa de Pós Graduação em Bioquímica, da UFRGS. Em qualquer etapa do estudo você terá acesso aos pesquisadores responsáveis pelo estudo para esclarecimento de eventuais dúvidas

Este estudo obteve aprovação junto ao Comitê de Ética em Pesquisa da Universidade Federal de Santa Maria, com protocolo n° 23081.019182/2007-10

112

Procedimentos a serem realizados

Você deverá realizar apenas uma coleta, onde serão retirados cerca de 8 ml de sangue, sem qualquer custo, no laboratório de Análises Clínicas Labimed na cidade de Santa Maria. O sangue será coletado em tubos estéreis e individuais para cada paciente e posteriormente será armazenado por um período de no máximo 24 meses, para a realização de todas as análises previstas. O sangue coletado será armazenado no Núcleo Interado de Desenvolvimento em Análises Laboratoriais (NIDAL, Departamento de Tecnologia e Ciência dos Alimentos) da Universidade Federal de Santa Maria, sob responsabilidade da Professora Tatiana Emanuelli. Você receberá os resultados dos exames laboratoriais de colesterol total, colesterol LDL e HDL e triglicerídeos. Eventualmente, se você se enquadrar em um grupo que já esteja completo, sua amostra não será utilizada no estudo e será descartada.

Riscos individuais, possibilidade de exclusão e benefícios

A coleta de sangue é um procedimento de baixo risco e desconforto. No entanto, em alguns casos, pode ocorrer formação de hematoma local, que será tratado através da realização de massagem local com gel ou pomada contendo medicamento para promover a absorção do hematoma, sem nenhum custo.

Fica claro que você não é obrigado a participar do projeto. No caso de recusa você não terá nenhum prejuízo no seu atendimento rotineiro, nem represálias. A qualquer momento da pesquisa você é livre para retirar-se da mesma.

No caso de aceite, fica claro que não haverá benefício financeiro pela sua participação, nem prejuízos ou riscos a sua saúde.

Ao receber os resultados dos seus exames de colesterol total, colesterol LDL e HDL e triglicerídeos você será orientado a procurar atendimento médico, caso os valores encontrados apresentem alguma alteração.

Confidencialidade

Os dados obtidos com esta pesquisa se constituirão em publicações em revistas médico-científicas. Os seus dados serão analisados em conjunto com outros pacientes, e será garantida a confidencialidade dos dados que possam lhe identificar.

Utilização dos dados obtidos

O material coletado e os seus dados serão utilizados somente para esta pesquisa.

Telefones para contato com os pesquisadores
Prof. Dra. Tatiana Emanuelli – Departamento de Tecnologia e Ciência dos Alimentos – CCR
(55) 3220 8547
email: tatiemanuelli@smail.ufsm.br

Msc. Paula Rossini Augusti - Pós Graduação em Ciências Biológicas-Bioquímica – ICBS – UFRGS
Email: paula_augusti@terra.com.br
(55) 3220 8547, (55) 32254728, (55) 96070821

Acredito ter sido suficientemente informado a respeito das informações que li ou que foram lidas para mim, descrevendo o estudo "POTENCIAL ANTIATEROGÊNICO DE CAROTENÓIDES IN VIVO E IN VITRO". Eu discuti com a Profa. Dra. Tatiana Emanuelli sobre a minha decisão em participar nesse estudo. Ficaram claros para mim quais são os propósitos do estudo, os procedimentos a serem realizados, seus desconfortos e riscos, as garantias de confidencialidade e de esclarecimentos permanentes. Ficou claro também que minha participação é isenta de despesas e que tenho garantia do acesso a tratamento hospitalar quando necessário. Concordo voluntariamente em participar deste estudo e poderei retirar o meu consentimento a qualquer momento, antes ou durante o mesmo, sem penalidades ou prejuízo ou perda de qualquer benefício que eu possa ter adquirido, ou no meu atendimento neste Serviço.

Identificação do (a) paciente

Nome: _____

RG (número da identidade: _____

Assinatura: _____

Santa Maria, _____ de _____de 2007.

Declaro que obtive de forma apropriada e voluntária o Consentimento Livre e Esclarecido deste sujeito de pesquisa ou representante legal para a participação neste estudo.

Santa Maria, _____ de _____de 2007.

_____

Assinatura do responsável pelo estudo

ANEXO II

Normas para preparação de manuscritos para submissão ao periódico Clinical Biochemistry

Clinical Biochemistry
Official Journal of the Canadian Society of Clinical Chemists

Guide for Authors

INTRODUCTION
• Types of paper
• Contact details for submission
• Page charges
BEFORE YOU BEGIN
• Ethics in Publishing
• Conflict of interest
• Submission declaration
• Authorship
• Copyright
• Retained author rights

• Role of the funding source
• Funding body agreements and policies
• Language and language services
• Submission
• Referees
PREPARATION
• Use of wordprocessing software
• Essential title page information
• Abstract
• Abbreviations
• Acknowledgements

• Footnotes
• Artwork
• Tables
• References
• Video data
• Supplementary data
• Submission checklist
AFTER ACCEPTANCE
• Use of the Digital Object Identifier
• Proofs
• Offprints
AUTHOR INQUIRIES

Introduction

Clinical Biochemistry publishes articles relating to the applications of molecular biology, biochemistry, chemistry and immunology to clinical investigation and to the diagnosis, therapy, and monitoring of human disease. Manuscripts are categorized as Analytical or Clinical Investigations and may be offered as Full Papers or as Short Communications. Critical Reviews are welcome, but contributors are encouraged to contact the Editor-in-Chief to avoid conflict with other forthcoming Reviews.

Types of paper

Full-length research articles, Short communications, Case Reports, Critical Reviews.

Contact details for submission

Papers should be submitted using the *Clinical Biochemistry* online submission system, http://ees.elsevier.com/clb.

Page charges

This journal has no page charges.

Before You Begin

Ethics in Publishing

For information on Ethics in Publishing and Ethical guidelines for journal publication see ⊟▸ http://www.elsevier.com/publishingethics and ⊟▸http://www.elsevier.com/ethicalguidelines.

Policy and ethics
The work described in your article must have been carried out in accordance with *The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans* ⊟▸http://www.wma.net/e/policy/b3.htm;
Uniform Requirements for manuscripts submitted to Biomedical journals ⊟▸ http://www.icmje.org, published by the International Committee of Medical Journal Editors. This must be stated at an appropriate point in the article

Please note: *Clinical Biochemistry* does not accept submission of papers based on animal studies.

STARD initiative
Clinical Biochemistry supports the STARD initiative on reporting of diagnostic accuracy. ⊟▸ http://www.stard-statement.org

Conflict of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also ⊞▸http://www.elsevier.com/conflictsofinterest.

Submission declaration

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see ⊞▸ http://www.elsevier.com/copyright). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult ⊞▸http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult ⊞▸http://www.elsevier.com/permissions.

Retained author rights

As an author you (or your employer or institution) retain certain rights; for details you are referred to: ⊞▸http://www.elsevier.com/authorsrights.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research

and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then this should be stated. Please see ⊟►http://www.elsevier.com/funding.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit ⊟►http://www.elsevier.com/fundingbodies.

Elsevier journals comply with current NIH public access policy.

Language and language services

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who require information about language editing and copyediting services pre- and post-submission please visit ⊟►http://www.elsevier.com/languageediting or our customer support site at http://epsupport.elsevier.com for more information.

Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

Referees

A minimum of six suitable potential reviewers (please provide their name, email addresses, and institutional affiliation). When compiling this list of potential reviewers please consider the following important criteria: they must be knowledgeable about the manuscript subject area; must not be from your own institution; at least two of the suggested reviewers should be from another country than the authors'; and they should not have recent (less than four years) joint publications with any of the authors. However, the final choice of reviewers is at the editors' discretion.

Types of submission and criteria
• <u>Original Research Communications</u> (designated as one of two categories: <u>Analytical</u> or <u>Clinical</u> Investigation) may be offered as <u>Full Papers</u> or as <u>Short Communications</u>. The latter format is recommended for presenting technical evaluations and short clinical notes, comprising up to 1,500 words of text, 10 references, and two illustrative items (Tables and/or Figures).

• <u>Case Reports</u> will be accepted only where they provide novel insight into disease mechanisms

or diagnostic applications.

• <u>Critical Reviews</u> will be welcome but prospective authors are strongly advised to seek authorization from the Editor-in-Chief to avoid conflict with scheduled reviews invited by the Editorial Board. They should address new topics or trends in clinical biochemistry or related fields.

• <u>Consensus recommendations</u> or guidelines on the use of laboratory test for clinical practice will be considered if they are compiled by a recognized organization or expert panel (e.g. IFCC, IUPAC, AACC, etc). Please contact the Editor-in-Chief for consideration. The responsibility for such material remains with the originating body.

Preparation

Use of wordprocessing software

It is important that the file be saved in the native format of the wordprocessor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the wordprocessor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. Do not embed "graphically designed" equations or tables, but prepare these using the wordprocessor's facility. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript. See also the section on Electronic illustrations.
To avoid unnecessary errors you are strongly advised to use the "spell-check" and "grammar-check" functions of your wordprocessor.

Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to "the text". Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient detail to allow the work to be reproduced, with details of supplier and catalogue number when appropriate. Methods already published should be indicated by a reference: only relevant modifications should be described.

Patients

If human subjects were used in the experiment please make a statement to the effect that this study has been cleared by your Institution Ethics Review Board for human studies and that patients have signed an informed consent. These are required by standards.

Experimental
Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Glossary
Please supply, as a separate list, the definitions of field-specific terms used in your article.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on.

Essential title page information

• *Title.* Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• *Author names and affiliations.* Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
• *Corresponding author.* Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.**
• *Present/permanent address.* If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be

retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Page 2 of the typescript should be reserved for the abstract which should be presented in a structured format and should not exceed 150 words for Full Papers, or 75 words for Short Communications. The following headings should be included followed by a colon: a) Objectives: b) Design and Methods: c) Results: d) Conclusions.

Keywords

Immediately after the abstract, provide a maximum of 10 keywords for full papers, or 5 keywords for Short Communications, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Please use terms from the most current issue of medical subject headings of *Index Medicus*. The key words should cover precisely the contents of the submitted paper and should give readers sufficient information as to the relevance of the paper to his/her particular field. Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
Table footnotes

Indicate each footnote in a table with a superscript lowercase letter.

Artwork

Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Save text in illustrations as "graphics" or enclose the font.
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Produce images near to the desired size of the printed version.
• Submit each figure as a separate file.

A detailed guide on electronic artwork is available on our website:
▣▶http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalised, please "save as" or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS: Vector drawings. Embed the font or save the text as "graphics".
TIFF: color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications please supply "as is".
Please do not:
• Supply embedded graphics in your wordprocessor (spreadsheet, presentation) document;
• Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color in print or on the Web only. For further information on the preparation of electronic artwork, please see ▣▶http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications which can arise by converting color figures to "gray scale" (for the printed version should you not opt for color in print) please submit in

addition usable black and white versions of all the color illustrations.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

The Editor-in-Chief, on accepting a manuscript, may recommend that additional tables containing important backup data, too extensive to be published in the article, may be published as supplementary material (see below) or deposited with the National Auxiliary Publications Service or made available by the author(s). In that event, an appropriate statement will be added to the text. Submit such tables for consideration with the manuscript.

References

Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either "Unpublished results" or "Personal communication". Citation of a reference as "in press" implies that the item has been accepted for publication and a copy of the title page of the relevant article must be submitted.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
This journal has standard templates available in key reference management packages EndNote (⊟▸ http://www.endnote.com) and Reference Manager (⊟▸ http://www.refman.com). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template

when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
Example: "..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ...."
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 163 (2000) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, third ed., Macmillan, New York, 1979.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 1999, pp. 281–304.

Journal abbreviations source
Journal names should be abbreviated according to
Index Medicus journal abbreviations: http://www.nlm.nih.gov/tsd/serials/lji.html;
List of serial title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php;
CAS (Chemical Abstracts Service): http://www.cas.org/sent.html.

Abbreviations and units
Standard abbreviations as listed in the *Council of Biology Editors Style Manual* may be used without definition. Use non-standard abbreviations sparingly, preceding their first use in the text with the corresponding full designation. Use units in conformity with the standard International System (SI) of units.

Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a maximum size of 10 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video

and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: ☞http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at ☞http://www.elsevier.com/artworkinstructions.

Supplementary material captions
Each supplementary material file should have a short caption which will be placed at the bottom of the article, where it can assist the reader and also be used by search engines.

Submission checklist

It is hoped that this list will be useful during the final checking of an article prior to sending it to the journal's Editor for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One Author designated as corresponding Author:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been "spellchecked" and "grammar-checked"
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black and white versions of the figures are also supplied for printing purposes
For any further information please visit our customer support site at
http://epsupport.elsevier.com.

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows (example taken from a document in the journal *Physics Letters B*):
doi:10.1016/j.physletb.2003.10.071
When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never to change.

Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Offprints

The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

Author Inquiries

For inquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage. You can track accepted articles at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.

ANEXO III

Comprovante de submissão do manuscrito "Astaxanthin improves paraoxonase activity and oxidative status in hypercholesterolemic rabbits: a lipid-lowering independent effect" ao periodico _British Journal of Nutrition._

Detailed Status Information

Manuscript #	BJN-2010-015476
Current Revision #	0
Submission Date	26th Jun 10
Current Stage	Under Review
Title	Dietary astaxanthin improves paraoxonase activity and oxidative status in hypercholesterolemic rabbits: a lipid-lowering independent effect
Running Title	Astaxanthin in hypercholesterolemia
Manuscript Type	Research Article
Special Section	N/A
Category	Metabolism and Metabolic Studies
Corresponding Author	Tatiana Emanuelli (tatiemanuelli@smail.ufsm.br) (Universidade Federal de Santa Maria)
Contributing Authors	Paula Augusti , Greicy Conterato , Sabrina Somacal , Rocheli Sobieski , Andréia Quatrin , Amanda Ruviaro , Luana Maurer , Marta Duarte
Sources of Funding	This work was supported by CNPq and FAPERGS. CNPq provided a research fellowship to T. Emanuelli, PhD degree fellowships to P.R.

Abstract	Oxidative stress plays an important role in hypercholesterolemia and atherosclerosis. This study explored the effects of the antioxidant astaxanthin on the lipid profile, oxidative stress and paraoxonase activity in hypercholesterolemic rabbits. Male New Zealand white rabbits were fed a standard or a hypercholesterolemic diet (1 % cholesterol) alone or supplemented with 50, 100 or 500 mg % of astaxanthin for 60 days. Serum levels of total cholesterol, triglycerides, oxidised LDL and oxidised LDL antibodies were measured. Thiobarbituric acid reactive substances levels and carbonyl content in proteins were also measured as lipid and protein oxidation indicators. Paraoxonase and antioxidant enzymes activities as well as fatty acids composition were evaluated in serum. The hypercholesterolemic diet increased serum total cholesterol and triglycerides levels. This increase in serum lipids was accompanied by elevated oxidised LDL and oxidised LDL antibodies, as well as lipid and protein oxidation. In addition, hypercholesterolemia decreased SFA and increased unsaturated fatty acids levels in the serum. Astaxanthin (100 and 500 mg %) attenuated protein oxidation in hypercholesterolemic rabbits, whereas 500 mg % of astaxanthin reduced protein oxidation per se. In addition, the activities of antioxidant enzymes superoxide dismutase and thioredoxin reductase were enhanced, while paraoxonase activity was inhibited in hypercholesterolemic rabbits. Although all astaxanthin doses prevented changes in thioredoxin reductase and paraoxonase activities, the change in superoxide dismutase activity was not improved by astaxanthin. Our study suggests that astaxanthin could play a beneficial role in hypercholesterolemia by preventing protein oxidation as well as changes in thioredoxin reductase and paraoxonase activities.
Key Words	Thioredoxin reductase, Fatty acids, oxidised LDL, Thiobarbituric acid reactive substances
Conflict of Interest	**No**, there is no conflict of interest that I should disclose, having read the above statement.
Word Count	6000

Stage	Start Date
Under Review	12th Jul 10
Under Consideration	27th Jun 10
Author Approved Converted Files	27th Jun 10
Waiting for Author Approval of Converted Files	27th Jun 10
File Conversion Complete	27th Jun 10
Waiting for File Conversion	27th Jun 10
Waiting for Files to be Sorted	27th Jun 10
Manuscript Submitted	27th Jun 10
Manuscript Files Submitted	27th Jun 10
Preliminary Manuscript Data Submitted	27th Jun 10

eJournalPress